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ABSTRACT
Introduction: Studies examining the association between individual dietary
components and breast cancer have been inconclusive. The use of dietary patterns is a
holistic approach which may yield stronger associations. We sought to develop a dietary
pattern based on an estrogen metabolite (EM) profile hypothesized to increase breast
cancer risk (high unconjugated estradiol and low ratio of 2- to 16-hydroxylated EMs
(2/16 ratio)). This estrogen-related dietary pattern (ERDP) was examined for associations
with postmenopausal breast cancer in two study populations and was incorporated into an
estrogen-related lifestyle score (ERLS) with other modifiable risk factors for breast
cancer. Methods: EM and dietary data from 653 postmenopausal women from the
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) were used to
develop the ERDP. Reduced rank regression modeling was applied to identify food
groups which explained the largest variation in the two EMs. The resulting dietary pattern
was then applied separately in 28,304 and 37,752 women from PLCO and the Sister
Study (SS), respectively, to examine associations with breast cancer using Cox
proportional hazards models. The ERDP was incorporated into the ERLS with alcohol
consumption, body mass index, and physical activity among PLCO participants.
Increasing scores of the ERLS represent a lower combined exposure to estrogen with a
total range of scores from 0 to 6. Results: ERDP scores contained foods with positively
weighted intakes (non-whole/refined grains, tomatoes, cruciferous vegetables, cheese,
fish/shellfish high in ω-3 fatty acids, franks/luncheon meats) and foods with negatively
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weighted intakes (nuts and seeds, other vegetables, fish/shellfish low in ω-3 fatty acids,
yogurt, coffee). In PLCO, a 1-unit increase in the ERDP score was associated with a 9%,
13%, and 13% increase in total (HR: 1.09, 95%CI: 1.01-1.18), invasive (HR: 1.13;
95%CI: 1.04=1.04-1.24) and estrogen receptor-positive (HR: 1.13, 95%CI: 1.02- 1.24)
breast cancer, respectively. No association was observed in SS. PLCO participants in the
highest ERLS category had a 34% (HR: 0.66; 95%CI: 0.56-0.78) reduction in risk of total
breast cancer compared to the lowest category. Conclusions: A dietary pattern correlated
with a high-risk estrogen profile was positively associated with postmenopausal breast
cancer within the cohort in which it was derived. Potential differences in other risk
factors or dietary assessment tools may explain differences in associations seen between
PLCO and SS. Adopting a lifestyle that has a lower combined exposure to estrogen is
likely effective in reducing the risk of postmenopausal breast cancer.
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CHAPTER 1
INTRODUCTION
1.1 Statement of the Problem
Breast cancer, the most commonly diagnosed cancer among women worldwide, is
a disease of strong hormonal influence.1 An attenuation in the production of ovarian
hormones is characteristic of the onset of menopause, which also corresponds to a change
in disease risk.2 Postmenopausal women, the population in which the highest proportion
of incident breast cancer cases occur, have significantly lower circulating levels of
estrogen compared to premenopausal women.2,3 Many of the well-established factors
associated with breast cancer, such as lactation, age at menarche, and parity are
significantly associated with estrogen metabolism.4–6 Additionally, serum and urinary
levels of estrogen metabolites (EM) have been shown to be consistently associated with
postmenopausal breast cancer risk in prospective investigations.4,7–12 Therefore,
modifiable lifestyle risk factors for postmenopausal breast cancer that are associated with
estrogen metabolism may present opportunities for primary prevention.
There are many nutrition-related lifestyle factors that have been identified with
sufficient evidence that influence the development postmenopausal breast cancer.2,13 Both
sides of the energy balance equation, excess intake in the form of adiposity and greater
energy expenditure in the form of physical activity (PA), show evidence of a positive and
inverse association with postmenopausal breast cancer, respectively.2,13 Consumption of
alcohol has also been shown to increase breast cancer risk.2,13 Using indices to assess
1

modifiable lifestyle factors as one aggregate score has been promising in identifying
associations with breast cancer risk.14–16 The study of dietary factors, however, with the
exception of alcohol, has yielded conflicting results in relation to breast cancer risk.2,13,17–
23

Other individual dietary factors, such as non-starchy vegetables and foods containing

carotenoids have limited but suggestive evidence of an association with breast cancer
according to the latest report by the World Cancer Research Fund (WCRF) and the
American Institute for Cancer Research (AICR).24 Furthermore, most other food
components (e.g., fiber, fruit, and total fat intake) have such limited or conflicting
evidence, the report deems their association with breast cancer to be entirely
inconclusive.24
It is likely that the practice of studying dietary components in isolation is
contributing to the inconclusive findings for associations with many diseases, according
to United States Department of Agriculture’s (USDA) Dietary Guidelines for Americans
(DGA).25 Nutrients are consumed in combinations, and many of these nutrients interact
with one another with regards to digestion and metabolism. Therefore, it is beneficial to
study diet in its entirety, as it is consumed, using dietary pattern analyses when
investigating a potential association with breast cancer.26 Emerging evidence has
supported an association between some dietary patterns and incident breast cancer
risk.17,18,27 Many of the diets that have indicated an inverse relationship with breast cancer
are characterized by high intakes of fruits and vegetables, and diets with increased risk
typically have higher intakes in fat and animal products.17,21,28 Although these
components show no or weak associations with breast cancer when studied in isolation,
they may influence risk when consumed as a part of a whole diet.
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In order to address the inconclusive findings in the literature on diet and breast
cancer, it may be beneficial to consider the mechanistic pathway by which a potential
association may occur. Nutritional status, namely malnutrition, can influence many
hormonal processes in women, such as the development of breasts, and the onset of both
menarche and menopause.29,30 Therefore, diet likely has some role in altering estrogen
metabolism and subsequently breast cancer risk, similar to adiposity and PA.13 A
relatively new approach to dietary pattern analyses, reduced rank regression (RRR),
allows the use of disease biomarkers, such as EMs, to develop a dietary pattern and then
investigate its association with disease endpoints.31 Previously, Fung et al. developed a
dietary pattern correlated with serum levels of estradiol and estrone sulfate using RRR,
but the pattern subsequently was not associated with breast cancer among
postmenopausal women in the Nurses’ Health Study (NHS).32 However, application of
the same estrogen-correlated dietary pattern in a Swedish cohort identified a positive
association with incident breast cancer.27 The potential effect of a dietary pattern based
on estrogen metabolism, in isolation and in combination with other nutritional lifestyle
factors, needs to be studied further in an attempt to identify primary prevention methods
for public health intervention.

1.2 Purpose and Objectives
We used data from postmenopausal women in the Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial (PLCO) to develop a dietary pattern based on food
groups that are correlated with serum estrogen levels. The estrogen-related dietary pattern
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(ERDP) was applied to examine associations with postmenopausal breast cancer in
PLCO. In order to examine the ERDP in a separate population from which it was
developed, associations with breast cancer were also examined in the Sister Study (SS).
Finally, in PLCO, the ERDP was combined with other lifestyle factors to assess the
impact of an estrogen-related lifestyle score (ERLS) on the development of breast cancer.
An initiative of the National Cancer Institute (NCI), PLCO is a large populationbased randomized trial to investigate the effect of regular cancer screenings on cancer
mortality in men and women aged 55-74.33 Control arm participants continued standard
of care screening practices, while participants in the intervention arm underwent more
frequent screenings over a six-year period. Enrollment took place from 1993-2001, with
follow-up collected until 2015. The SS, sponsored by the National Institute of
Environmental Health Sciences (NIEHS), is a large cohort study designed to examine
genetic and environmental risk factors of breast cancer.34 More than 50,000 sisters of
breast cancer patients aged 35-74 were enrolled from 2003-2009 with follow-up data
collection occurring every few years. Using these cohorts, we hypothesized that diets
high in whole grains and vegetables, particularly dark green vegetables, and low in
animal products would be characteristic of low ERDP scores. We expected the ERDP
scores to be associated with postmenopausal breast cancer independently, and as a part of
the ERLS. Our study aims were as follows:
Aim I: To derive a dietary pattern based on estrogen metabolites and apply it to
examine risk of postmenopausal breast cancer.
Fifteen EMs have been assayed using baseline serum samples from a nested casecontrol study of postmenopausal women enrolled in PLCO.35 In Aim #1, we identified
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food groups most strongly associated with EMs to create a dietary pattern that
characterized a woman’s diet based on its hypothesized cumulative estrogenic properties.
Two EMs with sufficient evidence of an association with postmenopausal breast cancer
were used in the development of the ERDP. Previous research on dietary patterns and
breast cancer has been inconclusive, however, most of the patterns have not considered
disease mechanisms specific to breast cancer.17,21,28,36–40 Evidence from two studies that
utilized an estrogen correlated dietary pattern have been mixed.27,32 Using data from all
postmenopausal women in PLCO’s intervention arm, the ERDP was used to
prospectively assess its association with overall postmenopausal breast cancer and by
estrogen receptor (ER) subtype, with consideration of potential effect modifiers. We
aimed to answer the following questions under Aim #1:
1. What food groups are most strongly correlated with serum EMs?
2. How much of the variation in serum EMs are explained by the ERDP?
3. Is there an association between the ERDP and overall breast cancer risk among
postmenopausal women?
4. Does the association between the ERDP and postmenopausal breast cancer vary
by ER subtype?
5. Is the association between the ERDP and postmenopausal breast cancer modified
by other estrogen-related risk factors (e.g., obesity, parity, alcohol consumption,
hormone replacement therapy (HRT))?

5

Aim II: To examine the association between the ERDP and postmenopausal breast
cancer in an external study population from which it was developed.
A potential association between the ERDP derived in Aim #1 and breast cancer
was investigated further in Aim #2, using prospective data from postmenopausal women
enrolled in SS. Use of data from the SS allowed for the examination of the association
between the ERDP and breast cancer in a different population from the one in which it
was derived as a potential validation study for any observed associations in PLCO.
Similar to Aim#1, the association was investigated for overall breast cancer and by ER
subtype, with consideration of potential effect modifiers. The following questions
pertained to Aim #2:
1. Is there an association between the ERDP and overall breast cancer risk among
postmenopausal women?
2. Does the association between the ERDP and postmenopausal breast cancer vary
by ER subtype?
3. Is the association between the ERDP and postmenopausal breast cancer modified
by other estrogen-related risk factors?
4. Did the association between the ERDP and postmenopausal breast cancer differ
between participants of SS and PLCO?
Aim III: To assess the relationship between an estrogen-related lifestyle score and
postmenopausal breast cancer risk.
In Aim #3, a lifestyle score was developed using the ERDP in combination with
other estrogen-related lifestyle factors known to be associated with postmenopausal
breast cancer. Previous aggregate lifestyle scores have shown strong inverse associations
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with breast cancer risk, but not always specific to postmenopausal breast cancer.14–16 The
scores have been based on cancer prevention recommendations from the WCRF/AICR,14
or using investigator-defined components,15 such as diet, physical activity, tobacco use,
alcohol intake, and/or anthropometry.16 Furthermore, to the best of our knowledge, no
lifestyle scores have been developed to focus on a single disease mechanism, such as
alteration of estrogen metabolism. Using data from all postmenopausal women in
PLCO’s intervention arm, the ERDP, body mass index (BMI), alcohol use, and PA were
used to characterize an ERLS. The ERLS was investigated in relation to overall
postmenopausal breast cancer and by ER subtype, with consideration of potential effect
modifiers. We aimed to answer the following questions under Aim #3:
1. Is there an association between the ERLS and overall breast cancer risk among
postmenopausal women?
2. Which components of the ERLS are the strongest contributors to a potential
association with breast cancer?
3. Does the association between the ERLS and postmenopausal breast cancer vary
by ER subtype?
4. Is the association between the ERLS and postmenopausal breast cancer modified
by other estrogen-related risk factors (e.g., parity, HRT)?

1.3 Significance of the research
Previous research on the association between diet and breast cancer has been
inconclusive. The research performed in this dissertation is innovative in that it addressed
a disease mechanism specific to breast cancer by identifying a dietary pattern associated
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with EMs. The association between the dietary pattern and breast cancer incidence was
assessed using two large, federally-sponsored prospective cohort studies. The EM data in
PLCO were generated using accurate and sensitive methods for assaying the low
concentrations present in postmenopausal women, allowing for minor discrepancies in
EM levels from dietary exposures to be quantified.41 The previously derived estrogencorrelated dietary pattern has shown mixed but promising associations between diet and
postmenopausal breast cancer.27,32 The methods employed in this dissertation are
believed to have improved on the previous study by creating a newly derived pattern
using different EMs, which may be more representative of breast cancer risk than the
previously-used parent estrogens. Furthermore, a more sensitive assay was used in
measurement of the EMs that may be particularly meaningful considering the low levels
of EMs present in postmenopausal women. Evaluation of the ERDP in multiple study
populations and as a part of the ERLS attempted to quantify the magnitude of the effect
of estrogen-related nutritional factors on breast cancer in postmenopausal breast cancer.
1.3.1 Public health impact
In recent years, advances in the treatment of breast cancer have led to a substantial
reduction in mortality rates.42 However, 1 out of every 8 women born in the U.S. will be
diagnosed with breast cancer in their lifetime.2 As increasing worldwide industrialization
and urbanization has resulted in rising global incidence rates, the need for primary
prevention methods for breast cancer is of upmost importance.24 The collaborative 2012
Breast Cancer Campaign, made up of over 100 international experts in breast cancer,
identified the need for sustainable lifestyle prevention methods as one of the 10 most
important gaps in translational breast cancer research.43 The results from this dissertation

8

contribute to the literature on dietary habits, alone and in combination with other lifestyle
factors, with the intent to lower future breast cancer incidence among postmenopausal
women.
1.3.2 Role of diet in breast cancer is inconclusive
Results from research examining dietary exposures and breast cancer risk have
been inconsistent, although a modest effect has been suggested.2,13,22 According to the
WCRF/AICR, the only nutritional factors with conclusive or probable evidence of an
association with postmenopausal breast cancer are alcohol consumption, body and
abdominal fatness, and PA.13,24 There is suggestive evidence of an effect from starchy
vegetables, foods containing carotenoids, and diets high calcium; however, the evidence
and biologic plausibility are lacking.24 Studying associations between diet and breast
cancer may be inconclusive due to the heterogeneity in disease characteristics for preand post-menopausal women and hormonal subtypes.22,44
However, it has been suggested that dietary habits and other lifestyle behaviors
are often adopted together, and may have a collective effect on cancer risk.45,46 There is
evidence that choosing to eat healthy foods together, thus improving overall diet quality,
is associated with reduced cancer risk, such as with the Mediterranean diet
(MeD).17,40,47,48 When higher dietary quality is measured by patterns based on
associations with certain markers of disease risk, such as inflammation or estrogen
metabolism, associations with breast cancer have been identified in some studies,27,49,50
but not all.32,51 Together, the research indicates that when diet is evaluated as the sum of
individual components, which likely interact with each other, a dietary influence on the
development of breast cancer in postmenopausal women is more likely to be found than
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when examining individual dietary factors. Individual components may influence disease
risk in multiple different mechanistic pathways or by predominantly converging on a
single pathogenic pathway.

1.4 Study outline
The overall goal of this dissertation was to investigate the relationship between
diet and postmenopausal breast cancer, in addition to other lifestyle factors, with
consideration of estrogen metabolism as a possible disease mechanism. The rationale and
significance of the research proposed is outlined in Chapter 1. Chapter 2 details the
background for all of the potential relationships considered, as well as important
confounders. The current knowledge on the associations between estrogen and breast
cancer, diet and estrogen, and diet and breast cancer are presented, along with other risk
factors for breast cancer, in Chapter 2. The background review served as the rationale for
the methods proposed in Chapter 3. Descriptions of the study populations and the analytic
approaches used can be found in Chapter 3. The results from each of the three
dissertation aims are reported in Chapters 4, 5, and 6 separately. Those chapters are
written in a manner so that each one represents a publishable manuscript. Chapter 7 is a
synthesis of the three aims and discussion of the collective results.
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CHAPTER 2
BACKGROUND
2.1 Estrogen and breast cancer
There are a number of well-established risk factors for breast cancer that, when
looked at collectively, highlight the presence of a hormonal influence on the development
and prognosis of breast cancer.2,4,12,13 Menopausal status, age at menarche, parity, age at
menopause, adiposity, and alcohol intake, to name a few, all have a commonality other
than their association with breast cancer risk.4,52 These factors, described in more detail in
section 2.4, have been shown to have a significant relationship with endogenous estrogen
levels.4,12 For example, adipose tissue is recognized to have endocrine functionality and
has been shown to promote the synthesis of estrogens via high expression of aromatase,
especially in postmenopausal women.53–56 Estrogen itself, measured either in serum or
urine, has repeatedly shown a positive association with postmenopausal breast cancer
risk, as discussed below (section 2.1.3).11,35,57 Although estrogen is the strongest sex
hormone correlate of breast cancer, there is evidence of an association with breast cancer
for various other sex hormones, including androstenedione, dehydroepiandrosterone
(DHEA) and testosterone.58–61
The role of hormones in breast cancer risk extends beyond steroidal hormones. In
addition to estrogen, adipose tissue has the capability of producing non-steroidal
hormones, such as leptin and adiponectin, which can influence mammary carcinogenesis
both directly and indirectly.62,63 Leptin has been shown to have a proliferative effect on
11

breast cancer cells through enhancement of multiple signaling pathways, whereas
adiponectin has been suggested to down-regulate cell proliferation and even induce
apoptosis.62,64 In addition, there are other breast cancer risk factors that are associated
with important hormones other than estrogen in the development of cancer, such as
prolactin in breastfeeding.13,65
Perhaps the most compelling argument to characterize breast cancer as a disease
of major hormonal influence is the recognition of four distinct molecular subtypes of
breast cancers.66 Characterized by the presence of hormonal receptors for estrogen and
progesterone (PR), in addition to levels of human epidermal growth factor 2 receptors
(HER2), each molecular subtype differs with regard to incidence rates, risk profiles, and
prognosis.2,67 The association between estrogen and many breast cancer risk factors,
along with its influence on the way the disease manifests and progresses, highlight the
importance of incorporating the extensive influence of estrogen in investigations of breast
cancer.
2.1.2 Laboratory methodology
The majority of epidemiologic research on estrogen metabolism in relation to
breast cancer risk over the last 20 years was conducted using a radioimmunoassay (RIA)
or an enzyme immunoassay (EIA).11,57,68 The RIA method is known as an extraction
assay because it includes an extraction and subsequent purification step, but also requires
a large volume of the serum sample, thus limiting its application.69 To help test the
association with estrogen and breast cancer in large epidemiologic studies, EIA was
developed because of its rapid and inexpensive application.11 The assay can be applied to
both urine and serum samples and was called a “direct” assay because it did not involve
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any purification or extraction steps in the process.68 Although useful in ranking
individuals, EIA was inadequate for absolute measurements of hormones from samples.69
A study evaluating EIA was able to show the method was reproducible in premenopausal
women, with a coefficient of variation (CV) between 8-14% for urine samples.68
However, when EIA was applied to urine samples from postmenopausal women the
mean levels increased over 50% from the 4-month interval to the 12-month interval of
reproducibility.68 Comparing against the standard at the time of publication, gas
chromatography-mass spectrometry (GC/MS), EIA was shown to have a lower
specificity and reproducibility.41,68 Quantitative comparison studies had shown that
although they were sensitive among premenopausal women, RIA and EIA had poor
specificity and accuracy, likely a result of cross-reactivity and batch-to-batch variation of
the antibodies in the urine samples.70 Cumulative evidence clearly showed that more
precise and accurate assay methods were needed to assess the relationship between
estrogen metabolism and breast cancer, particularly among postmenopausal
women.11,41,70,71
The use of GC/MS in large scale studies is impractical because of its cost and
arduous application, however mass spectrometry assays have been shown to be most
accurate and reproducible.70 Coupling the need for an inexpensive, accurate and
reproducible method with the increasing recognition of the influence of estrogen
metabolism in all its forms and pathways, liquid chromatography-tandem mass
spectrometry (LC/MS-MS) was developed for urine and serum samples.41,70 Comparing
urine samples from 430 women using EIA and LC/MS-MS, absolute concentrations of 2hydroxyestrone (2OHE-1) and 16-hydroxyestrone (16OHE-1) were consistently higher in
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EIA.72 The difference of the assays by menopausal status was particularly striking, with
mean concentrations for premenopausal 2-4 times higher and for postmenopausal 7-12
times higher when comparing EIA to LC/MS-MS.72
Using LC/MS-MS, researchers can concurrently measure 15 EMs in an accurate
and reproducible method with enough sensitivity to detect the low levels present in
postmenopausal women.11 In the nested case-control of postmenopausal women enrolled
in PLCO used in the present proposal, blind quality control serum samples were shown to
have a CV <5% for all 15 EMs using LC/MS-MS.35 Furthermore, the CV for the parent
estrogens, estradiol and estrone, were <3% in the samples.35 In the previous study of an
estrogen-correlated dietary pattern by Fung et al., the RIA method was utilized and only
estradiol and estrone sulfate were assayed with reported CVs<15%.32 The LC/MS-MS
method has been shown to have an intraclass correlation greater than 95% among
postmenopausal women and the lowest limit of detection with reliable and reproducible
estimates is between 1-2 pmol/L from serum samples.35,73,74 For reference, the measured
levels of estradiol in postmenopausal women who are not currently undergoing HRT
typically range from 0-117 pmol/L.69,75,76 The current and previously referenced evidence
supports the use of LC/MS-MS as an accurate, sensitive, and reproducible method to
measure EM in postmenopausal women.
2.1.3 Evidence from observational studies
The precursors and downstream metabolites of estrogen have different
physiologic effects as a result of their chemical structures.4 Both parent estrogens,
estradiol and estrone, are derived from the sex hormone, androstenedione (Figure 3.1).
Androstenedione can be directly aromatized in estrone, but requires an additional step to
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synthesize estradiol.77 Androstenedione must first be reduced to testosterone, which can
be subsequently aromatized to produce estradiol.77 Estrone can be converted to estradiol,
the most biologically active estrogen, by the 17β-hydroxysteroid dehydrogenase
enzyme.78 Once the parent estrogens have been synthesized, they may be metabolized
down one of three, competing and irreversible pathways.4 The three pathways are
characterized by the carbon position (2, 4, or 16) that is hydroxylated by the cytochrome
P540 enzyme.4 The result of the hydroxylation produces catechol estrogens, which may
undergo methylation to be further metabolized into methoxyestrogens.4
Early epidemiologic studies established a relationship between high levels of
circulating estradiol and estrone with breast cancer in patients using case-control study
designs.57 However, due to the potential for reverse causality, it was unclear whether the
higher levels among cases were markers of disease risk or of the presence of disease. The
estrogen hypothesis was studied further in large scale prospective studies, starting around
1990.57 An international group called the Endogenous Hormones and Breast Cancer
Collaborative Group (EHBCCG) conducted a meta-analysis of circulating hormones
from nine prospective studies of postmenopausal women not using exogenous hormones,
including 663 cases and 1765 controls.57 Results showed significant associations with
breast cancer comparing the highest quintile to the lowest for all hormones (estradiol, free
estradiol, non-sex hormone binding globulin (SHBG) bound estradiol, estrone, estrone
sulfate, androstenedione, DHEA, DHEA sulphate, testosterone).57 Most effect estimates
remained significant even after adjustment for estradiol, which was correlated with all
hormones investigated.57 The highest effect estimates were for free estradiol (relative risk
(RR): 2.58; 95% confidence interval (CI): 1.76-3.78) and non-SHBG (RR): 2.39, 95%
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CI: 1.62-3.54).57 Apart from SHBG (RR: 0.66; 95% CI: 0.43-1.00), all associations were
in the positive direction.57 The inverse association between SHBG and breast cancer risk
is hypothesized to be a result of its role in reducing circulating bioavailable estradiol.8
Since then, EHBCCG conducted an updated meta-analysis comparing results of eighteen
different prospective studies with consideration of the assay method used, while
excluding women currently taking exogenous hormones.69 The hormones of interest were
estradiol, estrone, and testosterone. All 3 hormones, across all three assay methods
(extraction, direct, and mass spectrometry), were significantly associated with
postmenopausal breast cancer risk, with the exception of testosterone measured by mass
spectrometry.69 Again comparing the highest quintile to the lowest, the effect estimates
ranged from 1.46 to 2.46.69 Combining results from all assay methods, individuals in the
highest quintiles experienced around twice the risk compared to the lowest quintile for
estradiol (RR: 2.15; 95% CI: 1.87-2.46), estrone (RR: 1.81; 95% CI: 1.56-2.10), and
testosterone (RR: 2.04; 95% CI: 1.76-2.37).69 Since the most recent EHBCCG metaanalysis has been published, results from three prospective studies of postmenopausal
women using LC/MS-MS have corroborated their results for the parent estrogens (estrone
and estradiol), with unconjugated estradiol consistently showing the largest magnitude of
an effect on breast cancer risk.35,79,80 Data from the nested PLCO study to be used in the
present proposal showed a doubling of risk comparing the highest and lowest decile for
unconjugated estradiol (hazard ratio (HR): 2.07; 95% CI: 1.19-3.62) using serum
samples.35
While there is an established relationship between circulating parent estrogens
and breast cancer risk among postmenopausal women, there is not as much research on
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other estrogen metabolites, partly due to limitations of previous laboratory assay
methods.11,57 As previously stated, the parent estrogens may be hydroxylated down one of
three different metabolic pathways.11 It has been hypothesized that shifts in these
competing pathways may influence breast cancer risk.11 Initial research in a case-control
study had shown that breast cancer patients had 60% higher circulating levels of 16OHE1 than controls, whereas 2OHE-1 and 4-hydroxyestrone (4OHE-1) levels were similar
across the two groups.11 Further research concluded the 2OHE-1 and 16OHE-1 were
competing metabolic pathways representative of breast cancer risk, with women having a
higher ratio of 2OHE-1 to 16OHE-1 (2/16 ratio) experiencing reduced risk of breast
cancer.11 Results of studies investigating the 2/16 ratio using EIA were inconsistent.11
However, in studies using the advanced LC/MS-MS to measure estrogen
metabolism in postmenopausal women, results have more consistently shown a reduction
in risk with increasing 2/16 ratio when looking at all estrogen metabolites combined, not
only estrone and its hydroxylated forms.35,79,80 In a nested case-control study from the
Columbia Missouri Serum Bank (CMSB), comparison of 215 postmenopausal cases and
215 matched controls yielded a non-significant reduction in risk for the 2/16 ratio (odds
ratio (OR): 0.63; 95% CI: 0.35-1.12) comparing the highest to the lowest quintiles.80 Data
from a larger case-cohort from the Breast and Bone Follow-up to the Fracture
Intervention Trial (B~FIT), including 407 postmenopausal cases and 487 controls,
identified a significant difference in risk comparing the highest and lowest quintile for the
total 2/16 ratio from serum samples.79 Women in the highest quintile had a 40%
reduction in risk of breast cancer (HR: 0.60; 95% CI: 0.40–0.90).79 In PLCO’s nested
case-control study, a similar reduction in risk was observed across the interdecile range of
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the 2/16 ratio before adjustment for unconjugated estradiol (HR: 0.62; 95% CI: 0.450.86) and retained a similar magnitude of association, although insignificant, after
adjustment (HR: 0.69; 95% CI: 0.47-1.02).35
The ratios of other EMs have also been investigated after the advent of LC/MSMS. While results have been inconsistent with regards to statistical significance, the
direction of the effects has been consistent throughout all three LC/MS-MS studies.11 In
addition to the 2/16 ratio, there is evidence the 2/parent estrogen ratio is associated with
reduced risk in postmenopausal women.35,79,80 In the CMSB study, the 2/parent ratio
yielded a non-significant reduction in risk (OR: 0.63; 95% CI: 0.35, 1.12).80 Similarly,
results from B~FIT showed a non-significant reduction in risk of a similar magnitude
(HR: 0.69; 95% CI: 0.46-1.05), but the test for trend was statistically significant
(p=0.01).79 In the PLCO population to be used in the present analysis, the 2/parent ratio
was associated with reduced risk before (HR: 0.66; 95% CI: 0.51-0.87) and after (HR:
0.72; 95% CI: 0.52-1.00) adjustment for unconjugated estradiol.35 In fact, data from
PLCO yielded significant effect estimates for both the 2/16 and 2/parent ratios, but not
unconjugated estradiol, when all three were entered into the model at once.35 In the same
PLCO study, the ratio of the 4-catechols to the 4-methylated catechols (4/4-methylated)
was positively associated with postmenopausal breast cancer.35 This supports laboratory
evidence indicating the instability of 4-cathechol DNA adducts can be blocked by
methylation.81 However, other observational evidence has failed to support the findings
from PLCO.11
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2.1.4 Potential mechanisms
Collectively, the results from epidemiologic studies suggest increased circulating
parent estrogens, particularly estradiol, is associated with an increase in postmenopausal
breast cancer risk. Furthermore, it appears that enhancement of the 2-hydroxylation
pathway, compared to both the 16-pathway and parent estrogens, is characteristic of a
reduction in the risk of postmenopausal breast cancer. The mechanisms behind the
influence of estrogen on breast cancer risk are not completely understood, and may act
both independently and dependently through their receptors.8 There is evidence of
carcinogenic effects of estrogen in mammary tissue through multiple pathways from
animal and human studies.4,8,82,83 Treatment of mice with estrogen has been shown to be
positively associated with mammary tumors.82 In mature human breast tissue, there is
evidence estrogen increases the rate of cellular proliferation.8,83 In vivo and in vitro
studies have shown downstream that metabolites of estrogen can lead to unstable adducts
of adenine and guanine in DNA, consequently leading to mutations.82 Conversely, other
quinones produced in estrogen metabolism can establish a redox cycle, resulting in
reactive oxygen species that can have detrimental oxidative effects on DNA.8
A pathway-specific investigation of estrogen metabolism may help to elucidate
how the metabolite ratios can potentially affect breast cancer risk. The increase in
2/parent and 2/16 ratios are indicative of a possible protective effect of metabolites in the
2-hydroxylation pathway.4,8,82 The downstream 2-hydroxylated metabolites have been
shown to have a lower affinity for estrogen receptors, possibly due to a decreased
hormonal effectiveness compared to estradiol.4 There is some evidence that metabolites
in the 2-hydroxylation pathway inhibit cellular growth and proliferation and are

19

associated with apoptosis.4 On the contrary, metabolites from the 16-hydroxylation
pathway have been shown to exhibit carcinogenic and genotoxic properties.84 Mouse
models with treatment of 16OHE-1 have resulted in spontaneous DNA synthesis in
mammary epithelial cells.4 Additionally, cancerous mammary tissue has been reported to
have nearly eight times the amount of 16OHE-1 compared to fat tissue in the breast.4 The
competing nature of the 2- and 16-hydroxylation pathways, and their relative cellular
effects, can help to explain why higher 2/16 and 2/parent ratios are associated with a
reduction in postmenopausal breast cancer risk.

2.2 Diet and estrogen
In order to reduce the incidence of postmenopausal breast cancer, it is imperative
to identify primary prevention methods, such as dietary intervention targets. While
circulating levels of estrogen are an established risk factor, and many other risk factors
are associated with estrogen metabolism, the evidence of a link between diet and estrogen
is scarce.2,13 The hypothesized relationship between diet and estrogen first originated in
an attempt to explain results from ecological and migrant studies. Women from Eastern
regions of the world experience much lower rates of breast cancer than Western women,
possibly due to vast differences in diet.85 When women migrate to the U.S., their disease
risk begins to parallel that of U.S. born women.86,87 A comparison of White U.S. women
with Asian immigrants reported a 3-fold increase in plasma estradiol and lower fecal
excretion of estrogen among Whites, hypothesized to be reflective of differences in diet.88
Supporting literature on diet and estrogen metabolism is scarce, highlighting the need for
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more investigations into the effects of single dietary components as well as dietary
patterns on EMs.
2.2.1 Single dietary components and estrogen
One of the earliest published studies of diet and estrogen investigated differences
in plasma, fecal, and urinary excretions between vegetarians and omnivorous women.89
Over 4 months of follow-up, fecal excretion of estrogen was higher among vegetarians
(p<0.001), and plasma estrone and estradiol levels were negatively correlated with fecal
excretion of estrogen (p=0.005).89 The researchers concluded that a vegetarian diet that
led to larger excretion of estrogen, and subsequently lower plasma levels of estrogen,
may be reflective of low intakes of fat and high fiber. Investigations of animal products in
relation to estrogen metabolism support a positive relationship between fat intake and
estrogen. A cross-sectional study of 766 postmenopausal women reported 13% lower
mean plasma levels of SHBG in women in the highest quartile of red meat consumption
compared to the lowest, with a significant test for trend (p<0.01).90 Women in the highest
quartile of dairy product consumption from the same study had 15% and 14% higher
levels of total and free estradiol compared to the first quartile, again with significant
trends (p=0.02 and p=0.03, respectively).90 The observed association may be a result of
the hormones that are present in the milk consumed, however, it has been suggested that
the levels in milk are too low to have a physiological effect and may become inactive
following digestion.91,92
Regarding dietary fiber, a mostly consistent inverse association with circulating
estrogen has been shown in premenopausal women.93–98 In postmenopausal women,
however, the evidence of an association is not as strong. A study of 291 women in a
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dietary intervention trial reported reduced serum bioavailable estradiol (p<0.01) and total
estradiol (p <0.05) concentrations as a result of increased fiber intake after one year of
follow-up.99 Using data from Hispanic women in the Multiethnic Cohort study (MEC),
differences of -22% (p=0.023) and -17% (p=0.045) for serum estrone and estradiol,
respectively, were observed when comparing postmenopausal women in the highest
quintile of fiber intake to the lowest.100 It has been hypothesized that steroid hormones
bind to certain types of fiber, which could also explain the increased fecal excretion of
estrogen among vegetarians.89,101 However, results from larger observational studies,
mostly of cross-sectional design, have reported no association between dietary fiber and
estrogen or other hormones.102–106
One of the more frequently studied dietary components in relation to estrogen is
fat intake because of the established relationship between adipose tissue and estrogen
synthesis. Results from intervention studies in postmenopausal women reported a
significant reduction of plasma estradiol after lowering dietary fat,107 a reduction in
estradiol after a low-fat, high carbohydrate diet,108 and lowered urinary excretion of
estrone after participation in a low-fat intervention with high ω-3 fatty acid intake.109 In a
subset of postmenopausal women with plasma samples from the Women’s Health
Initiative (WHI) Dietary Modification Trial, which was designed to assess the
relationship between a low-fat diet and breast cancer risk, a reduction of estradiol
(relative change in geometric mean: 0.85; 95% CI: 0.72-1.00) and increase in SHBG
(relative change: 1.09; 95% CI: 1.03-1.16) was observed among the intervention
group.110 A meta-analysis of 13 low-fat intervention studies reported a pooled estimate of
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a 23% reduction (95% CI: 18.1%-27.7%) in circulating estradiol post baseline among
postmenopausal women in the intervention groups.111
Results of observational studies examining associations between dietary fat and
estrogen have been less conclusive. Cross-sectional studies have repeatedly shown no
association between dietary fat intake and hormonal concentrations in postmenopausal
women.103,104,112,113 It is possible that weight loss mediated the association between a
decrease in dietary fat and circulating estrogen observed in intervention studies.
However, a cross-sectional analysis from the NHS reported 4.3% lower plasma estradiol
(95% CI: 0.2%-8.3%) for every 5% decrease in energy from fat intake among 384
postmenopausal women.102 In a Japanese study of postmenopausal women, baseline
serum estrone was positively associated with baseline percentage of calories from total
fat intake (p=0.04), and borderline significantly associated with monounsaturated fat
(MUFA) and polyunsaturated fat (PUFA) (p=0.05 for both) intakes.114 The same study
reported significant positive associations between DHEAS from serum samples with
percentage of energy from total fat (p=0.007), saturated fat (SFA) (p=0.009), MUFA
(p=0.006), and PUFA (p=0.04).105,114 Although a relationship between dietary fat and
estrogen is still inconclusive, it is possible an observed association is a combination of
effects from weight loss, reduced animal product intake, and increased fiber from plants.
In addition to vegetarianism or increased fiber from plants, other plant products
have been associated with estrogen metabolism. Indole-3-carbinol (I3C), abundantly
found in cruciferous vegetables, has displayed anti-estrogenic properties.115,116
Consumption of I3C extracts in 10 women for 2 months resulted in a 0.26
nmol/mmolcreatine decrease (95% CI: 0.06 to 0.46) in urinary estradiol after
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intervention.117 Decreases were also seen in estrone, estriol, and 16OHE-1 along with an
increase in 2OHE-1, indicative of a beneficial alteration in estrogen metabolism.117 An
intervention study of cruciferous vegetables, particularly broccoli, found a 0.08 increase
(95% CI, 0.02–0.15) in the 2/16 ratio from urine samples for each 10-g/day increase in
cruciferous vegetables, showing a beneficial shift in estrogen metabolism.118 In another
intervention study of 13 premenopausal women, consumption of a powder from dried
cruciferous vegetables increased the mean 2/16 ratio from 1.25 to 2.28 (p=0.01) using
urine samples.119 This association with serum or urinary estrogens has failed to be
replicated in epidemiologic studies, likely due to the low consumption levels of
cruciferous vegetables in some populations.120 However, in studies of tumor cells there is
evidence that cruciferous vegetables can shift estrogen metabolism in a favorable manner,
particularly in reference to the 2-hydroxylation pathway.121 The shift towards the 2hydroxylation pathway is possibly a change in the relative production of cytochrome
P540 proteins, resulting from exposure to I3C, which influences the metabolic pathways
of the parent estrogens.8,122
As a result of the drastic differences in breast cancer rates among Asian countries
and the U.S., and the relative differences in diet, soy intake has been hypothesized to
beneficially affect estrogen metabolism.88,123,124 Isoflavones, a type of phytoestrogen
contained in soy, may alter endogenous estrogen metabolism and have the ability to bind
to estrogen receptors.125 In experimental studies of premenopausal women, those
consuming increased soy products had decreased urinary estradiol, estrone, 16OHE-1,
and a significant increase in 2OHE-1.126,127 However, an intervention study of 97
postmenopausal women reported no change among urinary SHBG or estradiol after
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consuming a high-soy diet for four weeks.128 Collective evidence from a meta-analysis of
intervention studies concluded no statistically significant effects of soy or isoflavone
consumption on levels of estrone or SHBG among postmenopausal women, with similar
results among premenopausal women.129 A modest, non-significant increase in estradiol
in the soy consumption groups (14%, p = 0.07) was reported. It is possible the null results
were due to a failure to take into account the assay used to measure estrogen in the
pooled analysis, and the authors used a funnel plot to show studies finding extreme
increases or decreases in estradiol may have been excluded from their analysis.129
Data from observational studies regarding soy intake and estrogen metabolism are
limited. A cross-sectional study of Asian-American women reported significant 16%
higher urinary levels of 2OHE-1 (ptrend=0.02) accompanied by 11% lower levels of
16OHE-1 (ptrend<0.01) comparing the highest versus lowest tertiles of soy
consumption.130 Results from another study among postmenopausal Chinese women
showed 15% lower plasma levels of estrone among the highest quartile of soy consumers
compared to the lowest.112 In a study of predominantly White, British women, no
association was found between plasma EMs and soy milk intake for pre- and postmenopausal women.131 There is evidence of a reduction in estradiol which depends on the
presence of certain polymorphisms, suggesting a gene-diet interaction which could help
to explain the differences observed by race/ethnicity.132 It has also been hypothesized the
large discrepancies in intake and lifetime exposure to soy explain the differences
observed between Asian and non-Asian populations.124
Alcohol intake, another dietary factor that could explain the large differences in
breast cancer incidence rates across the world, has strong evidence of an association with
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estrogen metabolism.2,12,133,134 A positive association between alcohol intake and
circulating levels of hormones has been demonstrated in premenopausal women.135,136 In
a six-month cross-over trial of 34 premenopausal women, 30 g/day ethanol intake was
associated with increased levels of urinary estrone by 15.2% (p=0.05), estradiol by 21.6%
(p=0.02), and estriol by 29.1% (p=0.03).137 In a prospective study of 66 premenopausal
women, a modest but significant positive association was observed using Spearman
correlation coefficients (r=0.29; p<0.05) between alcohol intake and serum estradiol
concentrations.138 There has been some evidence of a stronger effect among women using
oral contraceptives (OC).139 Studies of postmenopausal women have been more
inconsistent.135,140–142 In a randomized, controlled 6 week cross-over trial in which 40 and
30 g of alcohol consumption per day for men and women, respectively, for three weeks
was compared to a three week abstinent period, plasma DHEAS increased but estradiol
was not affected by alcohol intake, among 10 postmenopausal women.143 In the
reanalysis of 13 studies of postmenopausal women, all hormones measured were
positively associated with at least 20 g/day of ethanol, with the highest difference in
mean concentrations observed for DHEA sulphate (25%; p<0.001) compared to women
who abstained from drinking.12 Using data from nearly 2000 women enrolled in the
European Prospective Investigation into Cancer and Nutrition (EPIC), pre- and
postmenopausal women who consumed at least 25 g/day of ethanol had nearly 40%
(p<0.001) and 20% (p<0.001) higher serum concentrations of estrone, respectively,
compared to non-consumers.136 Similar to a potential effect modification by OC in
premenopausal women, there is evidence of a stronger association between alcohol intake
and breast cancer among HRT users.135
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2.2.2 Dietary patterns and estrogen
The literature on dietary patterns and estrogen metabolism are scarce, but there is
some evidence of an association. Dietary data from postmenopausal women enrolled in
the NHS showed associations with sex hormones in a cross sectional analysis of dietary
patterns.144 The Alternate Healthy Eating Index (AHEI), an a priori dietary pattern based
on the USDA’s DGA, was inversely associated with plasma estradiol (p<0.001) and
positively associated with SHBG (p=0.01).144 The results indicate a beneficial effect of
better diet quality on estrogen metabolism, although results were attenuated after
adjustment for BMI (p=0.08 and p=0.37, respectively).144 Using principal component
analysis to derive a posteriori patterns, the prudent pattern, characteristic of intake of
plant products and whole grains, was not associated with EM.144 The Western pattern,
comprised of processed foods and animal products, was inversely associated with SHBG
(p=0.008) before adjustment for BMI, but not after adjustment.144 The Western pattern
also was positively associated with total (p=0.01) and free (p=0.006) estradiol, but after
adjusting for BMI, only the association with free estradiol remained statistically
significant (p=0.03) when comparing the highest and lowest quintiles of the dietary
pattern score.144 The association for the Western pattern was replicated in a case-control
of Mexican women, with authors reporting a 16.2% increase in the serum concentrations
of free estradiol (β=0.15; 95% CI: 0.01-0.29) for every 1-unit increase in the dietary
pattern score.145 Although premenopausal women may be less sensitive to dietary
estrogenic effects due to their higher mean circulating estrogen concentrations, an NHS
investigation observed associations for the AHEI.146 Women in the highest quartile of the
AHEI had lower mean plasma levels of total estradiol (-6.7 %; 95% CI: -14.3% -1.5%;
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ptrend=0.04) and androstenedione (-7.8%; 95% CI: -15.4%-0.4%; ptrend=0.03) compared to
the first quartile, although no associations were evident for adherence to the Dietary
Approaches to Stop Hypertension (DASH) or the alternate Mediterranean Diet
(aMeD).146 The (MeD) and its alternate form (aMeD) are based on the dietary
characteristic of people living in that region, as opposed to dietary guidelines like the
previously mentioned a priori indices. The MeD is usually high in fruits and vegetables,
legumes, oils, and other foods that result in a higher proportion of MUFA and PUFA
compared to saturated fats.47 While the previously mentioned study reported no
association for the aMeD, an intervention study using the MeD reported a roughly 40%
decrease in total urinary estrogen levels (p<0.02) in postmenopausal women, showing
some anti-estrogenic properties.147 Collectively, the published results show some
evidence of associations between dietary patterns and estrogen metabolism, although
results have been inconsistent.

2.3 Diet and breast cancer
An important lifestyle contributor to disease is diet, which has been estimated to
be the second most preventable cause of cancer.148 Prior research has indicated that 32%
of all cancers may be avoided through proper dietary modification, with at least 1 in 5
cancer deaths preventable through diet.149 However, cancers of differing anatomical sites
are different diseases, as is their etiology. Information on lifestyle prevention measures,
including diet, has been identified as one of the ten most important gaps in translational
breast cancer research.43 Although much of the research into diet and breast cancer has
been inconclusive, it may be due to the heterogeneity of cancer subtypes, or due to the
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relatively small effects from single dietary components, that may be magnified when
studying diet holistically.
2.3.1 Single dietary components and breast cancer
According to the most recent 2017 Continuous Update Project (CUP) of the
WCRF/AICR’s Second Expert Report, alcohol intake is the only dietary factor designated
to have a “convincing” association with an increased risk of breast cancer.24 The report
cited a recent meta-analysis of 22 prospective cohort studies, identifying an 9% increase
in postmenopausal breast cancer for every 10g of ethanol consumed each day.24 In an
additional pooled analysis of including over 33,000 incident breast cancer cases, a
significant increase in risk of 11% per 10g ethanol consumed per day was identified.24 In
analyses stratified by hormone receptor status, a meta-analysis of six studies did not find
an association with ER-/PR- breast cancer.24 However, for every 10g in ethanol
consumption per day, increased risks of 6% and 12% were seen for ER+/PR+ and
ER+/PR-, respectively.24
Animal and cell culture models provide evidence that ethanol metabolites enhance
mammographic carcinogenesis.24,135 It has been suggested that derivatives of alcohol act
as a carcinogen, increasing DNA damage in breast tissue.135 Alcohol also may promote
the movement of other carcinogens into cells within the breast due to its ability to act as a
solvent for other molecules.24 Characteristics of the diets of high alcohol consumers are
likely to contribute to the development of cancer, as they are typically deprived of certain
essential nutrients that can subsequently increase the susceptibility of cells to the effects
of carcinogens.24 Based on the CUP’s summation of observational studies and the
aforementioned biologic plausibility, the WCRF/AICR has concluded that alcohol intake
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has a convincing positive association with breast cancer risk, including sufficient
evidence of a dose-response relationship, although no threshold in risk has been
identified.24 Furthermore, the previously described epidemiologic evidence of the
estrogenic properties of alcohol intake in section 2.2.1 support the hypothesis of estrogen
metabolism mediating the association between alcohol intake and breast cancer.
Evidence of an inverse association between dietary fiber and estrogen
metabolism, outlined in section 2.2.1, has supported the hypothesis of an association
between dietary fiber and breast cancer risk. Data from case-control studies have reported
a reduction in risk with increasing fiber intake, but overall evidence is inconclusive
according to the WCRF/AICR.24 One meta-analysis of 16 prospective studies reported a
reduction in risk among the highest consumers compared to the lowest for total dietary
fiber (RR: 0.93; 95% CI: 0.89-0.98).150 Similar reductions in risk were observed for fruit
fiber, vegetable fiber, and cereal fiber, but the authors reported no association for
insoluble fiber.150 The associations observed between dietary fiber may be a result of
facilitated excretion of estrogen, or it could be due to the high correlation between fiber
with fruit and vegetable intake. Currently, the WCRF/AICR has concluded there is
limited evidence to suggest an association between fruit and vegetable intake with
postmenopausal breast cancer risk.24 In the 2017 CUP report, however, there is
suggestive evidence that non-starchy vegetables are associated with decreased risk of ERsubtypes, only.24 A pooled analysis of over 35,000 cases showed a 18% decrease in risk
of developing ER- subtypes when comparing the highest quintile of non-starchy
vegetables intake compared to the lowest.24 Data from the EPIC study reported no
association for fruits, but observed a significant inverse association between vegetable
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intake and overall breast cancer when comparing the highest and lowest quintiles (HR:
0.87; 95% CI: 0.80, 0.94), with the strongest association observed for ER-/PR- breast
cancer cases (HR: 0.74; 95% CI: 0.57, 0.96).151 An investigation in to the Italian section
of EPIC, identified a significant inverse association comparing the highest and lowest
quintiles of consumption for total vegetables (HR: 0.65; 95% CI: 0.53-0.81) and for leafy
vegetables (HR: 0.70; 95% CI: 0.57-0.86).152 A meta-analysis of 15 prospective studies
identified a significant association for fruits and vegetables combined (HR: 0.92; 95% CI:
0.86-0.98) but not vegetables alone when comparing the highest and lowest quintiles of
intake.20 A subgroup analysis of postmenopausal women identified an inverse association
for fruits only (RR: 0.89; 95% CI: 0.83-0.95), but not for vegetables or their
combination.20 A more recent pooled analysis of nearly 1,000,000 women reported no
associations between fruits and vegetables, only fruits, or only vegetables with overall
breast cancer.153 However, when only considering ER- breast cancer cases a significant
inverse association between the highest and lowest quintiles of vegetable intake was
identified (RR: 0.82; 95% CI: 0.74-0.90).153 Stronger associations were observed in
premenopausal women.153 One explanation for the inconclusive results is the method of
consumption. Fruits are almost always consumed raw, but vegetables are cooked in a
variety of ways that may alter the availability of constituents that influence breast cancer
risk.154
The 2017 CUP report has designated foods high in carotenoids with a “limited –
suggestive” association with a decrease in breast cancer risk.24 A meta-analysis of 9
studies showed an 18% decrease in risk of breast cancer per 100 μg/dL of circulating
carotenoids, however the report also cited a meta-analysis of 18 studies that found no
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association with dietary beta-carotene.24 In addition to non-starchy vegetables and foods
high in carotenoids, diets high in calcium have “limited – suggestive” designation for an
association with breast cancer.24 Six of seven studies cited in the CUP reported an inverse
association with postmenopausal breast cancer.24 In a dose-response meta-analysis, a 300
mg increase of dietary calcium was associated with a 4% reduction in risk.24 Although
mechanisms are unclear, it likely has to do with the prominent role of calcium in cellular
signaling that can influence proliferation and apoptosis.155
Many other dietary factors have been deemed to have a “limited – no conclusion”
designation with respect to the development of postmenopausal breast cancer in the
WCRF/AICR’s CUP.24 Dietary fat has been frequently studied with regard to increasing
risk of breast cancer, yet the evidence has been inconclusive.2 A meta-analyses from over
140 mice studies concluded dietary fat promoted mammary carcinogenesis independent
of total energy intake.156,157 However, results from observational evidence have failed to
support the animal models.158 The 2010 CUP report on breast cancer based its “limited”
designation for dietary fat on evidence from 10 cohort studies and 16 case-control
studies, with no updates in the 2017 report.24,159 Separate meta-analyses for the cohort
and case-control studies included in the report yielded a non-significant and significant
positive association for total dietary fat and postmenopausal breast cancer,
respectively.159 Of six cohort studies investigating percentage of total energy intake from
fat, the majority reported a decrease in risk, but one study reported a significant positive
association with postmenopausal breast cancer risk.159 In the WHI Dietary Modification
Trial, in which the intervention group was meant to reduce fat intake by 20%, no
significant difference in risk of postmenopausal breast cancer was seen after 8 years.110
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However, among women who consumed at least 36.8% of all energy from fat at baseline,
a significant decreased in risk was seen in the intervention group compared to controls
(HR: 0.78; 95% CI: 0.64-0.95).110 According to the authors, the HR estimates and upper
bound of the CI lowered when accounting for greater adherence to the intervention,
suggesting the presence of an association.110 If there is a true association between dietary
fat and breast cancer risk, it has been proposed that dietary fat may work through an
influence on estrogen metabolism.111
The bulk of evidence from studies of intakes of different types of fatty acids,
rather than total fat, has yielded similar inconclusive results. A cohort of nearly 50,000
women identified no association when examining SFA, MUFA, and PUFA in relation to
overall breast cancer risk.160 However, when only considering women over the age of 50,
most of whom were presumably postmenopausal, women in the highest MUFA and
PUFA quintile intake experienced less incidence of breast cancer compared to the lowest
quintile (HR: 0.45; 95% CI: 0.25-0.99 and HR: 0.54; 95% CI: 0.35-0.85, respectively).160
Inverse associations between PUFA intake and breast cancer risk have been observed, but
results are inconsistent.161,162 Women enrolled in EPIC who were in the highest
consumption quintile of SFA had 13% increased risk of breast cancer compared to the
lowest quintile (HR: 1.13, 95% CI: 1.00-1.27; ptrend=0.038).163 Meta-analyses of MUFA
and breast cancer have reported both positive164 and inverse associations with breast
cancer risk.165,166 The sources of the MUFA may be one reason for the inconsistencies.162
Studies of fat from animal sources in association with breast cancer have also been
inconclusive.23
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Consumption of soy foods has been associated with reduced risk of breast cancer,
however results across different study populations have been inconsistent.167 Two
different recent meta-analyses identified 35 and 14 studies investigating an association
between soy and breast cancer.168,169 The former identified a significant inverse
association comparing the highest consumption groups to the lowest groups (RR: 0.89;
95% CI: 0.79–0.99).169 When stratified by the origin of the study population, the
association remained significant for Asian countries (RR: 0.76; 95% CI: 0.65–0.86) but
not in Western study populations (RR: 0.97; 95% CI: 0.87–1.06).169 The other analysis
based on a smaller number of studies, stratified by menopausal status and reached the
same conclusion for both pre- (OR: 0.59, 95%CI: 0.48-0.69) and post-menopausal Asian
women (OR: 0.59, 95% CI: 0.44-0.74).168 In Western populations, results from
premenopausal women were not significant and postmenopausal women exhibited an
inverse association nearing significance (OR: 0.92; 95% CI: 0.83-1.00).168 Another
literature review concluded there was no association between breast cancer and soy
consumption in Japanese women.170 The differences in the associations observed between
Asian and Western study populations is most likely driven by the relative intakes of soy
foods, which is much more common among Asian countries.167 It also has been
hypothesized that early life exposure to soy may be more important than intake in
adulthood.132,167 As mentioned in section 2.2.2, it is possible genetic polymorphisms
affect the relationship between soy intake and breast cancer risk, through modulation of
soy’s effect on estrogen metabolism.124
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2.3.2 Dietary patterns and breast cancer
As shown in section 2.3.1, for many nutrients and dietary components there is
inconclusive evidence of an association with breast cancer risk. It is possible the
uncertainty in the hypothesized relationship between breast cancer and diet is due to the
complex interactions that occur in reality when combinations of foods and nutrients are
consumed. The USDA’s DGA called for a focus on dietary patterns because “the totality
of diet […] may have synergistic and cumulative effects on health and disease.”171
Dietary pattern analyses incorporate the potential for this web of influence by assessing
diet in its entirety, accounting for multiple foods consumed, rather than singular specific
components. Therefore, dietary pattern analyses may detect a dietary effect on breast
cancer due to the combinations of foods, that is not seen when studying isolated
components. However, similar to single nutritional factors, the evidence of an association
between dietary patterns and breast cancer has been inconclusive.17,18,21,39,40,172
There are two prevailing methods used in dietary pattern analyses.173 Data-driven
patterns, or a posteriori, are empirically determined from each study population in which
the analysis occurs.26,173,174 Within data-driven patterns, methods can be further
delineated by the outcome-dependent or -independent properties of the approach.26,173,174
Contrastingly, investigator-defined patterns, or a priori, are based on hypotheses of dietdisease relationships or on certain guidelines that constitute a healthy diet, before any
analysis occurs.26,173,174 It is possible that the inconsistency of associations between
dietary patterns and breast cancer is a result of the high heterogeneity in applied
methodologies to derive and study dietary patterns.
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In studies of breast cancer and data-driven dietary patterns, the “Western” or
“unhealthy” pattern is often hypothesized to increase the risk of breast cancer because it
is typically characterized by high intakes of animal products, refined grains, and sugars.
One meta-analysis did not identify an association,18 however multiple reviews and
original research articles have supported evidence for a positive association with breast
cancer.17,18,36,175–178 Among studies reporting no association between the “Western”
pattern and overall breast cancer, multiple studies identified a significant positive
relationship when limiting to postmenopausal,36,177–179 ER+,177,180 or normal weight
women.180 The “prudent” or “healthy” dietary pattern with high intakes of fruit and
vegetables, whole-grains, legumes, olive oil and fish, has shown a more consistent
association with evidence of a reduction in risk.17,18,21,28,177,181 Similar to the “Western”
pattern, some studies suggest the magnitude of the association is strongest in
postmenopausal21,182 or normal weight women,38,183 or with ER+ subtypes.37 When
looking at only vegetarians and non-vegetarians, no significant difference in risk has been
suggested.123,184 Using data from the EPIC-Potsdam study, a dietary pattern was derived
using RRR to explain variation in fatty acid intake (SFA, MUFA, ω-3 PUFA, ω-6
PUFA).185 Women in the highest tertile of the pattern had twice (HR: 2.00; 95% CI: 1.30
– 3.09) the risk of developing breast cancer, with no effect modification by menopausal
status.185
The heterogeneity of food groups identified in the “Western” or “prudent”
patterns is shared in development of a priori patterns. Although they differ in what
constitutes a healthy diet or are aimed at prevention of different diseases, some evidence
of associations with breast cancer have been shown. Typically, higher scores on these a

36

priori patterns correlate with high intakes of fruits, vegetables, legumes, whole grains,
and seafood. Contrastingly, low scores correlate with high intakes of red meat, highly
processed foods, including refined grains, and other animal products. In addition to the
AHEI, common a priori dietary patterns are the Recommended Food Score (RFS) which
is based on current intake guidelines in the U.S., and the Diet Quality Index Revised
(DQI-R) from the National Research Council. AHEI, which was inversely associated
with estrogen, also was inversely associated with postmenopausal breast cancer (HR:
0.78;95% CI: 0.59-1.04; ptrend=0.01) when comparing across quintiles, but not for overall
breast cancer.186 Another study also reported no association between the AHEI and
overall breast cancer risk, however they did not stratify by menopausal status.187
Similarly, the association for the RFS (HR: 0.69; 95% CI: 0.51-0.94) with
postmenopausal breast cancer was only present among ER- cases.188 Although they were
not statistically significant, associations with the AHEI and RFS with overall
postmenopausal breast cancer showed a consistent inverse association.186–188 The DQI-R
was not associated with breast cancer except women with genetic predispositions to
breast cancer.187,188 Although the majority of studies using dietary patterns based on
guidelines failed to find statistically significant associations, all have shown inverse
associations, suggesting overall diet quality may reduce the risk of breast cancer.
Selection of foods that are hypothesized to have an effect on breast cancer in an a priori
pattern, and not necessarily foods that constitute an overall healthy diet, may result in
stronger associations.
Like the AHEI, the previously described MeD has exhibited anti-estrogenic
effects,147 and is inversely associated with many chronic diseases.189 One recent review
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reported weak evidence of an association between MeD and breast cancer from
observational studies.40 However, a meta-analysis of 23 observational studies reported an
inverse association (RR: 0.93; 95%: CI 0.87-0.99).190 In the NHS, the aMeD was only
statistically significant for ER- breast cancer among postmenopausal women comparing
the highest quintile to the lowest (HR: 0.79; 95% CI: 0.60-1.03; ptrend=0.03).188 In a
randomized controlled trial of over 4,000 women aged 60 to 80, women allocated to the
MeD supplemented with extra virgin olive oil intervention group experienced nearly 70%
less risk of breast cancer than the control group (HR: 0.32; 95% CI: 0.13-0.79).48
Another commonly used category of a priori dietary patterns is those developed
based on hypothesized disease pathways. The DASH diet was developed as a potential
tool for intervening on hypertension.191 Surprisingly, even though it was developed based
on a mechanistic pathway for a different disease, the DASH diet has shown an
association with breast cancer, although only for HER-2 positive cases (HR: 0.44; 95%
CI: 0.25-0.77).186 A dietary pattern developed on the basis of foods associated with
inflammatory markers, the Dietary Inflammatory Index (DII™), has shown mixed results
for breast cancer.49–51,192,193 Although one study reported no association with
postmenopausal breast cancer,192 others have reported significant associations with breast
cancer, with larger estimates observed in postmenopausal49,193 or obese women,49 and
with breast cancer mortality.51 Together, the evidence suggests a pro-inflammatory diet is
associated with greater incidence and mortality from breast cancer. Specific to breast
cancer, a previously described pattern was based on food groups correlated with
circulating estrogen levels, which was subsequently not associated with postmenopausal
breast cancer in NHS.32 However, when the same pattern was applied in a Swedish
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cohort, a 29% increase in breast cancer risk (HR: 1.29; 95% CI: 1.08-1.55) was reported
when comparing women in the highest quartile with the lowest.27

2.4 Risk factors for breast cancer
Breast cancer is the most diagnosed cancer among women after non-melanoma
skin cancer, with over two-thirds of cases occurring in women over the age of 55, and
results in the second most cancer-fatalities after lung cancer.2 Established risk factors for
breast cancer include age, obesity, physical inactivity, alcohol intake, and reproductive
factors, most of which affect the development of mammographic tumors through
hormonal influences. Due to the high incidence of breast cancer, modifiable primary
prevention methods, such as dietary intervention, are of great interest.
2.4.1 Menopausal status
There is evidence that risk factors, incidence, and prognosis of breast cancer vary
between pre- and postmenopausal women, highlighting the significant differences
between the two disease strata.2,194,195 The heterogeneity in the two diseases may be
crucial to explaining some of the inconclusive findings in the relationship between diet
and breast cancer, as the grouping of both menopause statuses as one occurs frequently in
the literature.21 The onset of menopause is a marker for a reduction in ovarian endocrine
activity. Subsequently, levels of sex hormones, including estrogen, are significantly
attenuated in postmenopausal women.56,58 Sex hormones in premenopausal women have
high within-person variability corresponding to their menstrual cycle.196 Contrastingly,
due the termination of menstruation after menopause, postmenopausal women have
lower, less variable levels of circulation estrogen.56,197 The reduced variability and
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magnitude of the hormone levels is hypothesized to make postmenopausal women more
sensitive to estrogenic effects in relation to breast cancer risk.4,9,195,198,199 This hypothesis
is supported by many of the estrogen-related risk factors for breast cancer, as described
below, which appear to have a greater effect in postmenopausal women.2,13,195 In addition
to, and partially as a result of the hormonal changes after menopause, there are paralleled
atrophic changes to mammary tissue, with increasing amounts of adipose in the breast.198
Increased amounts of adiposity in the breast results in higher localized levels of estrogen
as a result of the estrogenic properties of adipose tissue.198
2.4.2 Weight status and physical activity
Multiple factors related to increased adiposity and PA are associated with the
development of breast cancer in postmenopausal women.13,200,201 Using the Centers for
Disease Control and Prevention’s (CDC) BMI cutoffs for overweight (25.0-29.9 kg/m2)
and obesity (≥30 kg/m2), risk of postmenopausal breast cancer is 1.5 and 2 times that of
normal weight women (18.5-24.9 kg/m2), respectively.2 In the WCRF/AICR’s Second
Expert Report CUP, total body fatness has “convincing” evidence and biological
plausibility to increase risk of postmenopausal breast cancer.24 The designation is based
on an updated meta-analysis of more than 56 studies showing a 12% significant increase
in risk per 5 kg/m2 increase in BMI, with stronger evidence among ER+ subtypes.24 In
addition to total body fatness, measures of abdominal fatness, such as waist
circumference (WC) and waist-to-hip ratio (WHR) have a “probable” association with
increased risk of postmenopausal breast cancer.13,24 Pooled evidence from 11 cohort
studies showed an 11% increase in risk for an 10 cm increase in WC.24 Similarly, the
report cited a 10% increase for a 0.1 increase in WHR.24 Estimates were slightly
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attenuated, but still significant, when only considering studies that adjusted for BMI.24
Women who gain weight as adults are even more susceptible to breast cancer.2,13 For a 5
kg gain in weight during adulthood, a meta-analyses of 15 studies reported a 6%
significant increase in risk of postmenopausal breast cancer.24
The biologic mechanisms of increased weight status and postmenopausal breast
cancer risk are due to the hormonal properties of adipose tissue.2,24 The chronic state of
inflammation that is present in obese individuals is mediated by adipokines, such as
tumor necrosis factor alpha (TNF-α).53,202 The downstream effects of adipokine secretion
lead to an altered immune response that can facilitate cell proliferation and tumor
growth.203 Furthermore, TNF-α in adipocytes inhibits glucose uptake resulting in
sustained levels of increased insulin.204,205 There is some evidence hyperinsulinemia is
associated with increased breast cancer risk, likely due to its ability to promote DNA
synthesis and the activity of insulin-like growth factor (IGF).63 The influence of IGF on
breast cancer risk has become increasingly apparent, primarily due to its mitogenic
properties affecting cellular growth and differentiation.63
The predominant hypothesis by which increased weight status, specifically
increased accumulation of adipose tissue, affects postmenopausal breast cancer risk is the
ability of adipose tissue to synthesize estrogen.62,63,206 Adipose tissue is the largest source
of endogenous estrogen in postmenopausal women, and there is strong evidence for a
positive linear association between adipose tissue and estrogen levels in postmenopausal
women.2,63,207 Adipose tissue contains high levels of the enzyme aromatase, which plays
a significant catalytic role in estrogen synthesis.63 Aromatization is the last step in the
conversion of cholesterol to estrogen for both estradiol and estrone.53 The influence of
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adipose tissue on breast cancer risk through estrogen metabolism is evident when looking
at various strata of estrogen-related breast cancer risk factors. For example, the influence
of HRT on breast cancer risk is strongest among lean women, likely because the
exogenous estrogen from the therapy has a relatively greater effect in the absence of (or
reduced amount of) adipose-derived estrogen.208
Contrary to postmenopausal breast cancer, increased adiposity is associated with a
decrease in the risk of breast cancer in premenopausal women.24 Results from the
WCRF/AICR’s CUP meta-analysis indicated an 7% decrease in risk of premenopausal
breast cancer for every 5 kg/m2 increase in BMI.24 The mechanisms behind the inverse
association between adiposity and premenopausal breast cancer are unclear. It has been
hypothesized that the increased levels of adipose-derived hormones, such as IGF, may
promote anovulation which reduces a woman’s lifetime exposure to estrogen.209 It is also
possible that increases early life exposure to adipose-derived estrogen may alter breast
differentiation in a way that is beneficial to prevent malignancies.210
Potentially through its effects on adiposity and other mechanisms, energy
expenditure through PA has an inverse association with postmenopausal breast cancer
risk.2 The majority of cohort studies in the WCRF/AICR’s report showed a significant
inverse association between recreational PA and postmenopausal breast cancer, resulting
in a “probable” designation for decreasing risk.24 A meta-analysis yielded a 13%
reduction in risk when comparing the highest level of PA with the lowest, with a similar
10% reduction in risk when only looking at vigorous PA.24 The hypothesized beneficial
effect of increasing PA is related to the promotion of metabolic efficiency, translating to
a reduction of adipose tissue and increase in lean mass.62 Subsequently, PA improves
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insulin response and protects against chronic inflammation.62 Increased PA has also been
shown to have an inverse association with circulating estrogen, possibly through
increased levels of SHBG.24,62 Intervention studies have shown a reduction of circulating
estrogen after participating in PA, suggesting PA may reduce breast cancer risk through
attenuation of exposure to estrogen.211,212
2.4.3 Hormone replacement therapy and contraceptives
Exogenous hormones use, such as in contraception or postmenopausal HRT, has a
positive association with breast cancer incidence.2 There is evidence that use of OCs that
contain estrogen and/or progesterone, has a minor effect on risk.2 Women who use OCs,
specifically those manufactured with high hormonal dosage, show the greatest increase in
risk when use starts before the age of 20.2 The increase in risk attenuates when use of
OCs is terminated.2 Evidence suggests that a previous user of OCs has the same risk
profile of someone who never used if it has been at least 10 years since their last use.2
The other main source of exogenous estrogen, HRT, is used among women who
underwent hysterectomy and cannot produce their own estrogen, or among women who
are trying to mitigate the effects of menopause due to low levels of estrogen. There has
been a drastic reduction in the latter HRT use after initial results from the landmark
randomized controlled trial in the WHI.213,214 Originally designed to investigate a
hypothesized protective effect of estrogen plus progestin in relation to coronary heart
disease and all-cause mortality among women, the trial was prematurely terminated as
intermediate results identified an increase in risk of many conditions in the intervention
group.214 Compared to controls, women who underwent estrogen plus progestin therapy
had a significant 26% increase in risk of breast cancer.214 Increasing duration of use
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showed stronger associations, however, termination of use causes a women’s risk to
revert to what it would be if she never used, similar to what has been observed among OC
users.214,215 Results from the WHI were corroborated in multiple other studies with
regards to the effect of estrogen plus progestin.208,215,216 Interestingly, there is evidence of
an effect modification by BMI in the association between HRT and breast cancer risk.208
Although adipose tissue promotes estrogen production, the risk estimates between HRT
and breast cancer were higher in lean women, compared to obese women, in a reanalysis
of 51 observational studies.208 It is possible that the amount of estrogen produced by
adipose tissue is enough to cause a sufficient increase in risk, thereby masking any
additional effect of HRT use on breast cancer risk. This would explain why HRT has a
greater effect on risk among lean women, because these women do not have as much
adipose-derived estrogen.
There are forms of HRT that do not use the combination of estrogen plus
progestin, which have shown inconclusive results regarding breast cancer risk.208 The
Million Women Study in the United Kingdom showed a significant 30% increased risk of
breast cancer among women who used an estrogen-only replacement therapy compared
to women with no HRT.215 Contrastingly, women in the WHI’s estrogen-only trial
showed evidence of a significant decrease in risk after adjustment for adherence (HR:
0.67; 95%CI: 0.47-0.97).217 Tibolone, a synthetic hormone with androgenic properties,
has also been shown to increase risk.215
2.4.4 Reproductive factors
Numerous factors regarding a women’s reproductive history can influence their
risk of postmenopausal breast cancer, often also effecting their exposure to endogenous
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estrogens, as evident by a stronger association with ER+ cases.2 The earliest reproductive
factor affecting breast cancer is age at menarche. There is an inverse association between
age at menarche and breast cancer, with women who experience menarche at the age of
12 and younger with the greatest risk.2,218 After the age of 12, a 10-20% reduction in risk
has been estimated for each 1-year increase in age that menarche occurs.218 Similar to the
relationship with late onset of menopause and breast cancer, women who experience
early menarche typically have a greater lifetime exposure to ovarian hormones.2,218
Once of child-bearing age, those women who never have children, or do so at an
older age, are at an increased risk of breast cancer compared to women who have an
earlier age at first birth.2,219,220 Increasing parity and age at first birth are both inversely
associated with breast cancer.2,219,220 Compared to nulliparous women, those who were
parous have significantly lower levels of serum estrogen and greater concentrations of
SHBG. Therefore, it is plausible that multiparous women who gave birth at a young age
have a lower lifetime exposure to estrogen.221 However, it also is possible that a woman’s
nulliparity status results from infertility due to low levels of steroid hormones, which
would indicate a lower exposure to estrogen.222
Among women who have children, there is evidence that those who breastfeed are
at a lower risk.2 Furthermore, the longer a women breastfeeds has shown greater
reduction in risk.2 The mechanism behind this decrease in risk most likely has to do with
increased differentiation of breast tissue, however it is also possible the paralleled
inhibition of menstruation that occurs during lactation plays a role.2,13 By inhibiting the
number of menstrual cycles, lactation reduces a woman’s lifetime exposure to
endogenous estrogen.2,13
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2.4.5 Inherited risk
Although most incident breast cancer cases occur in women without a history of
the disease, there is a strong link between risk and an individual’s personal and family
history of breast cancer. Early onset breast cancer is often a result of inherited risk, as
genetic factors are likely to have a stronger influence, whereas accumulation of
environmental and lifestyle factors take effect in cases of older, postmenopausal
women.2,223 Women who have one, two or at least three first-degree relatives experience
2, 3, and 4 times the risk of developing breast cancer, respectively.2 The younger the
relatives were diagnosed the stronger the association with risk in family members.2 In
addition to family history of breast cancer, women with relatives who have been
diagnosed with ovarian, prostate and endometrial cancers, all of which are cancers with
strong hormonal properties, are also at increased risk.2,224 Women who have previously
been diagnosed with cancer are approximately 1.5 times as likely to develop a secondary
breast cancer compared to women with no personal history.2
For some previously diagnosed women, the increased risk of secondary breast
cancer is due to their genetic predisposition. The strongest associated and most frequently
analyzed genetic mutations for increased breast cancer risk are in the BRCA1 and BRCA2
genes.2 Although the mutations occur in less than 1% of the female population, there are
estimates that they account for as much as 10% of all breast cancer cases.2 Women who
carry the a mutation in BRCA1 and BRCA2 have between a 50-80% lifetime risk of breast
cancer, compared to a 12% lifetime risk in the general population.225 There is evidence
that other genetic variations present low increases in risk, in addition to a strong belief
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that these variations interact with lifestyle factors, such as dietary habits, to affect breast
cancer risk.2,226
2.4.6 Demographics
As with most major chronic diseases, there are multiple demographic risk factors
strongly associated with incident breast cancer. Incidence rates differ among many strata
of age, social class, ethnicities, and races. Many, but not all, demographic and
socioeconomic risk factors for breast cancer are related to screening behaviors.2 For
example, the lifetime risk of developing breast cancer has increased in the past 40 years,
partly as a result of increased life expectancy, but also due to better detection and
increased participation in screening.2
The strongest risk factor for breast cancer is age, due to the prominent role of
cellular damage, or mutations, in the development of proliferation of cancer cells.6 As
women age and the number of cellular divisions take place over time, there is a greater
chance of improper division and damage to the DNA. The subsequent effect of the
damage in the mutated DNA is exacerbated in the diminished capability of cellular repair
mechanisms of older individuals.6 Furthermore, environmental exposures that accumulate
over time can result in DNA damage and alter DNA expression.227 According to the
American Cancer Society (ACS), the median age at breast cancer diagnosis in the U.S.
was 61 years old between 2008-2012.2 The Surveillance, Epidemiology, and End Results
(SEER) program estimated the age group with the highest percentage of incident cases is
between 55-64 years old using data from 2009-2013.228 Only 10.7% of all new cases
occur in women under the age of 45, whereas 68% of all new cases occur in women 55
years and older.228
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Annual age-adjusted incidence rates reported in the 2009-2013 SEER database
were highest among White women (128.0 per 100,000), with Black women experiencing
similar rates (125.2) during this time period.228 However, comparing White and Black
women, the ACS reported significantly higher rates of breast cancer among White
women between the ages of 60 to 84, and higher rates in Black women younger than 45.2
In addition to being diagnosed at younger ages, Black women are more likely to have
aggressive cases, such as triple negative, or advanced stage cancer and subsequently
higher breast cancer mortality over their lifetime compared to White women.228,229 Risk
of developing breast cancer is lower among Hispanics and Asian/Pacific Islanders
compared to Black and White women.2,228
Regardless of ethnicity or race, socioeconomic status has repeatedly shown a
positive association with breast cancer incidence, using education, income, or their
aggregate measure to define social class.229–231 More years of education and highest
degree obtained have both shown positive associations with breast cancer incidence,232–
234

as well as annual income234,235 and occupational supervisory rank.236 This association

is strongly influenced by screening behaviors, as shown in ACS data from 2010 where
the prevalence of a mammography within the past two years ranged from 24-28% less in
poor women (defined as 100-199% of poverty) compared to non-poor.206 Incidence is
lower and mortality is higher among women who reside in rural areas compared to urban
dwellers, due to the aforementioned reduced access to screening and detection at a more
advanced stage.237–239
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2.4.7 Tobacco use
Evidence of an association between smoking tobacco and breast cancer has been
suggestive but inconclusive.2 Some have hypothesized an association among those who
are heavy smokers, or who have been smoking for a long duration.2 A recent metaanalysis reported an 8% increase in risk of breast cancer when comparing current
smokers and never smokers using data from 27 prospective studies (RR: 1.08; 95 % CI:
1.02-1.14).240 When looking at passive smoking, a meta-analysis reported an increase in
risk (OR: 1.62; 95% CI: 1.39-1.85) but no association with active smoking.241 Together,
the results suggest tobacco smoke may play a role in developing breast cancer. The
predominant pathway by which tobacco smoking affects breast cancer is through
increased inflammation, along with the carcinogenic effects of tobacco smoke.242 Some
have identified associations between high levels of estrogen and smoking,12 while others
have reported an anti-estrogenic effect,243 and even associations with the 2-hydroxylation
pathway suggesting a beneficial alteration of estrogen metabolism with smoking.244
2.4.7 Lifestyle indices
There is evidence of an association between individual modifiable lifestyle
characteristics, such as PA and alcohol use, with development of postmenopausal breast
cancer. Lifestyle factors often cluster together in individuals who adopt healthy or
unhealthy lifestyle, so it may be beneficial to study lifestyle factors using a combined
lifestyle score.245 An a priori healthy lifestyle index score (HLIS) based on diet, tobacco
use, alcohol, PA and BMI reported 21% lower risk of breast cancer (HR: 0.79, 95% CI:
0.73-0.85) among the fourth, or most healthy group, compared to the second group in the
EPIC cohort.246 Application of the HLIS, with a slight modification of the diet to include
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fish, folate, glycemic index, and other breast cancer risk-specific dietary components also
showed an inverse association with postmenopausal breast cancer risk comparing the
highest category to the second (HR: 0.74; 95% CI: 0.66–0.83).16 The association was
strongest for ER-/PR- (HR: 0.60; 95% CI: 0.40-0.90) but also significant for ER+/+
breast cancer (HR: 0.81; 95% CI: 0.67-0.98).16 In both of the previously mentioned
HLIS’s, the second group served as the referent due to low numbers of individuals
adopting the healthiest behaviors for some of the scoring components in the first group.
Also using data from EPIC, a lifestyle score was developed to evaluate adherence to the
WCRF/AICR recommendations on body fatness, PA, energy dense foods and drinks,
plant foods, animal foods, alcohol use, and breastfeeding in women. Compared to the
lowest scores, all categories showed a significant inverse association with breast cancer,
with the strongest association in the highest scoring groups (HR: 0.84; 95% CI: 0.780.90).14 Adherence to WCRF/AICR recommendations and their association with breast
cancer risk has been studied in other populations, as well.247–249 In the Swedish
Mammography cohort, women who met at least six of the seven recommendations had
nearly half the risk (HR: 0.49; 95% CI: 0.35-0.70), with a greater reduction in ER+/PR+
subtypes compared to ER-/PR-.247 In the Iowa Women’s Health Study, an inverse
association was observed with postmenopausal breast cancer, and that association did not
differ in the presence of non-modifiable risk factors, such as taller height, family history
of breast cancer, or greater number of potentially fertile years.249
Some lifestyle scores have been developed for a specific study population. One
score was developed to assess increasing incidence of breast cancer among indigenous
women in New Zealand using 11 scoring criteria (red meat, protein, seafood, energy
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dense foods, solid fats, plant foods, smoking, exercise, BMI, and breastfeeding).250 No
association was observed among non-indigenous women but the highest lifestyle score
tertile had a significantly lower odds of breast cancer (OR: 0.47; 95% CI: 0.23-0.94)
compared to the lowest tertile among indigenous women.250 Investigators of a large casecontrol study of Mexican women developed a similar lifestyle score using the same five
components, except adherence to the “Western” diet was used to inversely derive the
dietary component.15 The authors reported an inverse association with breast cancer in
postmenopausal women (OR: 0.20, 95% CI: 0.11–0.37) when comparing the highest
versus lowest quintiles, with PA and alcohol use as the main contributors to the
association.
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CHAPTER 3
METHODS
3.1 Statement of aims and hypotheses
The overarching goal the dissertation work was to derive and evaluate a dietary
pattern based on estrogen metabolism in relation to postmenopausal breast cancer risk
solely as a dietary exposure and as part of an aggregate score for estrogen-related lifestyle
factors. We hypothesized that a dietary pattern that is characteristic of increased estrogen
exposure would be positively associated with postmenopausal breast cancer. An
aggregate lifestyle score representative of habits that are beneficial to estrogen
metabolism was hypothesized to be inversely associated with postmenopausal breast
cancer. We expected to see the strongest associations for ER+ cancer subtypes, with
effect modification by other estrogen-related risk factors for breast cancer.
In Aim #1, a dietary pattern was developed based on food groups associated with
various measures of estrogen metabolism, and was subsequently applied in a prospective
investigation into postmenopausal breast cancer risk. We hypothesized that diets high in
animal products, and low in vegetables and fiber would be associated with high
estrogenic potential, measured as a high ERDP score. Similar to the first aim, we
investigated an association between the ERDP with postmenopausal breast cancer risk in
Aim #2, but used a study population different from the one in which it was derived. In
both prospective investigations, using the PLCO and SS, we hypothesized a positive
association between the ERDP and incident breast cancer. We expected to see a stronger
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association among breast cancer cases that are ER+ compared to ER-. We also
hypothesized that the strongest association would be observed in strata of effect modifiers
assumed to lower estrogen exposure, such as leaner women compared to overweight
women, where the estrogenic effect of diet will have a larger relative influence. In Aim
#3, the ERDP was incorporated into the ERLS with alcohol intake, BMI, and PA, all of
which are hypothesized to influence estrogen metabolism. We hypothesized that higher
ERLS scores, representative of a lower collective estrogenic effect of lifestyle factors,
would be inversely associated with postmenopausal breast cancer. Like the ERDP, we
expected to see the largest magnitude of associations for ER+ cases, and among strata of
effect modifiers that have a smaller estrogenic effect.

3.2 Descriptions of the study populations
Multiple study populations, including a subset of one of the larger studies, were
used to complete the dissertation aims. Participants of PLCO were utilized in Aim #1 and
Aim #3. Derivation of the ERDP within Aim #1 took place in a subset of PLCO
participants with information on baseline serum EM concentrations, which is described in
detail after an overview of PLCO below. To examine the ERDP in a study population
external to the one in which it was developed, the SS was used in Aim #2. Detailed
descriptions can be found in the next three sections.
3.2.1 Prostate, Lung, Colorectal and Ovarian Screening Trial
An initiative of the NCI, the PLCO is a large population-based screening trial
designed to determine the effects of screening on cancer prognosis and mortality. Design
and implementation has been described in detail elsewhere.33 Briefly, participants were
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recruited between 1993 and 2001, with the intervention trial completing in 2006 and
follow up continuing through 2015. Recruitment of 76,685 men and 78,216 women aged
55 to 74 at enrollment took place at 10 different screening centers across the nation. After
randomization to the intervention arm, women participated in regular chest x-rays,
flexible sigmoidoscopy, CA-125 blood tests, and transvaginal ultrasound during the first
six years and were followed up for an additional seven years. Women were excluded at
recruitment if they had a history of lung, colorectal, or ovarian cancer. If women were
currently undergoing treatment for any previously diagnosed cancers, or if they were
participating in another screening or primary prevention trial, they were also excluded.
Prior to October 1996, women who previously had both ovaries surgically removed were
excluded from enrollment. Eligible participants underwent a physical examination and
filled out a questionnaire with information on demographics, medical history, family
history, lifestyle factors, and recent history of participation in screening examinations at
baseline.
For the dissertation work, only data from the 39,104 women randomized to the
intervention arm of the study, who participated in standard of care screening practices,
were used. Use of only women in the intervention arm is required for a couple of reasons.
First, the sample of women included in the nested case-control study with baseline serum
estrogen data were selected as a subset of the intervention arm. Additionally, only women
in the intervention arm were asked to complete the dietary questionnaire (DQX) at
baseline. A different dietary instrument, the diet history questionnaire (DHQ), began to
be administered to both arms of the study 3 years after baseline. Therefore, it would be
inappropriate to use the DHQ in an investigation of baseline serum estrogen levels due to
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the issue of temporality. Before any analytic exclusions were made, less than 15% of
women in the intervention arm self-identified as a racial/ethnic minority: 5.5% nonHispanic Black (n=2,170), 1.5% Hispanic (n=605), and 3.2% Asian (n=1,259).
3.2.1 PLCO nested case-control
A subset of postmenopausal women randomized to the intervention arm of PLCO
with information on serum EMs were included in the analyses to derive the ERDP.
Complete information on the nested study has been published elsewhere.35 Briefly, the
nested study population was drawn from all 1,141 incident breast cancer cases diagnosed
from the start of recruitment in 1993 through June 30, 2005, and a random sample of
1,141 control subjects. After excluding women who were not postmenopausal, were
using HRT at baseline, or had prior diagnoses of cancer, the sample was reduced to 390
cases and 453 controls. For the purposes of the present analysis, cases who were
diagnosed <2 years after serum sample donation (n=98) were excluded to avoid the
possibility of disease processes affecting estrogen levels. Women without a valid DQX
(n=77) or with implausible EM levels (i.e., if they were outside of 25th and 75th
percentile, plus/minus three times interquartile range; n=15) were further excluded. The
final analytic sample included 393 controls and 260 confirmed cases, with a mean of 5.25
years from sample donation to breast cancer diagnosis among cases. Use of some cases
served to increase the sample size for this aim and is justifiable because most breast
cancer cases are diagnosed without symptoms. Therefore, we believe their diets likely did
not change dramatically leading up to their diagnosis. Details of the laboratory methods
used are explained in section 3.3.
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3.2.3 Sister Study
The SS is a large prospective cohort study designed by the NIEHS to investigate
environmental and genetic determinants of breast cancer.34 A total of 50,884 women aged
35 to 74 who had a sister that was diagnosed with breast cancer were recruited between
2003 and 2009 from all 50 U.S. states and Puerto Rico. Community based recruitment
efforts were used through local volunteers, study participants, local and national events,
and extensive media campaigns. Recruitment strategies included attempts to enroll
women who were of racial/ethnic minorities, older age, and lower income. After
enrollment, baseline information was collected via Computer Aided Telephone Interview
(CATI) and self-completed risk factor questionnaires on demographics, dietary
information, lifestyle and medical history, and exposures from the prior 24 hours. Study
staff conducted a home visit to collect blood and urine samples, toenail clippings, and
dust collection from the home for environmental exposures. Anthropometric and blood
pressure measurements also took place at the home visit. All women are being followed
up for at least 10 years. Participants were contacted annually for brief health updates,
with a comprehensive follow-up questionnaire administered every two to three years.
A similar proportion of participants enrolled in SS identified as non-Hispanic
White (81.0%; n=42,558) as in the PLCO study population. The distribution of
racial/ethnic minorities was slightly different, however, with 8.5% identifying as nonHispanic Blacks (n=4,462) and 4.8% identifying as Hispanic (n=2,515). Over half of the
participants were aged 55 and older at baseline (50.97%). In the present work, all women
who contributed person-time after the onset of menopause with complete information
were used in the investigation of the ERDP and breast cancer.
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3.3 Dietary assessment
In PLCO, usual dietary intakes over the prior 12 months were collected via the
DQX, which is a 137-item food frequency questionnaire (FFQ) administered at baseline.
Over 82% of participants in the intervention arm completed the DQX. Dietary data in SS
was assessed using two different versions of the 110-item 1998 Block full diet FFQ.
Version 2 of the FFQ contains the same information as the first version, with additional
questions on organic foods, microwave use, restaurant and frozen foods – none of which
were used in the current dissertation work. Over 16% of SS participants completed
version 1, with another 81% completing version 2, totaling over 97% of participants with
dietary information.
A qualitative side-by-side comparison of dietary assessment tools used in PLCO
and SS showed strong agreement in the foods measured. Both study populations filled out
dietary information on usual food consumption, preparation methods, and supplement
use. Overall, both dietary assessment tools include the same foods with some minor
differences. The DQX had a larger number of line items dedicated to fruits and
vegetables than the Block FFQ. However, most of the fruits and vegetables in the DQX
are on the 1998 Block FFQ, just combined into fewer lines. Other minor differences
included a greater number of lines designed to assess grain intakes and nuts/seed
consumption on the 1998 Block FFQ. Both the DQX and 1998 Block FFQ used the
USDA’s National Nutrient Database for Standard Reference for nutrient analysis.
Usual intakes from the dietary assessment tools were categorized into 1 of 29
food groups based on the USDA’s My Pyramid Equivalents Database (MPED).251
Additional groups were added for cruciferous vegetables, coffee and tea because of their
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suggested influence on estrogen metabolism or breast cancer. A number of other groups
were omitted to reduce the redundancy of some commonly eaten foods. Namely, the
“total” groups for each section was excluded. For example, the “total fruits” group was
removed because of the foods that would be contained in the “total fruits” group are
accounted for in the “citrus fruits, melons, and berries” or the “other fruits” groups. In
total, 32 food groups were used. The food groups, presented in Table 3.1, were used as
the predictor variables in the RRR analysis, which is explained in greater detail in section
3.6.1.

3.4 Estrogen metabolite measurement
Serum samples collected at baseline and stored at −80°C from women in the
PLCO nested study were thawed at 4°C. The previously described LC/MS-MS assay was
used to concurrently quantify levels of 15 EMs. The parent estrogens were measured
along with their metabolites in the 2-, 4-, and 6-hydroxylation pathways make up the 15
EM (estrone, estradiol, 2OHE-1, 2-methoxyestrone, 2-hydroxyestradiol, 2methoxyestradiol, 2-hydroxyestrone-3-methyl ether, 4OE-1, 4-methoxyestrone, 4methoxyestradiol, 16OHE-1, estriol, 17-epiestriol, 16-ketoestradiol, and 16-epiestriol).
Quantification of the individual metabolic pathways allows for ratios of those pathways
to be used, which is potentially influential in the development of postmenopausal breast
cancer.11 The specifics of sample preparation and LC/MS-MS methods have been
described in greater detail elsewhere.41 An enzyme hydrolytic step is used to elucidate the
unconjugated and conjugated forms of parent estrogens. Quality control was assessed
using four samples which were inserted into each batch by blinded laboratory staff. The
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CV for all EMs was <5%, with even lower CV evident for the parent estrogens (<3%)
and unconjugated estradiol (<2%).35 Levels of EMs between 1–2 pmol/L were able to be
quantified in this population of postmenopausal women, with no EMs in the study at
undetectable readings.35

3.5 Breast cancer ascertainment
Incident breast cancer cases among postmenopausal women in PLCO were
identified primarily through self-report via annually mailed follow-up questionnaires, or
through the National Death Index, physician reports, state cancer registries, and next of
kin reports. Over 96% of the cases were confirmed through hospital records.252 Using
most recent follow-up data from PLCO, a total of 1,652 cases of breast cancer have been
ascertained over an average follow-up of about 11.5 years, with 1,316 of the cases
diagnosed as invasive (before analytic exclusions). Prior to 2007, breast cancer cases in
PLCO were confirmed from medical records with only information on diagnosis date and
codes from the second edition of the International Classification of Diseases for
Oncology. After 2007, a Breast Cancer Supplemental form was used to capture more
information, include ER status of the tumor. There was limited data on ER status of in
situ cases before the implementation of the supplemental form, as ER status was not
routinely assessed among in situ cases in the past. The supplemental form was available
for 98% of the cases. ER status was available for 70% of total cases (75% of invasive and
35% of in situ cases).
In the SS, incident breast cancer cases were ascertained via completion of annual
health updates, biennial surveys, and the National Death Index. Response rates for the
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surveys were over 94%.253 Medical record abstraction was used to confirm over 80% of
cases and to identify information on treatment and diagnosis, such as ER subtype.254
Agreement between self-reports and medical records were over 99% for total breast
cancer, invasive breast cancer and ER-positive breast cancer. Thus, self-reported
information is used when medical records were not obtained. Currently, 2,081 incident
postmenopausal cases (n=1,589 invasive) have been reported among SS participants
(before analytic exclusions).

3.6 Statistical approaches
The first step in the dissertation work was to develop the ERDP using data from
the nested PLCO study (Aim #1). After the ERDP was derived, it was applied in a
prospective investigation with postmenopausal breast cancer risk among women
randomized to the intervention arm of PLCO (Aim #1) and women enrolled in SS (Aim
#2). The final application of the ERDP in the dissertation work was incorporating it into
the ERLS (Aim #3). In a similar fashion to the ERDP, the ERLS was used in a
prospective investigation of an association with postmenopausal breast cancer risk among
women randomized to the intervention arm of PLCO (Aim #3). Development of the
ERDP and ERLS, along with a description of how they were used in prospective analyses
are described in the following sections. All statistical tests and models were performed in
SAS 9.4 (SAS Inc., Cary, NC) using two-sided tests with α=0.05.
3.6.1 Derivation of estrogen-related dietary pattern
Unconjugated estradiol and the 2/16 ratio were identified a priori for inclusion
because of the cumulative evidence, particularly from recent studies using the advanced
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LC/MS-MS, which has supported their role in the development of postmenopausal breast
cancer.11,35,84,255 Furthermore, these two EMs were associated with postmenopausal breast
cancer risk in the nested PLCO study used to derive the ERDP.35 It is hypothesized that
unconjugated estradiol the 2/16 ratio are representative of total exposure from circulating
estrogens as well as the competing metabolic pathways which are suspected to have
opposing influences with regards to breast cancer risk, respectively.11 The bulk of this
evidence, as well as biologic plausibility of the hypothesized relationships, have been
presented in section 2.1.
To identify foods that are correlated with unconjugated E2 and the 2/16 ratio,
RRR modeling was applied to the subsample of 653 participants with EM data. An
approach using RRR determines linear functions of predictors, which in the present case
are food groups, by maximizing the explained variation in multiple disease-specific
response variables, comprised of E2 and the 2/16 ratio.256 The primary benefit of using
RRR in nutritional epidemiology is it combines data-driven and hypothesis-driven
approaches into one.31 The hypothesis-driven aspect comes from the response variables
that are predefined by the investigators to be important mediators in disease risk. The
data-driven aspect comes from identification of predictor variables, or food groups,
which explain the greatest variation in EMs specific to our study population. Previous
comparisons of RRR with other data-driven methods, such as principal component
analysis, have shown stronger association with RRR in predicting cardiometabolic
diseases.31,257 A limitation of RRR is its dependence on selecting response variables that
are strongly associated with disease risk. If the response variables do not mediate disease
risk, it is unlikely an association between dietary factors and the disease endpoint will be
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identified. However, we believed there is clear and sufficient evidence of a strong
association between estrogen metabolism and breast cancer risk, as outlined in section
2.1.
In order to ensure RRR factors are based on how much variation in the outcome
they explain, all intakes are centered and scaled so that their mean ± standard deviation
(SD) is equal to 0 ± 1. Only the first factor was retained for development of the ERDP
because it represented a dietary pattern that explains the largest variation in the EM.
Initially, all 32 food groups were entered into the model at once. Those with a variable
importance in projection statistic (VIP) greater than 0.8 were retained and re-entered into
the RRR model, as they represented the food groups which are the strongest contributors
to RRR factors scores.258 RRR factors scores can only be calculated in participants with
EM data, therefore, to apply the ERDP to the full analytic populations in PLCO and SS,
we calculated the ERDP score so that it is perfectly correlated with the RRR factor scores
among the subsample. To do so, food group intakes were centered and scaled, then
multiplied by the corresponding model weight for each of the retained food groups,
which was then summed to calculate the total ERDP score. This same calculation method
was applied to score the ERDP for the full analytic cohorts in PLCO and SS. Scores with
higher ERDP values theoretically represent diets with the largest collective potential to
affect unconjugated E2 and the 2/16 ratio.
3.6.2 Estrogen-related lifestyle score
After the ERDP was derived and evaluated on its own, it was incorporated into
the ERLS. The other lifestyle components with sufficient evidence of an effect on
estrogen metabolism that completed the score were alcohol consumption, obesity status,
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and PA.12 The parameters used as criteria for scoring all of the components, with the
exception of the ERDP, were similar to those outlined in the WCRF/AICR Second Expert
Report, and the USDA’s 2015 DGA.13,25 Scoring criteria for the ERDP component was
based on the median score for the PLCO population. Women with a score greater than or
equal to the median received a 0, as those diets were hypothesized to be positively
associated with estrogen metabolism and subsequent breast cancer risk. Women with an
ERDP score below the median received a 1. Due to the strength of evidence for
associations between alcohol intake and obesity status with breast cancer risk, and robust
evidence of an estrogenic effect, they were given a stronger weight in the scoring of the
ERLS by assigning women to one of three levels instead of only two levels.13 For alcohol
intake, women who abstained from drinking (0 drink/week) were scored a 2; women who
consumed >0 to 7 drinks/week were scored a 1; and those who consumed >7 drinks/week
were scored a 0. Women were scored a 2 if they were normal weight (BMI <25.0 kg/m2),
a 1 if overweight (BMI 25.0-29.9 kg/m2), and 0 if obese (BMI ≥30.0 kg/m2). For PA,
women who reported >2 hours/week of vigorous PA were considered active and scored a
1, and those who reported ≤2 hours/week were scored a 0. The score for each of the four
different ERLS components was summed. Women with the minimum score of 0 were
hypothesized to have the largest risk profile, and those with a maximum of 6 were
hypothesized to have the lowest collective risk profile from estrogen-related lifestyle
factors. A summary of the ERLS scoring is portrayed in Table 3.2.
3.6.3 Prospective investigations
The methods used in the prospective application of the ERDP in both study
populations and of the ERLS in PLCO were principally the same. The primary exposure
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in Aims #1 and #2 was the ERDP, and the ERLS in Aim #3. The primary outcome for all
prospective investigations was postmenopausal breast cancer followed by investigations
of ER subtypes of postmenopausal breast cancer. Using descriptive statistics, study
participants for the full intervention arm of PLCO and SS were characterized in terms of
potential confounders and effect modifiers within strata of ERDP score quartiles in Aims
#1 and #2. In Aim #3, women from the intervention arm of PLCO were characterized by
categories of ERLS score (0-2; 3; 4; 5-6). Statistical comparisons of ERDP quartiles and
ERLS categories were performed using t-tests and chi-square tests for continuous and
categorical variables, respectively.
3.6.3a The ERDP
In time-to-event analyses, the association between breast cancer and ERDP scores
were determined in Aims #1 and #2. The lowest ERDP quartile served as the referent,
representing diets least associated with estrogen. Cox proportional hazards models were
used to analyze the relationship between ERDP scores and incident breast cancer events,
with person-time contributed as time scale variable. A test for the proportional hazards
assumption was performed by inclusion of an interaction term between exposure with
follow-up time, log of follow-up time, and was evaluated using Martingale-based
residuals. Estimates of associations were presented as HRs with 95% CIs. An initial
model was performed with adjustment for age and a second model adjusted for age and
total caloric intake. The third model included multivariable adjustment. Potential
confounders were selected based on a directed acyclic graph (DAG) for the hypothesized
relationship between the ERDP and postmenopausal breast cancer (Figures 3.2 & 3.3) as
well as evidence from the previous literature and model selection procedures. According
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to the DAG, age, education, PA, and BMI in young adulthood represent the minimally
sufficient set of confounders to include. Demographic factors of age, education,
race/ethnicity and study center were included in the multivariable-adjusted models, along
with total caloric intake for their putative roles as confounders for breast cancer. The
remaining covariates included in multivariable-adjusted models were chosen using
stepwise model selection for each of the aims with entry/exit criteria of p=0.2 to improve
model efficiency and reduce the potential for over adjustment. Potential confounders for
the stepwise model selection included: baseline BMI, BMI in young adulthood, HRT, OC
use, family history of breast cancer, smoking status, bilateral oophorectomy, prior
hysterectomy, parity, age at first birth, age at menarche, and age at menopause.
Categorization of each of the potential confounders are described in more detail in the
chapters corresponding to each aim (4, 5, & 6). Each of the previously described three
models were performed within strata of ER subtype. A competing risk model was
performed to assess a differential association for the ERDP on ER+ and ER- subtypes
using a Wald test for heterogeneity in the stratified Lunn-McNeil approach.259 A
sensitivity analysis was performed to evaluate BMI as a potential mediator in the
association between the ERDP and breast cancer. BMI was omitted from the full Cox
proportional hazards model in order to assess the potential for mediator bias. It is possible
BMI lies on the causal pathway between ERDP and breast cancer, as seen in Figure 3.2,
therefore adjusting for it would be inappropriate and introduce bias into the association.
Other sensitivity analyses related to the respective study populations were also conducted
and are described further in the chapters corresponding to each analytic aim.
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Lastly, the role of potential effect modifiers was assessed in the final Cox
proportional hazards models. It is hypothesized that other estrogen-related risk factors
may modify the association between the ERDP and breast cancer as a result of their
relative estrogenic effects. To assess effect modification, an interaction term was
included in the model between the ERDP and the following risk factors: BMI, HRT,
alcohol consumption, parity, and PA.
Unmeasured confounding may introduce bias into epidemiologic investigations.
While the PLCO and SS collected data on all known risk factors for breast cancer, it is
possible that early life nutritional factors may confound the relationship between the
ERDP and breast cancer. The SS has information on early life diet, but PLCO does not.
Therefore, we planned to use effect estimates between early life diet in SS to estimate the
potential for unmeasured confounding in PLCO using the methods proposed by
VanderWeele et al.260 However, intake of meat, plant, and fish servings at age 10 were
not associated with postmenopausal breast cancer in SS, nor was a vegetarian diet before
the age of 21 associated (data not shown), therefore these methods were not applied. It is
possible that the recall of intake at these younger ages was afflicted by measurement
error, which may partially explain the null associations and would argue for pursuing
unmeasured confounding analyses. However, this type of analyses requires the estimation
of effect for the unmeasured confounders which is difficult to assess from the available
literature. Furthermore, both study populations contained data on BMI as a young adult,
which has been shown to have an inverse association with breast cancer.24 Therefore, we
were able to account for one early life nutritional factor with a known influence on breast
cancer risk.
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3.6.3b The ERLS
Many of the same techniques used to investigate the ERDP in Aims #1 and #2
were used to investigate the ERLS in Aim #3, with slight differences with respect to
confounders and effect modifiers. Again, a time-to-event analysis was performed with
person-time contributed as time scale variable and the lowest ERLS scores of 0-2 as the
referent. According to the DAG, age, BMI at young adulthood, education, and
race/ethnicity are the minimally sufficient set needed for adjustment. Three different Cox
proportional hazards models were performed: an initial model with adjustment for age, a
second model with adjustment for age and total caloric intake, and a final model with
multivariable adjustment for potential confounders. The same approach to confounders
outlined above in the ERDP studies was used, with the exception of those included in the
development of the ERLS (alcohol, BMI, and PA). As with the ERDP, the previously
described three models were performed within strata of ER subtype in order to assess a
differential effect using a competing risk model, and effect modification by other
potential estrogen-related risk factors was evaluated using a stratified approach.
3.6.3c Power Calculations
Estimates for statistical power over a range of effect sizes and baseline
probabilities of disease are displayed in Table 3.3. The NCI’s Power software was
utilized in all calculations, with α=0.05.261 The analytic study population, described in
section 4.3.1 includes 27,488 participants. The analytic population in SS, as described in
section 5.3.1, includes 37,752. As shown in the table, we had sufficient power to detect
moderately small effect sizes (≥1.2) across a range of baseline disease probabilities. The
baseline probability of breast cancer in both populations is around 6%.
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3.7 Limitations and strengths
The present work was susceptible to minor, yet reconcilable limitations. As with
most prospective nutritional epidemiologic studies, there was the potential for bias due to
the selection of subjects, loss to follow-up, and dietary measurement error. Although
FFQs may not generate accurate estimates for absolute intakes of nutrients, they have
been shown to be effective in ranking individuals, as was the purpose in this study.173 As
previously mentioned, the two different FFQs used in the PLCO and SS may introduce
some bias as a result of slight differences in the measurement of certain foods. There is
always potential for unmeasured confounding, but the use of studies designed to
investigate relationships with cancer helped to provide complete information on any
known confounders.
It was possible the food pattern derived from a subsample of PLCO participants
would not result in an association with breast cancer risk in the full PLCO screening arm.
However, we planned to test the association in the SS to see if a lack of an association
held true for another group of women. If no association was identified in both the PLCO
and SS, it was possible the ERDP may still contribute to risk as a part of a lifestyle score,
which was evaluated in Aim #3. It also is possible that the ERDP does not explain
enough variation in EMs to influence breast cancer risk on its own, therefore we
incorporated it into a lifestyle score to assess its influence with other estrogen-related risk
factors. A minor limitation in regards to study populations was the lack of heterogeneity
of race and ethnicities. However, our populations are predominately non-Hispanic White
women, who experience the highest incidence of breast cancer so our results have public
health significance.
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There are many strengths in the approach and design to offset some of the
limitations in the proposed research. The use of large, prospective cancer cohorts allowed
for the associations of interest to be investigated with complete information on known
confounders and enough power to detect moderately small effects. The application of
RRR to derive the ERDP has shown larger associations than other data-driven methods in
nutritional epidemiology while also incorporating hypothesized pathogenic
pathways.31,257 A major improvement upon the previous estrogen-correlated dietary
pattern was in our assessment of EMs. EMs were measured using a more sensitive assay,
and EMs which have been shown to be most strongly related to breast cancer risk were
used in the RRR.
The resulting information from the proposed dissertation work will help to
address a critical gap in translational breast cancer research. The burden of breast cancer
is far-reaching, as it remains the most frequently diagnosed cancer and one of the most
fatal cancers among women.2 There is still a major need to identify primary prevention
methods for breast cancer, and investigations into diet to date have been inconclusive.43
Derivation of a dietary pattern evaluating the influence of diet as a whole based on a
plausible mechanistic pathway may help to resolve the inconsistencies in previous
studies. Overall, the present dissertation research contributes much-needed information
about risk factors for a relatively common cancer among women, and potentially
identifies novel intervention targets for primary prevention
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3.8

Tables and figures

Table 3.1 Food groups used in the development of the estrogen related dietary pattern
(ERDP)
Food Group
Whole grain
Non-whole/refined grain
Dark-green vegetables
Cruciferous vegetables
Orange vegetables
White potatoes
Other starchy vegetables
Tomatoes
Other vegetables
Citrus fruits, melons, and berries
Other fruits
Milk
Yogurt
Cheese
Meat (beef, pork, veal, lamb, game)
Organ meats (meat, poultry)
Frankfurters and luncheon meats
Poultry
Fish and shellfish high in ω-3 fatty acids
Fish and shellfish low in ω-3 fatty acids
Eggs
Cooked dry beans and peas
Soybean products
Nuts and seeds
Discretionary oil
Discretionary solid fat
Added sugars
Beer
Liquor
Wine
Tea
Coffee

Units/day
ounces
ounces
cups
cups
cups
cups
cups
cups
cups
cups
cups
cups
cups
cups
ounces
ounces
ounces
ounces
ounces
ounces
ounces
cups
ounces
ounces
grams
grams
teaspoons
drinks
drinks
drinks
cups
cups

ERDP: estrogen-related dietary pattern; MPED: My Pyramid
Equivalents Database.
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Table 3.2 Scoring parameters for estrogen-related lifestyle score (ERLS)
ERLS factor
ERDP

Score
0
1

Description
≥ median ERDP score
< median ERDP score

Alcohol use

0
1
2

Heavy: >7 drinks/week
Moderate: >0 to 7 drinks/week
Abstainer: 0 drinks/week

Weight Status

0
1
2

Obese: BMI ≥30 kg/m2
Overweight: BMI 25.0-29.9 kg/m2
Normal weight: BMI <25 kg/m2

Physical Activity (PA)

0
1

Inactive: ≤2 hours/week of vigorous PA
Active: >2 hours/week of vigorous PA

BMI: body mass index; ERDP: estrogen related dietary pattern; ERLS: estrogen related lifestyle score;
PA: physical activity
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Table 3.3 Power calculationsa
Baseline Probability of Breast Cancer
Study
PLCO

SSS

Effect size

0.04

0.05

0.06

0.07

1.1
1.2
1.3
1.1
1.2
1.3

0.25
0.72
0.99
0.33
0.84
0.98

0.30
0.80
0.99
0.39
0.91
>0.99

0.35
0.86
>0.99
0.45
0.95
>0.99

0.39
0.91
>0.99
0.41
0.97
>0.99

ERDP: estrogen-related dietary pattern; ERLS: estrogen-related lifestyle
score; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial; SS: The Sister Study.
a
α=0.05; PLCO n=27,488; SS=37,752;
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Figure 3.1 Estrogen synthesis and metabolisma
a

Adapted from Furhman et al.35
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Figure 3.2 Directed acyclic graph for the association between ERDP and postmenopausal
breast cancera
BMI: body mass index; ERDP: estrogen-related dietary pattern; HRT: hormone
replacement therapy; OC: oral contraceptive; PA: Physical activity.
a
Parity, age at menarche, age at menopause, age at first birth, and
oophorectomy/hysterectomy are included in reproductive factors.
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Figure 3.3 Directed acyclic graph for the association between ERLS and postmenopausal
breast cancera
BMI: body mass index; ERDP: estrogen-related dietary pattern; ERLS: estrogen-related
lifestyle score; HRT: hormone replacement therapy; OC: oral contraceptive; PA: Physical
activity.
a
Parity, age at menarche, age at menopause, age at first birth, and
oophorectomy/hysterectomy are included in reproductive factors.
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4.1

Abstract

Increased exposure to estrogen is an established risk factor for postmenopausal breast
cancer, and dietary factors have been shown to influence estrogen metabolism. However,
investigations of diet and breast cancer have been inconclusive. We developed a dietary
pattern associated with levels of unconjugated estradiol and the ratio of 2- and 16hydroxylated estrogen metabolites in a subsample of Prostate, Lung, Colorectal and
Ovarian Screening Trial (PLCO) participants (n=653) using reduced rank regression, and
examined its association with postmenopausal breast cancer prospectively in the larger
PLCO cohort (n=27,488). The newly developed estrogen-related dietary pattern (ERDP)
was comprised of foods with positively weighted intakes (non-whole/refined grains,
tomatoes, cruciferous vegetables, cheese, fish/shellfish high in ω-3 fatty acids,
franks/luncheon meats) and foods with negatively weighted intakes (nuts and seeds, other
vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, coffee). A 1-unit increase in the
ERDP score was associated with a 9%, 13%, and 13% increase in total breast cancer risk
(HR: 1.09, 95%CI: 1.01-1.18), invasive (HR: 1.13; 95%CI: 1.04=1.04-1.24) and estrogen
receptor (ER)-positive (HR: 1.13, 95%CI: 1.02- 1.24) breast cancer, respectively, after
adjustment for confounders. Associations were seen for the fourth quartile of ERDP for
overall breast cancer (HR: 1.14; 95% CI: 0.98, 1.32), invasive cases (HR: 1.20, 95%CI:
1.02, 1.42) and ER -positive cases (HR: 1.19; 95%CI: 0.99-1.41) compared to the first.
The increased risk associated with increasing ERDP score was more apparent in strata of
some effect modifiers (non-hormone replacement therapy users and non-obese
participants) where the relative estrogen exposure due to that factor was lowest. Our
results suggest a dietary pattern based on EM is positively associated with
postmenopausal breast cancer risk, possibly through an estrogenic influence.
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4.2

Introduction
Breast cancer, the most commonly diagnosed cancer among women worldwide, is

a disease of strong hormonal influence.1 Serum and urinary levels of estrogen metabolites
(EMs) have consistently been associated with postmenopausal breast cancer risk in
prospective studies.11 Therefore, modifiable lifestyle risk factors for postmenopausal
breast cancer that are associated with estrogen metabolism may present opportunities for
primary prevention.
Diet is commonly studied as a point of intervention for reducing cancer risk,
however there have been conflicting results in dietary investigations into breast cancer
risk, with the exception of alcohol which is considered an established risk factor.17–19,24 It
is likely that the practice of studying dietary components in isolation may contribute to
the inconclusive findings for associations with breast cancer, as it does not take into
account the interactions between nutrients and phytochemicals.25 Therefore, it is
beneficial to study diet in its entirety using dietary pattern analyses when investigating a
potential association with breast cancer.26 Emerging evidence has supported an
association between some dietary patterns and incident breast cancer risk.17,18,27 Many of
the diets that have indicated an inverse relationship with breast cancer are characterized
by high intakes of fruits and vegetables, and diets with increased risk typically have
higher intakes of fat and animal products.17,21,28
In order to address some of the inconclusive findings in the literature on diet and
breast cancer, it may be advantageous to consider the mechanistic pathway by which a
potential association may occur. Nutritional factors can influence many hormonal
processes in women, such as the development of breasts, and the onset of both menarche
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and menopause.29,30 Therefore, diet may have a role in altering estrogen metabolism and
subsequently breast cancer risk, although data on the relationship between diet and
estrogen metabolism is scarce.13 A relatively new approach to dietary pattern analyses,
reduced rank regression (RRR), allows for the use of biomarkers, such as EMs, in
developing a dietary pattern that can then be investigated in association with disease
endpoints.31 Previously, Fung et al. developed a dietary pattern correlated with serum
levels of estradiol and estrone sulfate using RRR, but the pattern subsequently was not
associated with breast cancer among postmenopausal women in the Nurses’ Health Study
(NHS).32 However, application of the same estrogen-correlated dietary pattern in a
Swedish cohort identified a positive association with incident breast cancer.27
In the present analysis, we used RRR to develop a dietary pattern that is
associated with EMs that are hypothesized to be associated with breast cancer risk. Using
a liquid chromatography-tandem mass spectrometry assay (LC/MS-MS), 15 EMs can be
measured in an accurate and reproducible method with enough sensitivity to detect the
low levels present in postmenopausal women.262 Measurement of the parent estrogens’
downstream EMs allows for ratios of competing metabolic pathways to be quantified.
There is evidence that 2-hydroxylation of the parent estrogens is inversely associated, and
16-hydroxylation is positively associated with postmenopausal breast cancer.11 Therefore,
increases in the ratio of 2- to 16-hydroxylated EMs (2/16) is hypothesized to indicate a
beneficial shift in estrogen metabolism with respect to breast cancer risk.11 Based on this
evidence, and established evidence linking unconjugated estradiol (E2) to
postmenopausal breast cancer risk,11,57 we used RRR to develop a dietary pattern
associated with 2/16 and E2. This newly developed estrogen related dietary pattern
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(ERDP) was applied in a prospective cohort of women to examine an association with
total postmenopausal breast cancer and by estrogen-receptor (ER) subtype. The potential
for effect modification by other estrogen-related risk factors was examined.

4.3

Methods

4.3.1 Study Population
The Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial (PLCO) is a
large population-based trial designed to determine the effects of screening on cancer
prognosis and mortality. Design and implementation has been described in detail
elsewhere.33 Briefly, 76,685 men and 78,216 women aged 55 to 74 were recruited at 10
different screening centers across the United States between 1993 and 2001. Eligible
participants underwent a physical examination and filled out a questionnaire with
information on demographics, medical history, family history, lifestyle factors, and recent
history of participation in screening examinations at baseline. Follow-up continued for 13
years or until December 31, 2009. For the current study, the analysis was restricted to
screening arm participants (n=39,104) as this group provided blood samples used for
assessing estrogen metabolites and were asked to complete the dietary instrument (DQX).
Over 82% of participants in the screening arm completed the DQX. The population was
further limited to women who completed the baseline questionnaire, a valid DQX (caloric
intake between 1st and 99th percentiles, <8 missing line items), and without a personal
history of cancer (n=28,438). Participants were further excluded if they had an extreme
body mass index (BMI) (<15 or >55 kg/m2; n=74), if they did not contribute any
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person-time (n=58) or were missing covariate data (n=818), bringing the final analytic
sample to 27,488.

4.3.2 Subsample and EM Assay
A subset of postmenopausal women randomized to the screening arm of PLCO
for whom information on serum EMs was available was utilized to derive the ERDP.
Complete information on the nested study has been published elsewhere.35 Briefly, the
nested study population was drawn from all 1,141 incident breast cancer cases diagnosed
from the start of recruitment in 1993 through June 30, 2005, and a random sample of
1,141 control subjects. After excluding women who were not postmenopausal, were
using hormone replacement therapy (HRT) at baseline, or had prior diagnoses of cancer,
the sample was reduced to 390 cases and 453 controls. For the purposes of the present
analysis, cases who were diagnosed <2 years after serum sample donation (n=98) were
excluded to avoid the possibility of disease processes affecting estrogen levels. Women
without a valid DQX (n=77) or with implausible EM levels (i.e., if they were outside of
25th and 75th percentile, plus/minus three times interquartile range; n=15) were further
excluded. The final analytic sample for the RRR procedure included 393 controls and 260
subsequent cases, with a mean of 5.25 years from sample donation to breast cancer
diagnosis.
Serum samples from women in the subsample were collected at baseline, stored at
−80°C and were thawed at 4°C. The LC/MS-MS assay was used to measure the parent
estrogens along with their metabolites in the 2-, 4-, and 16-hydroxylation pathways, for a
total of15 EMs. The specifics of sample preparation and LC/MS-MS methods have been
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described elsewhere.41 The coefficient of variation for all EMs was <5%, with even lower
coefficients evident for the parent estrogens (<3%) and E2 (<2%).35

4.3.2 Dietary Measurement
The DQX, a 137-item food frequency questionnaire, was designed specifically for
PLCO and asked about typical frequency of intake over the past year. Typical portion
size was assessed for 77 of the items. Nutrient and food intake amounts were calculated
using US dietary data and the pyramid food group servings database from the US
Department of Agriculture (USDA).263 Food and nutrient values were used to create food
groups based on the USDA’s My Pyramid Equivalents Database (MPED), with
additional groups created for cruciferous vegetables, tea, and coffee.251 The 32 groups
used in the present analysis are shown in Table 3.1.

4.3.4 Breast Cancer Ascertainment
Incident breast cancer cases were identified primarily through self-report via
annually mailed follow-up questionnaires. Other sources of ascertainment included the
National Death Index, physician reports, state cancer registries, and next of kin reports.
Over 96% of the cases were confirmed through hospital records.252 In the analytic cohort,
a total of 1,569 incident breast cancer cases occurred. A supplemental form was
implemented in 2007 to capture more detailed information about the diagnosis, available
for 98% of cases.
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4.3.5 Development of the ERDP
To identify foods that are correlated with unconjugated E2 and the 2/16 ratio,
RRR modeling was applied to the subsample of 653 participants with EM data. An
approach using RRR determines linear functions of predictors, which in the present case
are food groups, by maximizing the explained variation in multiple disease-specific
response variables, comprised of E2 and the 2/16 ratio.256 In order to ensure RRR factors
are based on how much variation in the outcome they explain, all intakes were centered
and scaled so that their mean ± standard deviation (SD) is equal to 0 ± 1. Only the first
factor was retained for development of the ERDP because it represented a dietary pattern
that explained the largest variation in the EM. Initially, all 32 food groups were entered
into the model at once. Those with a variable importance in projection statistic (VIP)
greater than 0.8 were retained and re-entered into the RRR model, as they represent the
food groups which are the strongest contributors to RRR factors scores.258 The model
weights were extracted from the final RRR model from PROC PLS and SAS version 9.4
(SAS Inc., Cary, NC). To calculate the ERDP score in the full analytic PLCO cohort
food group intakes were centered and scaled, then multiplied by their corresponding
model weights (Table 4.1) for each of the retained food groups. The total ERDP score
was calculated by summing over the weighted intakes. This same calculation method was
applied to score the ERDP for the full analytic cohort.

4.3.6 Statistical Analysis
Baseline comparisons of participant characteristics by ERDP quartiles were
performed using t-tests and chi-square tests for continuous and categorical variables,
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respectively. Cox proportional hazards models were applied to prospectively analyze the
relationship between ERDP scores and incident breast cancer events, with person-time
contributed as a time scale variable. ERDP scores were categorized into quartiles, with
the first quartile set as the referent. The first quartile hypothetically represents diets with
an estrogen profile associated with the lowest breast cancer risk (low levels of
unconjugated E2 and high 2/16 ratio). The hazard ratio and 95%CI also were calculated
for the continuous ERDP score variable, and the p-value reported as a test for trend.
Covariates for multivariable adjusted models were chosen using stepwise model selection
with entry/exit criteria of p=0.2. We adjusted for age (years), HRT use (current; former;
never), body mass index (BMI) (kg/m2), alcohol consumption (abstainer; 1-7; >7
drinks/week), family history of breast cancer (yes; no), education (less than high school;
high school and some college; college degree; graduate degree), bilateral oophorectomy
(yes; no), parity (6 categories), age at menopause (5 categories), hours of vigorous
physical activity per week (6 categories), and total energy intake (kcal/day). Age at first
birth, age at menarche, oral contraceptive use, race/ethnicity, smoking status, and prior
hysterectomy were also considered as potential confounders but were not included after
performing the stepwise model selection. The potential for effect modification by BMI
(18.5-29.9 kg/m2; ≥30 kg/m2), baseline HRT use (yes; no), alcohol consumption (<1
drink/week; ≥1/week), parity (nulliparous; parous), and vigorous physical activity per
week (<2 hours; ≥2 hours) was assessed using a multiplicative interaction term in the
model. All models were performed with overall breast cancer and by ER subtype. A
competing risk model was used to assess a differential association for the ERDP on ER+
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and ER- subtypes using a Wald test for heterogeneity in the stratified Lunn-McNeil
approach.259

4.4

Results
Unconjugated E2 and the 2/16 ratio were moderately and inversely correlated (r=

-0.51; p<0.0001) in the subsample of 653 women. After applying the VIP criteria, 11
food groups with a VIP >0.8 were retained and re-entered into the RRR procedure. The
final list of food groups included in the ERDP is shown in Table 4.1. Overall, 4.9% of
the variation in the EMs was explained by the ERDP. Intakes of non-whole/refined
grains, tomatoes, cruciferous vegetables, cheese, fish/shellfish high in ω-3 fatty acids, and
franks/luncheon meats were added; and intakes of nuts and seeds, other vegetables,
fish/shellfish low in ω-3 fatty acids, yogurt, and coffee were subtracted to calculate the
ERDP score. The “other vegetables” group includes vegetables except for tomatoes,
potatoes and orange, dark leafy, cruciferous, and starchy vegetables. For example, this
group includes cucumber, onion, green pepper, beet, celery, and lettuce. The resulting
ERDP scores were weakly but significantly correlated with unconjugated E2 (r=0.27;
p<0.0001) and the 2/16 ratio (r=-0.16; p<0.0001) (Table 4.2). When considering the
intakes of ERDP food groups, the strongest correlates with unconjugated E2 were nonwhole/refined grains (r=.10; p=0.01), cheese (r=0.16; p<0.0001), yogurt (r=-0.10;
p=0.01), and franks/luncheon meats (r=0.11; p=0.001). Only intakes for nonwhole/refined grains (r=-0.09; p=0.02) and cheese (r=-0.08; p=0.05) were significantly
correlated with the 2/16 ratio. Increasing ERDP scores are positively correlated with
unconjugated E2 and negatively correlated with the 2/16 ratio.
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Table 4.1 compares the mean intakes of included food groups across extreme
quartiles of unconjugated E2 and the 2/16 ratio. On average, participants in the highest
quartile of unconjugated E2 consumed higher amounts of non-whole/refined grains (4.45
vs. 3.90; p=0.01), cheese (0.43 vs. 0.29; p<0.01), and franks/luncheon meats (0.34 vs.
0.21; p=0.01) compared to participants in the first quartile. Mean consumption of coffee
(2.30 vs. 3.09; p=0.04) and yogurt (0.08 vs 0.12; p=0.03) were significantly lower among
participants in the highest quartile of unconjugated E2 compared to the first. There were
no significant differences in mean intakes when comparing extreme quartiles of the 2/16
ratio.
There were 1,592 confirmed incident cases of breast cancer (n=1,248 invasive)
over an average follow-up of 10.9 years. Among the cases, 1,097 were ER+ and 189 were
ER-. The mean ± SD ERDP score was -0.006± 0.646 with a range of -4.515 to 6.578.
Women who were diagnosed with breast cancer during follow-up had significantly higher
mean ERDP scores at baseline compared to women who were not diagnosed during
follow-up (0.037 vs. -0.009, respectively; p=0.006). Baseline characteristics for the full
analytic cohort, stratified by ERDP quartiles, are shown in Table 4.3. There was a
stepwise increase in the number of total cases from the first to fourth quartiles although
the differences across quartiles was not significant (p=0.12). Women in the fourth
quartile of the ERDP were younger, had a higher mean BMI, higher daily caloric intake,
were more likely to have had a bilateral oophorectomy, and were more likely to be nonHispanic White compared to women in the first quartile. There was no clear trend for
alcohol, with a higher proportion of both abstainers and heavier drinkers in the highest
quartile of ERDP. A similar pattern was seen for physical activity. There were no
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differences in HRT use, parity, family history of breast cancer, or age at menopause
across ERDP quartiles. Participants in the highest quartile of ERDP score consumed the
most non-whole/refined grains, tomatoes, cheese, and franks/luncheon meats. On the
contrary, participants in the lowest quartile consumed the most coffee, nuts and seeds,
fish/shellfish low in ω-3 fatty acids, yogurt, and other vegetables.
Results from the time-to-event analyses are shown in Table 4.4. In models using
ERDP quartiles, participants in the fourth quartile were at increased risk of
postmenopausal total breast cancer (HR: 1.14; 95% CI: 0.98, 1.32) and invasive breast
cancer (HR: 1.20; 95%CI: 1.02, 1.42) after multivariable adjustment. All quartiles were
positively associated with risk, with increasing magnitude of effect estimates with
increasing quartiles, compared to the first for total (p-trend=0.04) and invasive breast
cancer (p-trend=0.005). The continuous ERDP variable was positively associated with
total and invasive breast cancer risk. A 1-unit increase in ERDP was associated with a 9%
increase in risk (HR: 1.09; 95% CI: 1.01, 1.18) for total and 13% increase in risk for
invasive (HR: 1.13; 95%CI: 1.04, 1.24) after multivariable adjustment.
The ERDP was associated with ER+ but not ER- breast cancer (Table 4.4). The
multivariable effect estimates for continuous ERDP were 1.13 (95%CI: 1.02-1.24; ptrend=0.02) and 1.07 (95%CI: 0.85-1.35; p-trend=0.54), respectively. The competing risk
model did not indicate evidence of a differential effect of the ERDP by ER subtypes
(p=0.87; data not shown).
There was no evidence for effect modification by alcohol consumption and PA.
However, there was some indication that HRT, BMI, and parity may modify the effect of
the ERDP (Table 4.5). In stratified results, estimates of association were higher in strata
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of some effect modifiers where estrogen exposure is thought to be lowest (e.g., among
HRT non-users, and participants with lower BMI). In the case of parity, estimates were
higher in nulliparous women.

4.5

Discussion
We developed a dietary pattern that was significantly associated with serum levels

of unconjugated E2 and the 2/16 ratio in postmenopausal women. Intakes of nonwhole/refined grains, cheese, franks/luncheon meats, and yogurt were most strongly
correlated with the derived pattern. When applied in a prospective cohort of women, the
ERDP was positively associated with total and invasive postmenopausal breast cancer
risk, and the association was present in ER+ but not ER- breast cancer. The risk
associated with high ERDP scores was higher within strata of some effect modifiers
hypothesized to have lower exposure to estrogen. These results suggest that women who
consume a diet that adheres to higher ERDP scores may be at moderately increased risk
of developing postmenopausal breast cancer, possibly through an influence on estrogen
metabolism.
This is the first study to develop a dietary pattern based on estrogen metabolism
that is specific to breast cancer risk, due to inclusion of the 2/16 ratio. Quantification of
estrogen’s downstream metabolic pathways that may be indicative of breast cancer risk
was possible through use of a highly sensitive LC/MS-MS assay. Previously, Fung et al.
used RRR to derive a dietary pattern correlated to estradiol and estrone sulfate. High
scores for the pattern were characterized by high intakes of red meat, legumes, and pizza;
and low intakes of whole grains and coffee. In the MPED food groups used in the ERDP,
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food items that make up mixed dishes are decomposed into their individual food groups,
(for example, pizza is decomposed into cheese, tomatoes, and refined grains). We
observed moderate similarities between the ERDP and Fung et al.’s estrogen pattern with
regard to cheese and tomatoes (in the form of pizza in Fung et al.’s pattern), coffee, and
their respective directions of association with the derived patterns. Fung et al. observed
an inverse association between whole grains and estrogen, and although whole grains
were not a significant contributor to the ERDP, non-whole/refined grains had a
significant positive association, suggesting the importance of choosing whole grains and
limiting processed grains.
Other literature on dietary patterns and estrogen metabolism is scarce. However,
the Alternate Healthy Eating Index and the Western pattern, comprised of processed
foods and animal products, have been inversely and positively associated with estradiol,
respectively.144 An intervention study using the Mediterranean Diet, usually high in fruits
and vegetables, legumes, oils, and other foods that result in a higher proportion of
unsaturated fats compared to saturated fats, reported a roughly 40% decrease in total
urinary estrogen levels (p<0.02) in postmenopausal women, showing some antiestrogenic properties.147 Although there is evidence linking alcohol52 and soy products130
with estrogen metabolism, they were not included in the ERDP because they failed to
meet the inclusion criteria of a VIP >0.8 in the first RRR model. This indicated these
groups did not explain a large enough variation in the EMs, possibly due to a small range
of intakes for these groups in our subsample of women.
Evidence of a moderate but significant association between the ERDP and
postmenopausal breast cancer was observed in our study population. A significant
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association was limited to ER+ subtypes, possibly due to an influence on estrogen
metabolism. Fung et al.’s estrogen diet pattern was not associated with total
postmenopausal breast or ER subtype-specific cancer risk in NHS,32 which the authors
concluded was a result of the low correlation between their pattern and the estrogens
(r=0.22 and r=0.24 for estradiol and estrone sulfate, respectively), which may be
insufficient to affect breast cancer risk. However, when the same pattern was applied in
the Swedish Mammography Cohort (SMC) a 29% increase in risk of developing breast
cancer (HR: 1.29; 95% CI: 1.08, 1.55) was observed when comparing women in the
highest quartile with the lowest, and no heterogeneity was observed between the ER
subtypes.27 The authors cited a wider range of intakes, higher consumption of coffee, and
lower levels of other breast cancer risk factors in SMC as reasons for results that differed
from the NHS. Our results are consistent with those of the SMC. Explanations for
different results between the previous studies and ours are difficult to discern because of
our use of different EMs which resulted in a different dietary pattern. The use of LC/MSMS to accurately quantify the EMs, and inclusion of the 2/16 ratio that has more
consistently been associated with breast cancer risk than other EMs is a strength of our
investigation.
Qualitative evidence of effect modification by HRT, BMI, and parity in the
association between the ERDP and postmenopausal breast cancer risk was observed.
Based on prior evidence, we expect women who are not using HRT or who are not obese
to have lower lifetime exposure to estrogen.67 In these women, a dietary influence,
through estrogen or other pathway may be easier to detect than in women with higher
lifetime estrogen exposure. In the NHS, no effect modification by BMI was observed
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using their estrogen correlated dietary pattern, though other effect modifiers were not
examined.32 It is possible a woman’s nulliparity is a result of low fertility due to low
hormone levels.264 However, nulliparous women typically experience more menstrual
cycles, resulting in greater lifetime exposure to estrogen and higher breast cancer risk,219
therefore these results need to be explored further.
There are multiple possible mechanisms by which the ERDP effects estrogen
metabolism and breast cancer risk, such as through influences on microbiome
diversity.265 The intestinal microbiome is strongly influenced by dietary behaviors, and
the composition of the microbiome can have implications on many important
physiological processes.266 The fate of conjugated, or inactive, estrogens is dependent on
the state of the intestinal microbiome, which influences whether or not the conjugated
estrogens are excreted through feces or transformed to their unconjugated forms and
subsequently reabsorbed.267 If reabsorbed, there is a greater estrogenic exposure
throughout the body. Therefore, diet may influence development of a microbiome that is
favorable to excretion of estrogens, lowering breast cancer risk, or one that is conducive
to reabsorption of the estrogens which increases risk. In addition to absolute exposure to
estrogen, the composition of EMs is also influenced by the micriobiome.268 More
specifically, there is evidence of microbial effects on interconversions of the parent
estrogens and hydroxylation down the 16-pathway from in vitro and human studies.269,270
The intestinal microbiome is strongly influenced by fiber intake, or lack thereof, through
consumption of grains and vegetables, both of which are included in the ERDP.266 The
ERDP also is comprised of animal products, such as meats, cheese, and yogurt, which
can impact microbiome diversity.271–273 Considering the presence of a microbial influence
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on estrogen metabolism and its established relationship with diet, modification of the
intestinal microbiome is a plausible mechanism by which the ERDP influences estrogen
metabolism and breast cancer risk.
Considering other mechanisms, it is possible the ERDP was associated with breast
cancer through effects on inflammation. Coffee, as well as processed meats, dairy, and
refined grains which are common in the Western diet, have all exhibited associations with
inflammation,274,275 and inflammation may play a role in mammary tumor
development.276 The Mediterranean Diet, characterized by foods with anti-inflammatory
properties has been inversely associated with breast cancer,48 and a dietary pattern based
on inflammatory potential has shown evidence of an association with breast cancer50 and
breast cancer mortality.51
There are some limitations in our study that need to be considered when
interpreting the results. As with most prospective nutritional investigations, there is the
potential for bias due to the selection of subjects, loss to follow-up, and dietary
measurement error. Although food frequency questionnaires may not generate accurate
estimates for absolute intakes of nutrients, they have been shown to be effective in
ranking individuals, as is the purpose in this study.173 Unexpected results from fish with
low and high ω-3 fatty acids could have been due to preparation methods that were not
ascertained. Low numbers of ER- cases may have limited our ability to detect an
association in this subtype and a heterogeneity in effect by ER subtype, however, there
were ample ER+ cases for analyses. A limitation of the PLCO study population is the
lack of racial/ethnic diversity. However, non-Hispanic White women experience the
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highest incidence of breast cancer compared to other races/ethnicities in the US, so
results are generalizable to this group at the highest risk.
There are strengths in the approach and design to note, as well. The use of a large,
prospective cancer cohort allowed the associations of interest to be investigated with
enough power to detect moderately small effects and with information on multiple known
risk factors with which to adjust for potential confounding. The application of RRR to
derive the ERDP provides the ability to incorporate a hypothesized pathogenic pathway
in dietary pattern development.31,257 As noted, the EMs included in the RRR models have
been shown to be strongly related to breast cancer risk and were measured using a more
sensitive assay method, thus improving upon the previous RRR-derived estrogen dietary
pattern.32
In conclusion, we identified a dietary pattern to be associated with an estrogen
profile (high E2 and low 2/16 ratio) hypothesized to increase breast cancer risk. Women
who had high ERDP scores tended to consume higher amounts of non-whole/refined
grains, tomatoes, cheese, franks/luncheon meats; and lower amounts of nuts and seeds,
cruciferous vegetables, other vegetables, fish/shellfish, yogurt, and coffee. A subsequent
prospective investigation indicated that this estrogenic diet was associated with an
increased risk of postmenopausal breast cancer risk, possibly through an influence on
estrogen metabolism. Future studies should be conducted in populations from other
regions with larger variation in intakes in food groups, or in study populations using
open-ended dietary assessment tools to capture all foods or food groups that potentially
influence estrogen metabolism
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4.6

Tables

Table 4.1 Comparison of mean (±standard deviation) food or beverage intake across extreme quartiles of estrogen metabolites for the
eleven foods and beverages included in the estrogen-related dietary pattern (ERDP)
Unconjugated E2

2/16 Ratio
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Model Weighta

Q1 (n=164)

Q4 (n=163)

p-valueb

Q1 (n=163)

Q4 (n=163)

p-valueb

Non-whole/refined grains (oz/day)

0.12

3.90 ± 1.81

4.45 ± 2.00

0.01

4.39 ± 2.06

4.10 ± 1.91

0.18

Tomatoes (cups/day)

0.09

0.40 ± 0.22

0.45 ± 0.27

0.06

0.43 ± 0.30

0.43 ± 0.24

0.79

Other vegetables (cups/day)

-0.13

0.96 ± 0.52

0.95 ± 0.45

0.89

1.02 ± 0.58

1.07 ± 0.60

0.42

Cruciferous vegetables (cups/day)

0.08

0.28 ± 0.21

0.26 ± 0.20

0.6

0.30 ± 0.26

0.32 ± 0.23

0.46

Cheese (cups/day)

0.16

0.29 ± 0.23

0.43 ± 0.38

<0.01

0.38 ± 0.37

0.33 ± 0.26

0.2

Yogurt (cups/day)
Fish/shellfish high in ω-3 fatty
acids (oz/day)
Fish/shellfish low in ω-3 fatty
acids (oz/day)
Franks and luncheon meats (oz/day)

-0.12

0.12 ± 0.19

0.08 ± 0.15

0.03

0.09 ± 0.17

0.12 ± 0.21

0.15

0.2

0.16 ± 0.17

0.15 ± 0.15

0.55

0.15 ± 0.17

0.16 ± 0.19

0.53

-0.27

0.53 ± 0.47

0.49 ± 0.38

0.46

0.46 ± 0.36

0.52 ± 0.49

0.21

0.08

0.21 ± 0.23

0.34 ± 0.56

0.01

0.28 ± 0.31

0.22 ± 0.28

0.07

Nuts and seeds (oz/day)

-0.11

0.45 ± 0.70

0.38 ± 0.42

0.32

0.44 ± 0.79

0.44 ± 0.64

0.99

Coffee (cups/day)

-0.1

3.09 ± 3.59

2.30 ± 3.27

0.04

2.64 ± 3.34

3.18 ± 3.73

0.17

ERDP: estrogen related dietary pattern; EM: estrogen metabolite
a
Model weight from final RRR model that is used for ERDP scoring.
b
t-test for the comparison of means in the first and fourth quartiles.

Table 4.2 Correlations for the estrogen-related dietary pattern (ERDP) and food group intakes with factor score and estrogen
metabolite response variables among subset of women with estrogen metabolite values (n=653)a
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Total ERDP score
Non-whole/refined grains (oz/day)
Tomatoes (cups/day)
Other vegetables (cups/day)
Cruciferous vegetables (cups/day)
Cheese (cups/day)
Yogurt (cups/day)
Fish/shellfish high in ω-3 fatty acids
(oz/day)
Fish/shellfish low in ω-3 fatty acids (oz/day)
Franks and luncheon meats (oz/day)
Nuts and seeds (oz/day)
Coffee (cups/day)

RRR Factor Score

Unconjugated
Estradiol

2/16 Pathway
Ratio

1.00 (<0.01)
0.41 (<0.01)
0.28 (<0.01)
-0.07 (0.07)
-0.02 (0.61)
0.55 (<0.01)
-0.34 (<0.01)

0.27 (<0.01)
0.10 (0.01)
0.08 (0.03)
-0.03 (0.46)
-0.03 (0.47)
0.16 (<0.01)
-0.10 (0.01)

-0.16 (<0.01)
-0.09 (0.02)
-0.03 (0.48)
0.00 (0.90)
-0.04 (0.34)
-0.08 (0.05)
0.05 (0.25)

-0.06 (0.10)

-0.02 (0.56)

0.00 (0.98)

-0.18 (<0.01)
0.39 (<0.01)
-0.14 (<0.01)
-0.22 (<0.01)

-0.04 (0.27)
0.11 (<0.01)
-0.05 (0.17)
-0.06 (0.10)

0.04 (0.32)
0.00 (0.92)
-0.05 (0.24)
0.03 (0.51)

ERDP: estrogen related dietary pattern; EM: estrogen metabolite; RRR: reduced rank regression
a
Pearson's correlation coefficient (p-value).

Table 4.3 PLCO population characteristics across the estrogen-related dietary pattern (ERDP) quartiles
ERDP Quartile
(score range)
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n
Breast cancer cases Total
Invasive
ER+
ERERDP score (mean ± SD)
Age (mean ± SD)
BMI (kg/m2; mean ± SD)
BMI at age 20 (kg/m2; mean ± SD)
Total energy intake (kcal/day; mean ± SD)
HRT use (%)
Current
Former
Never
Race (%)
White, Non-Hispanic
Black, Non-Hispanic
Hispanic
Asian
Alcohol (%)
Abstainer
0-7 drinks/week

1st
(-4.515,
-0.350)
6,872
366
280
246
45
-0.77 ± 0.43
62.6 ± 5.3
26.6 ± 5.1
21.4 ± 2.9
1,691 ± 578

2nd
(-0.351,
-0.021)
6,872
392
309
275
41
-0.18 ± 0.09
62.8 ± 5.4
26.6 ± 5.1
21.1 ± 2.7
1,542 ± 528

3rd

4th

(-0.022, 0.328)

(0.329, 6.578)

6,872
403
331
274
55
0.14 ± 0.10
62.5 ±5.3
27.1 ± 5.3
21.2 ± 2.7
1,659 ± 535

6,872
431
348
302
48
0.77 ± 0.48
61.8 ± 5.2
28.1 ± 5.9
21.4 ± 3.0
2,078 ± 621

51.7
15.8
32

51.9
16.4
31.3

51.6
16
32

51.6
15.8
32.1

88.4
4.8
1.1
5.1

90.6
4.5
1.2
3.1

91.9
4.1
1.4
2.1

93.1
3.9
1.4
1.1

24.4
62.4

25.7
60.8

28.7
58.4

29.9
55.5

>7 drinks/week

13.2

13.5

12.9

14.6

Current
Former
Never

9.6
38.7
51.7

8.8
33.7
57.5

7.8
31.8
60.4

9.3
32.4
58.3

< High school
High school grad and some college
College grad
Postgraduate

5.4
62.2
15.9
16.6

5.8
65.2
15.3
13.8

5.9
65.2
15.6
13.4

5.6
64
16.1
14.3

9.9
7.4
24.6
25.2
32.9

8.8
6.6
23.8
25.4
35.4

8.5
7
23.1
25.3
36.1

8.6
7.2
22.7
25.5
36

14.4
14.3
23.9
36.2
11.2

14
13.6
23.9
37.3
11.3

13.3
14.5
23.2
37.9
11.2

13.3
13.4
23.2
38.2
12

85
13.9
0.2

85.7
13.4
0.1

84.6
14.1
0.2

84.3
14.5
0.1

90.3
9.8

88.9
11.1

88.5
11.5

88.3
11.7

Smoking (%)

Education (%)

Live births (%)
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None
1
2
3
≥4
Age at menopause (%)
< 40
40-44
45-59
50-54
≥55
Family history of breast cancer (%)
No
Yes, immediate female
Male only
Bilateral oophorectomy (%)
No
Yes
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Hours of vigorous PA per week (%)
None
<1
1
2
3
≥4
Non-whole/refined grains (oz/day; mean ± SD)
Tomatoes (cups/day; mean ± SD)
Other vegetables (cups/day; mean ± SD)
Cruciferous vegetables (cups/day; mean ± SD)
Cheese (cups/day; mean ± SD)
Yogurt (cups/day; mean ± SD)
Fish/shellfish high in ω-3 fatty acids (oz/day; mean ± SD)
Fish/shellfish low in ω-3 fatty acids (oz/day; mean ± SD)
Franks and luncheon meats (oz/day; mean ± SD)
Nuts and seeds (oz/day; mean ± SD)
Coffee (cups/day; mean ± SD)

12.2
16.3
11.3
17.7
17.8
24.9
3.51 ± 1.58
0.38 ± 0.23
1.14 ± 0.64
0.30 ± 0.28
0.23 ± 0.18
0.25 ± 0.30
0.19 ± 0.21
0.65 ± 0.63
0.14 ± 0.17
0.63 ± 0.97
3.83 ± 4.22

14.5
18.9
12.4
16.5
16.7
21
3.50 ± 1.52
0.36 ± 0.22
0.93 ± 0.51
0.27 ± 0.24
0.24 ± 0.18
0.10 ± 0.15
0.14 ± 0.15
0.45 ± 0.37
0.16 ± 0.17
0.35 ± 0.48
2.37 ± 2.50

15.6
19.4
11.7
17
17
19.3
4.10 ± 1.60
0.41 ± 0.24
0.90 ± 0.48
0.27 ± 0.24
0.32 ± 0.21
0.07 ± 0.12
0.13 ± 0.15
0.43 ± 0.35
0.22 ± 0.22
0.33 ± 0.42
1.86 ± 2.18

19.4
19.7
12.3
16.1
14.9
17.6
5.66 ± 2.19
0.56 ± 0.42
0.98 ± 0.52
0.30 ± 0.28
0.60 ± 0.40
0.06 ± 0.12
0.17 ± 0.22
0.49 ± 0.42
0.42 ± 0.45
0.38 ± 0.45
1.86 ± 2.29

ERDP: estrogen related dietary pattern; ER: estrogen receptor; BMI: body mass index; HRT: hormone replacement therapy; PA: physical activity; PLCO:
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SD: standard deviation

Table 4.4 Hazard ratios (95% CI) for the relationship between the estrogen-related dietary pattern (ERDP) score and postmenopausal
breast cancer in PLCO
Estimate for continuous
ERDP scorea, p-trend

ERDP quartiles
1st

2nd

3rd

4th

366

392

403

431

Age-adjusted

1.00 (ref)

1.07 (0.93, 1.24)

1.10 (0.95, 1.26)

1.18 (1.03, 1.36)

1.12 (1.03, 1.20)
p=0.005

Age- and-TEI adjusted

1.00 (ref)

1.09 (0.94, 1.25)

1.10 (0.95, 1.27)

1.15 (1.00, 1.33)

1.10 (1.01, 1.18)
p=0.02

Multivariable-adjustedb

1.00 (ref)

1.08 (0.94, 1.25)

1.10 (0.95, 1.27)

1.14 (0.98, 1.32)

1.09 (1.01, 1.18)
p=0.04

No. of cases

280

309

331

348

Age-adjusted

1.00 (ref)

1.11 (0.94, 1.30)

1.18 (1.00, 1.38)

1.25 (1.07, 1.47)

1.16 (1.07, 1.26)
p=0.0006

Age- and-TEI adjusted

1.00 (ref)

1.12 (0.95, 1.32)

1.18 (1.01, 1.38)

1.21 (1.03, 1.43)

1.14 (1.04, 1.24)
p=0.003

Multivariable-adjustedb

1.00 (ref)

1.12 (0.95, 1.31)

1.18 (1.01, 1.39)

1.20 (1.02, 1.42)

1.13 (1.04, 1.24)
p=0.005

No. of cases

246

275

274

302

Age-adjusted

1.00 (ref)

1.12 (0.94, 1.33)

1.11 (0.93, 1.32)

1.23 (1.04, 1.46)

Total breast cancer
No. of cases

99
Invasive

ER+

1.15 (1.05, 1.26)
p=0.003
Age- and-TEI adjusted

1.00 (ref)

1.13 (0.95, 1.35)

1.11 (0.94, 1.32)

1.20 (1.01, 1.42)

1.13 (1.03, 1.24)
p=0.01

Multivariable-adjustedb

1.00 (ref)

1.13 (0.95, 1.34)

1.11 (0.94, 1.32)

1.19 (0.99, 1.41)

1.13 (1.02, 1.24)
p=0.02

No. of cases

45

41

55

48

Age-adjusted

1.00 (ref)

0.92 (0.60, 1.40)

1.21 (0.82, 1.80)

1.06 (0.71, 1.59)

1.09 (0.87, 1.35)
p=0.46

Age- and-TEI adjusted

1.00 (ref)

0.93 (0.61, 1.43)

1.22 (0.82, 1.81)

1.01 (0.66, 1.53)

1.06 (0.85, 1.32)
p=0.63

Multivariable-adjustedb

1.00 (ref)

0.94 (0.61, 1.44)

1.24 (0.83, 1.84)

1.04 (0.68, 1.59)

1.07 (0.85, 1.35)
p=0.54

74,615

74,375

74,932

74,468

ER-

100
Person-years accumulated

ERDP: estrogen related dietary pattern; TEI: total energy intake; ER: estrogen receptor; BMI: body mass index; HRT: hormone replacement therapy; PA:
physical activity; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
a
HR corresponds to 1-unit increase in ERDP score.
b
Includes adjustment for age, TEI, BMI, BMI at age 20, HRT, alcohol use, education, bilateral oophorectomy, parity, age at menopause, PA, race/ethnicity,
recruitment center, and family history of breast cancer.

Table 4.5 Hazard ratios (95% CI) for the relationship between the estrogen-related dietary pattern (ERDP) score and postmenopausal
breast cancer within strata of estrogen-related risk factors in PLCOa
ERDP quartiles
1st
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HRT use at baseline
No
Yes
2
BMI (kg/m )
18.5-29.9
≥30
Alcohol consumption
<1 drink/week
≥1 drinks/week
Parity
Nulliparous
Parous
Vigorous PA
<2 hours/week
≥2 hours/week

2nd

3rd

p interactionb
4th
0.64

1.00 (ref)
1.00 (ref)

1.20 (0.96, 1.50)
1.02 (0.85, 1.23)

1.27 (1.02, 1.59)
1.01 (0.84, 1.21)

1.24 (0.99, 1.56)
1.07 (0.88, 1.29)
0.59

1.00 (ref)
1.00 (ref)

1.09 (0.92, 1.28)
1.12 (0.83, 1.51)

1.14 (0.97, 1.34)
1.01 (0.75, 1.35)

1.20 (1.02, 1.43)
0.99 (0.75, 1.32)

1.00 (ref)
1.00 (ref)

1.11 (0.92, 1.34)
1.05 (0.84, 1.32)

1.15 (0.96, 1.38)
1.03 (0.82, 1.30)

1.15 (0.95, 1.39)
1.14 (0.90, 1.44)

0.90

0.58
1.00 (ref)
1.00 (ref)

1.24 (0.77, 2.00)
1.06 (0.91, 1.24)

1.44 (0.90, 2.28)
1.07 (0.92, 1.24)

1.45 (0.91, 2.32)
1.10 (0.95, 1.28)

1.00 (ref)
1.00 (ref)

1.18 (0.95, 1.47)
1.01 (0.83, 1.22)

1.11 (0.89, 1.38)
1.10 (0.91, 1.33)

1.12 (0.90, 1.40)
1.17 (0.96, 1.42)

0.61

ERDP: estrogen related dietary pattern; TEI: total energy intake; ER: estrogen receptor; BMI: body mass index; HRT: hormone replacement therapy; PA:
physical activity; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
a
Includes adjustment for age, TEI, BMI, BMI at age 20, HRT, alcohol use, education, bilateral oophorectomy, parity, age at menopause, PA, race/ethnicity,
recruitment center, and family history of breast cancer.
b
P-value for the product term of ERDP quartiles with the potential effect modifier.
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5.1

Abstract
Introduction: The results of previous studies on diet and postmenopausal breast

cancer risk have been inconclusive. There is some evidence that dietary patterns
developed to correlate with estrogen have positive associations with breast cancer,
however, results are mixed. We applied an estrogen-related dietary pattern (ERDP) that
was developed in a subsample of the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) to the Sister Study and examine associations with
postmenopausal breast cancer. Methods: Participants from the Sister Study without a
personal history of cancer and who contributed postmenopausal person-time at risk were
included in the present analysis. Intakes of non-whole/refined grains, tomatoes,
cruciferous vegetables, other vegetables, cheese, yogurt, fish/shellfish, franks/luncheon
meats, nuts and seeds, and coffee were measured via food frequency questionnaires and
used to calculate the ERDP. Cox proportional hazards models were used to estimate
hazard ratios (HR) and 95% confidence intervals (CI) for the association between the
ERDP and postmenopausal breast cancer. Results: Over 274,308 person-years of followup 1,951 incident cases occurred. ERDP was not associated with total, invasive, ER+, or
ER- subtypes of breast cancer either as a continuous or categorical variable. The
association did not differ across strata of other estrogen-related risk factors. Results were
robust to various sensitivity analyses. Conclusion: Our investigation did not support
previous studies observing an association between an estrogen-derived dietary pattern
and postmenopausal breast cancer risk. Null results may be partially explained by higher
levels of other breast cancer risk factors, such as a family history of breast cancer within
the study population.
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5.2

Introduction
Breast cancer accounts for nearly one-third of incident cancer cases among U.S.

women and imposes a significant disease burden.277 Primary prevention may help ease
this burden, yet the identification of modifiable lifestyle factors for prevention remains a
large gap in translational breast cancer research.43 Diet represents a commonly studied
lifestyle behavior in cancer prevention, however, results from studies of individual
dietary components has yielded inconsistent results.17–19,24 Among dietary factors, only
alcohol is recognized by the World Cancer Research Fund and American Institute for
Cancer Research to have a probable influence on postmenopausal breast cancer risk, as
determined by the observational evidence and biologic plausibility from experimental
studies.24
It is possible that focusing on a known biologic mechanism while considering the
totality of diet and not only individual foods or nutrients may result in the identification
of stronger dietary associations with breast cancer. In postmenopausal breast cancer,
circulating or urinary estrogen metabolites have been associated with disease risk.11
Postmenopausal women have low endogenous levels of estrogen, therefore relatively
small changes in estrogen resulting from dietary exposures may play a role in breast
cancer risk.
Accordingly, we and others have developed dietary patterns based on associations
between specific food groups and measured levels of estrogens or estrogen
metabolites.27,32 Results of studies linking these dietary patterns to postmenopausal
breast cancer risk have been mixed. In the Nurses’ Health Study (NHS), a dietary pattern
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based on estradiol (E2) and estrone sulfate was not associated with postmenopausal
breast cancer risk.32 However, the same pattern was applied in a group of Swedish
women and a positive association with breast cancer was observed.27 A second estrogenrelated dietary pattern (ERDP) was developed using data from a nested study of
participants from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
(PLCO).35,278 The ERDP was developed using unconjugated E2 and the ratio of 2- to 16hydroxylated (2/16 ratio) estrogen metabolites (EM). Fifteen downstream metabolites,
including the 2- and 16-pathways, could be quantified using a liquid chromatographytandem mass spectrometry assay (LC/MS-MS) which has enough sensitivity to detect the
low levels present in postmenopausal women.262 The ERDP was positively associated
with postmenopausal breast cancer risk in a time-to-event analysis in the PLCO cohort.278
We applied the ERDP in a study population different from the one in which it was
developed and examined its association with postmenopausal breast cancer risk.
Outcomes included total and invasive breast cancer, as well as estrogen receptor (ER)
subtypes of breast cancer. The potential for a differential effect in strata of other
estrogen-related risk factors was assessed. We hypothesized the ERDP to be positively
associated with breast cancer. We expected to see the strongest associations in ER+
subtypes and among strata of other risk factors where the relative estrogen exposure was
lowest.
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5.3

Methods

5.3.1 Study Population
The Sister Study, an initiative of the National Institute of Environmental Health
Sciences, is a large prospective cohort study to investigate environmental and genetic
determinants of breast cancer.34 A total of 50,884 women aged 35 to 74 who had a sister
who was diagnosed with breast cancer were recruited between 2003 and 2009 from all 50
U.S. states and Puerto Rico. Women completed self-administered questionnaires and a
computer-assisted telephone interview to ascertain information on demographics and
potential risk factors. Breast cancer incidence was assessed annually via a brief study
update and a comprehensive follow-up questionnaire was administered every two to three
years. The Institutional Review Board of the National Institute of Environmental Health
Sciences and the Copernicus Group Institutional Review Board approved the study. In
the present analysis, participants were excluded if they had a personal history of cancer
(n=2,757), or if they did not contribute any person-time at risk for postmenopausal breast
cancer (n=8,004). Participants were further excluded if they reported an extreme caloric
intake (<500 or >5,000 kcal/day; n=1,163), had an extreme body mass index (BMI; <15
or >50 kg/m2; n=68), or if they had missing covariate data (n=1,140); bringing the total
analytic sample to 37,752.

5.3.2 Dietary Assessment
Intakes over the prior 12 months, as measured by the 110-item 1998 Block food
frequency questionnaire (FFQ) at baseline, were used to calculate the ERDP. Briefly, the
ERDP was previously developed using reduced rank regression modeling to identify food
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groups that were associated with serum levels of unconjugated E2 and the 2/16 ratio in a
nested case-control study of 653 postmenopausal women from PLCO. The resulting
ERDP was comprised of non-whole/refined grains, tomatoes, cruciferous vegetables,
cheese, fish/shellfish high in ω-3 fatty acids, franks/luncheon meats, nuts and seeds, other
vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, and coffee. Intakes of the food
groups were centered and scaled, then multiplied by their corresponding model weights
which were derived using the PLCO data (Table 4.1). The total ERDP score was
calculated by summing over the weighted intakes. In the present study, intakes from the
FFQ were categorized into food groups using the U.S. Department of Agriculture’s Food
Patterns Equivalents Database.279 Additional food groups were created for cruciferous
vegetables and coffee. Higher ERDP scores are hypothesized to be positively associated
with unconjugated E2 and inversely associated with the 2/16 ratio.

5.3.3 Breast Cancer Ascertainment
Participants were followed until breast cancer diagnosis, death, or end of followup. Incident breast cancer cases were ascertained via completion of annual health updates
and biennial surveys. Response rates for the surveys were over 94%.253 Access to medical
records was requested after a breast cancer diagnosis was self-reported. Medical record
abstraction was used to confirm over 80% of cases and to identify information on
treatment and diagnosis, such as ER subtype.200 The positive predictive value of selfreported breast cancer, invasive cancer, and ER breast cancer was over 90% and therefore
self-reported information is used when medical records could not be obtained.254
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5.3.4 Statistical Approach
Baseline comparisons of participant characteristics by ERDP quartiles were
performed using t-tests and chi-square tests for continuous and categorical variables,
respectively. Cox proportional hazards models were applied to analyze the relationship
between ERDP scores and incident breast cancer events, using age as the time scale
variable. The proportional hazards assumption was evaluated using Martingale-based
residuals and was not violated by exposure variables or covariates. ERDP scores were
categorized into quartiles, with the first quartile set as the referent. The first quartile
hypothetically represents diets with an estrogen profile associated with the lowest breast
cancer risk (low levels of unconjugated E2 and high 2/16 ratio). The hazard ratios and
95%CIs also were calculated for the continuous ERDP score variable, and the p-value
reported as a test for trend. Demographic factors of age (years), education (less than high
school; high school and some college; college degree; graduate degree), race/ethnicity
(non-Hispanic White, non-Hispanic Black, Hispanic, Asian, other), and total caloric
intake (kcal/day) were included in the multivariable-adjusted models for their putative
roles as confounders, as identified by a DAG. The remaining covariates included in
multivariable-adjusted models were chosen using stepwise model selection with
entry/exit criteria of p=0.2, and include hormone replacement therapy (HRT) use (never,
former – estrogen + progesterone, former – estrogen only, current – estrogen +
progesterone, current – estrogen only, ever – unknown type), baseline body mass index
(BMI; kg/m2), BMI at age 30 kg/m2), physical activity (metabolic equivalent of task
(MET)-hours/week), alcohol consumption (abstainer, ≤1 drink/day, >1 drink/day),
number of first degree relatives with history of breast cancer, age at menarche, age at
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menopause, parity, and prior hysterectomy (yes, no). Oral contraceptive (OC) use, age at
first birth, bilateral oophorectomy, and smoking status were considered but were not
retained after stepwise selection in order to improve model efficiency and reduce the
potential for over adjustment. Models were used with total breast cancer, invasive only,
and ER subtypes among invasive cases as outcomes. A competing risk model assessed a
differential association for the ERDP on ER+ and ER- subtypes using a Wald test for
heterogeneity in the stratified Lunn-McNeil approach.259 Effect modification by baseline
HRT use (yes, no), BMI (18.5-29.9 kg/m2, ≥30 kg/m2), alcohol consumption (abstainer,
≤1 drink/day, >1 drink/day), parity (nulliparous, parous), and whether or not participants
met the Physical Activity Guidelines for Americans (PAG; <500 MET-min/week, ≥500
MET-min/week).280 Soy products are not a component of the ERDP. However, soy foods
(e.g., tofu, tempeh, soy milk, and other soy substitutes) may modify dietary influences on
breast cancer due to their high phytoestrogen content.167 Additional questions on soy food
intake were added to the Sister Study FFQ. Therefore, the association between the ERDP
and breast cancer was assessed in strata of soy food consumption (non-consumer, >0 to
4.9 g/day, ≥5 g/day).
Multiple sensitivity analyses were conducted. The first set of sensitivity analyses
assessed changing parameters in the model. If BMI lies on the causal pathway between
the ERDP and postmenopausal breast cancer, there is the potential for mediator bias.
Therefore, a sensitivity analysis was conducted by removing BMI as a covariate. Because
hormone receptor status was not routinely obtained for in situ cases during the study
period, ER receptor subtype analyses were limited to invasive cases. However, a
sensitivity analysis was carried out including in situ cases. A second set of sensitivity
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analyses examined the relationship between the ERDP and breast cancer in population
subgroups. Minority population recruitment was prioritized at later stages in the
recruitment process and therefore minority women have slightly shorter average followup time. Thus, the relationship was investigated when restricting to non-Hispanic Whites.
In another subgroup analysis, participants who contributed ≤12 months of follow-up were
excluded to minimize the possibility of reverse causality. The final subgroup analysis was
restricted to women with no more than one full sister having a history of breast cancer, as
effects of lifestyle factors such as diet may be harder to detect in women with a strong
inherited risk. All statistical tests were two-sided at α=0.05, with the exception of
interaction p-values which were considered statistically significant at p<0.10. All
analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).

5.4

Results
There were 1,951 incident cases of postmenopausal breast cancer over 274,308

person-years of follow-up. Among the 1,484 invasive cases, 1,098 and 199 were ER+ and
ER-, respectively. The mean ± standard deviation (SD) ERDP score was -0.05 ± 0.71
with a range of -8.32 to 4.67. Average ERDP scores among women who were diagnosed
with incident breast cancer during follow-up were not significantly different than women
who were not diagnosed (-0.06 vs 0.04, respectively; p=0.28). Baseline characteristics
across strata of ERDP quartiles are shown in Table 5.1. Women in the fourth ERDP
quartile were typically younger, had a higher BMI at baseline and at age 30, consumed
more calories but less alcohol, and were more likely to have never used HRT or be
former users of an estrogen + progesterone formula of HRT. These women also were

110

more likely to be non-Hispanic White or Hispanic. Intakes of non-whole/refined grains,
tomatoes, cheese, franks and luncheon meats were highest among participants in the
fourth ERDP quartile. Conversely, participants in the first ERDP quartile consumed
higher amounts of other vegetables, yogurt, fish/shellfish, nuts and seeds, and coffee.
In multivariable models comparing the highest ERDP quartile with the first
(Table 5.2), or diets with the most estrogenic potential compared to the least potential, no
association was observed for total (HR: 0.98; 95%CI: 0.86, 1.11; ptrend=0.70), invasive
(HR: 0.96; 95%CI: 0.83, 1.11; ptrend=0.41), invasive ER+ (HR: 0.91; 95%CI: 0.77, 1.07;
ptrend=0.12), or invasive ER- (HR: 1.23; 95%CI: 0.82, 1.84; ptrend=0.17) breast cancer.
Results from a competing risk model indicated there was no differential effect of the
ERDP on ER+ and ER- subtypes (p=0.18; data not shown). Table 5.3 shows evidence for
potential effect modification between the ERDP and total breast cancer by alcohol
consumption (p=0.03), parity (p=0.03), and whether or not participants met the criteria of
500 MET-min/week from the PAG (p=0.07). In the fourth ERDP quartile estimates of
association were highest among participants who consumed ≥1 alcohol drink per day
(HR: 1.18; 95%CI: 0.83, 1.69), were nulliparous (HR: 1.34; 95%CI: 1.00, 1.80), or who
exercised for 500 MET-min/week (HR: 1.13; 95%CI: 0.95, 1.34), although CIs included
the null value. There was no evidence of effect modification by HRT use at baseline
(p=0.34) or BMI status at baseline (p=0.44).
No association for the relationship between the ERDP and postmenopausal breast
cancer was observed in sensitivity models with different model parameters (Table 5.4) or
within different population subgroups (Table 5.5). Similarly, there was no association
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between the ERDP and total breast cancer within strata of soy food consumption levels
(Table 5.6).

5.5

Discussion
A dietary pattern derived in PLCO to correlate with a high-risk estrogen profile

(high unconjugated E2, low 2/16 ratio) was applied in the Sister Study, prospective
cohort of women with a family history of breast cancer. Results from the time-to-event
analysis showed no association for the ERDP with total, invasive, or ER subtypes of
postmenopausal breast cancer. Participants in the fourth ERDP quartile, who were
suspected to have the most estrogenic potential from their diets, did not experience
greater risk of postmenopausal breast cancer compared to individuals in the first quartile.
Prior application of the ERDP in PLCO participants yielded a 9% increase in risk
of total postmenopausal breast cancer for a 1-unit increase in ERDP score (Table 4.4).
Furthermore, a 20% and 19% increase in risk was observed for invasive (HR: 1.20;
95%CI: 1.01, 1.42) and ER+ cases (HR: 1.19; 95%CI: 0.99, 1.41) when comparing
participants in the fourth quartile of ERDP scores to the first. In addition to the potential
for a true null association, differences in results from the PLCO and present analyses may
be due to differences in the FFQs used to measure dietary intakes as well as due to
characteristics of the populations with respect to other breast cancer risk factors. As the
FFQs used in the present analysis and the PLCO cohort are close-ended, the intakes of
the food groups used in the ERDP are dependent upon quantity and description of the line
items containing those foods. It is likely that these differences resulted in different
distributions of the scores between the two populations, as evident by the range of -8.23
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to 4.67 in the Sister Study compared to a range of -4.52 to 6.58 in PLCO participants.
Furthermore, there was a stepwise decrease in person-time contributed across the ERDP
quartiles. Participants in the fourth quartile, which was hypothesized to be most strongly
associated with breast cancer, were younger and contributed the least amount of persontime (Table 5.2). It is possible that some of these participants with the most estrogenic
diets did not contribute enough postmenopausal time at risk in order for a dietary
influence on estrogen to take effect and result in incident breast cancer, although the
relative difference time contributed per person was minimal.
It is also possible that the relative prevalence of other breast cancer risk factors
between the two populations contributed to different results. A prominent difference
between the two study populations is the presence of a family history of breast cancer for
all Sister Study participants compared to a much lower proportion in PLCO (discussed
further in section 7.1). Women with at least one first-degree relative have roughly two
times the risk of developing postmenopausal breast cancer.281 Therefore, it is plausible
that the increase in risk associated with a family history of breast cancer may render a
dietary association more difficult to detect, although evidence for a modifying effect by
family history in dietary studies is limited.227 In addition to inherited risk, Sister Study
participants had higher levels of other risk factors compared to PLCO. For example,
participants in the present analysis were less educated, more likely to drink alcohol, had
higher prevalence of past hysterectomy, and were more likely to experience the onset of
menopause after the age of 55. Harris et al. also cited lower prevalence of other risk
factors in the Swedish women as a potential explanation as to why they observed an
association with the estrogen correlated dietary pattern which was not seen in the NHS.27
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Although significant p-values were observed for modifying effects of alcohol,
parity, and PA on the ERDP’s association with breast cancer, all of the estimates of
association were null and there were no clear trends in the quartiles. There was a
suggestion of higher risk for the ERDP among nulliparous women (HRQ4vsQ1: 1.34;
95%CI: 1.00, 1.80). It is possible that some women did not have children as a result of
low or imbalanced hormones affecting their fertility,264 which would potentially explain
why a hormone-related dietary influence was detected and the association observed in the
fourth ERDP quartile for nulliparous women.
An important take away from these results, along with those from Harris et al., are
the implications of adapting dietary patterns, particularly a posteriori patterns, across
study populations with different dietary assessment tools. Intakes of commonly
consumed foods in one population may be measured differently or be completely absent
in another population, thereby having an influence on the scoring of the dietary pattern.
For example, in the NHS estrogen correlated dietary pattern, pizza was a contributing
food group. However, pizza is not commonly consumed in Sweden, so Harris et al.
dichotomized pizza consumption into consumers versus not, rather than use the
servings/day intake as in the NHS. It is likely that an estrogen-related dietary pattern
derived from RRR in a population with different diets, such as in Asia, could result in a
different pattern of food groups with little to no overlap. An open-ended dietary
questionnaire would allow for full ascertainment of foods that may influence estrogen
metabolism, which was not applicable in the present population or the one in which the
ERDP was derived.
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There are some other minor limitations in addition to the challenges associated
with applying dietary patterns across different study populations. As with all self-reported
data, there is the potential for inaccurate reporting, which could result in misclassification
of dietary intakes or other risk factors. There also is the potential for selection bias due to
loss to follow up, although response rates in this highly motivated cohort were high
(>90%). Our study was primarily comprised of non-Hispanic White women, therefore
generalizability may be limited, although breast cancer incidence is highest in this
population.277 Low numbers of ER- cases may have made it difficult to detect a potential
association and assess a differential effect of the ERDP on ER subtypes. Strengths in the
present analysis include a prospective study population with complete information on
known confounders for the relationship between diet and breast cancer. The large sample
size allowed for relatively small effects to be detected, therefore it is unlikely that a lack
of power contributed to the null results.
In conclusion, the ERDP, which was based on an estrogen profile hypothesized to
increase breast cancer risk, was not associated with risk of postmenopausal breast cancer.
All participants in the present study population had a family history of breast cancer,
therefore the inherited risk and high prevalence of other breast cancer risk factors may
have contributed to the lack of an association. Our analysis highlights the difficulties in
comparing a posteriori dietary patterns across populations, and suggests the importance
of considering dietary measurement tools when interpreting results from dietary
investigations.
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5.6

Tables

Table 5.1 Sister Study population characteristics across quartiles of the estrogen-related dietary pattern (ERDP) score
ERDP Quartile
(score range)

ERDP score (mean ± SD)
Age (mean ± SD)

1st
(-8.230 -0.444)
9,438
515
393
308
46
-0.90 ± 0.48
58.3 ± 7.3

2nd
(-0.445, -0.058)
9,438
472
372
272
45
-0.24 ± 0.11
58.0 ± 7.5

3rd
(-0.059, 0.347)
9,438
481
349
247
53
0.13 ± 0.12
57.1 ± 7.8

4th
(0.348, 4.670)
9,438
483
370
271
55
0.82 ± 0.47
56.0 ± 7.6

BMI (kg/m2; mean ± SD)

27.0 ± 5.5

27.3 ± 5.6

28.0 ± 6.1

28.7 ± 6.6

22.7 ± 3.3
1,600 ± 590
53.3 ± 31.9
12.6 ± 1.5
50.3 ± 5.8
1.27 ± 0.59
1.95 ± 1.35
18.2

22.7 ± 3.3
1,440 ± 533
51.1 ± 31.0
12.6 ± 1.5
50.1 ± 5.9
1.28 ± 0.59
2.01 ± 1.36
16.6

23.0 ± 3.5
1,527 ± 535
49.6 ± 30.9
12.6 ± 1.5
49.9 ± 6.1
1.27 ± 0.58
2.01 ± 1.37
17.2

23.4 ± 4.0
1,910 ± 650
49.7 ± 31.0
12.7 ± 1.6
49.8 ± 5.9
1.26 ± 0.56
1.96 ± 1.36
18.5

44.5
24.2

45.7
22.7

47.9
21.7

51.8
19.3

n
Breast cancer cases

Total
Invasive
Invasive ER+
Invasive ER-
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BMI at age 30 (kg/m2; mean ± SD)
Total caloric intake (kcal/day)
MET-hours/week (mean ± SD)
Age at menarche (mean ± SD)
Age at menopause (mean ± SD)
Number of relatives with family history (mean ± SD)
Parity (mean ± SD)
Nulliparous (%)
HRT status (%)
Never
Former - Estrogen+Progesterone

Former - Estrogen only
Former - unknown what type
Current - Estrogen+Progesterone
Current - Estrogen only

16.8
2.6
5.2
6.7

17.0
2.6
4.9
7.1

15.5
2.8
5.1
7.0

14.6
2.9
4.6
6.8

White, Non-Hispanic
Black, Non-Hispanic
Hispanic
Asian
Other

85.7
8.2
2.8
0.9
2.4

84.8
8.0
4.3
0.7
2.2

85.1
7.9
4.5
0.4
2.1

86.5
5.5
5.1
0.3
2.6

Abstainer
≤1 drink/day
>1 drink/day

17.7
70.9
11.4

18.5
70.0
11.5

19.8
69.7
10.5

21.1
67.1
11.8

Current
Former
Never

7.9
41.7
50.4

7.8
38.5
53.7

7.6
34.9
57.6

8.0
35.1
56.9

< HS
HS grad and some college
College grad
Postgraduate

0.9
32.4
39.5
27.2

1.1
35.0
39.1
24.8

1.2
36.2
39.6
23.0

1.2
34.8
41.3
22.7

65.6
34.4

65.6
34.4

65.1
34.9

66.9
33.1

2.32 ± 1.26

2.39 ± 1.24

2.82 ± 1.34

3.94 ± 1.98

Race/ethnicity (%)

Alcohol (%)
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Smoking (%)

Education (%)

Hysterectomy
No
Yes
Non-whole/refined grains (oz/day; mean ± SD)

Tomatoes (cups/day; mean ± SD)
Other vegetables (cups/day; mean ± SD)
Cruciferous vegetables (cups/day; mean ± SD)
Cheese (cups/day; mean ± SD)
Yogurt (cups/day; mean ± SD)
Fish/shellfish high in ω-3 fatty acids (oz/day; mean ± SD)
Fish/shellfish low in ω-3 fatty acids (oz/day; mean ± SD)
Franks and luncheon meats (oz/day; mean ± SD)
Nuts and seeds (oz/day; mean ± SD)
Coffee (cups/day; mean ± SD)

0.24 ± 0.17
0.63 ± 0.51
0.23 ± 0.27
0.26 ± 0.21
0.23 ± 0.28
0.18 ± 0.23
0.58 ± 0.63
0.38 ± 0.32
2.11 ± 2.26
2.19 ± 1.71

0.23 ± 0.17
0.44 ± 0.33
0.20 ± 0.25
0.28 ± 0.21
0.10 ± 0.14
0.14 ± 0.17
0.40 ± 0.37
0.41 ± 0.33
1.31 ± 1.32
1.58 ± 1.43

0.25 ± 0.19
0.40 ± 0.29
0.22 ± 0.25
0.36 ± 0.24
0.08 ± 0.12
0.13 ± 0.17
0.38 ± 0.34
0.51 ± 0.37
1.14 ± 1.17
1.19 ± 1.28

0.35 ± 0.27
0.45 ± 0.31
0.29 ± 0.40
0.66 ± 0.41
0.06 ± 0.11
0.15 ± 0.22
0.42 ± 0.41
0.78 ± 0.59
1.20 ± 1.20
1.02 ± 1.25

BMI: body mass index; ER: estrogen receptor; ERDP: estrogen related dietary pattern; HRT: hormone replacement therapy; HS: high school; MET: metabolic
equivalent of task.
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Table 5.2 Hazard ratios (95% CI) for the relationship between the estrogen related dietary pattern (ERDP) score and postmenopausal
breast cancer in the Sister Study
ERDP quartiles
Estimate for
continuous ERDP
scorea

1st

2nd

3rd

4th

515

472

481

483

Age-adjusted

1.00 (ref)

0.93 (0.82, 1.05)

0.98 (0.87, 1.11)

1.03 (0.91, 1.17)

1.02 (0.95, 1.08)
p=0.60

Age- and TEI-adjusted

1.00 (ref)

0.94 (0.83, 1.06)

0.99 (0.87, 1.12)

1.00 (0.88, 1.14)

1.00 (0.94, 1.07)
p=0.93

Multivariable-adjustedb

1.00 (ref)

0.93 (0.82, 1.05)

0.97 (0.85, 1.10)

0.98 (0.86, 1.11)

0.99 (0.93, 1.06)
p=0.70

No. of cases

393

372

349

370

Age-adjusted

1.00 (ref)

0.96 (0.83, 1.10)

0.94 (0.81, 1.09)

1.04 (0.90, 1.20)

1.02 (0.95, 1.09)
p=0.65

Age- and TEI-adjusted

1.00 (ref)

0.98 (0.85, 1.13)

0.95 (0.82, 1.10)

1.00 (0.87, 1.16)

1.00 (0.93, 1.07)
p=0.92

Multivariable-adjustedb

1.00 (ref)

0.96 (0.83, 1.10)

0.92 (0.79, 1.06)

0.96 (0.83, 1.11)

0.97 (0.90, 1.04)
p=0.41

No. of cases

308

272

247

271

Age-adjusted

1.00 (ref)

0.89 (0.76, 1.05)

0.85 (0.72, 1.01)

0.99 (0.84, 1.16)

Total breast cancer
No. of cases
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Invasive

Invasive ER+
0.98 (0.90, 1.07)
p=0.71

Age- and TEI-adjusted

1.00 (ref)

0.91 (0.78, 1.08)

0.86 (0.73, 1.02)

0.95 (0.80, 1.12)

0.96 (0.89, 1.05)
p=0.37

Multivariable-adjustedb

1.00 (ref)

0.90 (0.76, 1.06)

0.84 (0.71, 0.99)

0.91 (0.77, 1.07)

0.94 (0.86, 1.02)
p=0.12

No. of cases

46

45

53

55

Age-adjusted

1.00 (ref)

0.99 (0.66, 1.49)

1.19 (0.80, 1.77)

1.26 (0.85, 1.87)

1.17 (0.96, 1.43)
p=0.11

Age- and TEI-adjusted

1.00 (ref)

1.00 (0.66, 1.51)

1.20 (0.81, 1.78)

1.24 (0.83, 1.85)

1.16 (0.95, 1.42)
p=0.15

Multivariable-adjustedb

1.00 (ref)

0.99 (0.66, 1.50)

1.19 (0.80, 1.76)

1.23 (0.82, 1.84)

1.16 (0.94, 1.42)
p=0.17

69,826

69,274

68,102

67,106

Invasive ER-

Person-years accumulated
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ER: estrogen receptor; ERDP: estrogen related dietary pattern; TEI: total energy intake.
aHR corresponds to 1-unit increase in ERDP score.
bIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, age at
menarche, age at menopause, parity, and hysterectomy.

Table 5.3 Hazard ratios (95% CI) for the relationship between the estrogen related dietary pattern (ERDP) score and postmenopausal
breast cancer within strata of estrogen-related risk factors in the Sister Studya

HRT use at baseline
No
Yes
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BMI (kg/m2)
<30
≥30
Alcohol consumption
Abstainer
<1 drink/week
≥1 drinks/week
Parity
Nulliparous
Parous
Meets Physical Activity Guidelines
<500 METmin/week
≥500 METmin/week

ERDP quartiles
3rd

1st

2nd

1.00 (ref)
1.00 (ref)

0.89 (0.77, 1.02)
1.14 (0.84, 1.55)

0.96 (0.84, 1.10)
1.03 (0.75, 1.41)

4th

p interactionb
0.34

0.94 (0.81, 1.08)
1.28 (0.94, 1.74)
0.44

1.00 (ref)
1.00 (ref)

0.92 (0.79, 1.07)
0.92 (0.73, 1.16)

1.02 (0.88, 1.18)
0.85 (0.68, 1.07)

0.96 (0.82, 1.12)
1.00 (0.80, 1.25)
0.03

1.00 (ref)
1.00 (ref)
1.00 (ref)

1.14 (0.85, 1.54)
0.81 (0.70, 0.95)
1.29 (0.93, 1.80)

1.07 (0.80, 1.45)
0.88 (0.76, 1.02)
1.37 (0.98, 1.92)

0.90 (0.66, 1.22)
0.98 (0.84, 1.14)
1.18 (0.83, 1.69)

1.00 (ref)
1.00 (ref)

1.03 (0.76, 1.41)
0.90 (0.79, 1.03)

0.93 (0.68, 1.28)
0.97 (0.84, 1.11)

1.34 (1.00, 1.80)
0.91 (0.79, 1.04)

0.03

0.07
1.00 (ref)

0.94 (0.78, 1.13)

0.91 (0.76, 1.10)

0.84 (0.70, 1.02)

1.00 (ref)

0.90 (0.76, 1.07)

1.01 (0.85, 1.20)

1.13 (0.95, 1.34)

BMI: body mass index; ERDP: estrogen related dietary pattern; HRT: hormone replacement therapy.
aIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of
breast cancer, age at menarche, age at menopause, parity, and hysterectomy.
bP-value for the product term of ERDP quartiles with the potential effect modifier.

Table 5.4 Sensitivity analyses with different model parameters

ER+ including non-invasive cases
No. of cases

ER+ including non-invasive cases
No. of cases

Assess BMI mediator biasc
No. of cases

122

1st

2nd

ERDP quartiles
3rd

383

340

335

337

1.00 (ref)

0.90 (0.78, 1.04)

0.91 (0.79, 1.06)

0.92 (0.79, 1.07)

63

59

71

71

1.00 (ref)

0.95 (0.67, 1.36)

1.18 (0.84, 1.67)

1.21 (0.86, 1.72)

515

472

481

483

1.00 (ref)

0.94 (0.83, 1.06)

0.99 (0.88, 1.12)

1.02 (0.89, 1.15)

4th

Estimate for continuous
ERDP scorea

0.95 (0.88, 1.03)
p=0.19

1.11 (0.93, 1.33)
p=0.25

1.01 (0.95, 1.08)
p=0.81

BMI: body mass index; ER: estrogen receptor; ERDP: estrogen related dietary pattern.
a
HR corresponds to 1-unit increase in ERDP score.
b
Includes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, age at
menarche, age at menopause, parity, and hysterectomy.
c
Includes adjustment for all variables in "b" except for BMI.

Table 5.5 Sensitivity analyses among different analytic population subgroupsa
ERDP quartiles
n
Restricting to non-Hispanic
Whites
No. of cases

Excluding participants with
≤12 months follow-up
No. of cases
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Excluding participants with
>1 full family member with
breast cancer
No. of cases

1st

2nd

3rd

4th

453

416

429

416

1.00 (ref)

0.92 (0.81, 1.06)

0.97 (0.85, 1.11)

0.96 (0.84, 1.10)

489

439

455

452

1.00 (ref)

0.91 (0.80, 1.03)

0.97 (0.85, 1.10)

0.97 (0.85, 1.11)

337

300

308

318

1.00 (ref)

0.90 (0.77, 1.06)

0.95 (0.81, 1.11)

1.00 (0.85, 1.17)

Estimate for
continuous ERDP
scoreb

32,282
0.99 (0.93, 1.05)
p=0.70

37,369
0.98 (0.91, 1.04)
p=0.48

27,828

0.99 (0.92, 1.08)
p=0.89

ERDP: estrogen related dietary pattern.
a
Includes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer,
age at menarche, age at menopause, parity, and hysterectomy.
b
HR corresponds to 1-unit increase in ERDP score.

Table 5.6 Relationship between the estrogen related dietary pattern (ERDP) and postmenopausal breast cancer across strata of soy
food consumptiona

ERDP Quartile
Total (no. of cases)
1st
2nd
3rd
4th
Invasive (no. of cases)
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1st
2nd
3rd
4th
Invasive ER+ (no. of cases)
1st
2nd
3rd
4th
Invasive ER- (no. of cases)
1st
2nd
3rd
4th

Non-consumers
(0 g/day)
351
1.00 (ref)
1.02 (0.76, 1.38)
0.81 (0.60, 1.11)
0.92 (0.67, 1.25)
266
1.00 (ref)
0.97 (0.69, 1.37)
0.83 (0.59, 1.19)
0.88 (0.61, 1.25)
185
1.00 (ref)
0.88 (0.60, 1.35)
0.78 (0.51, 1.19)
0.77 (0.50, 1.17)
35
1.00 (ref)
0.91 (0.35, 2.38)
0.77 (0.29, 2.09)
1.21 (0.46, 3.19)

Consumption of soy foods
Low consumers
(>0 to 4.9 g/day)
992
1.00 (ref)
0.95 (0.79, 1.13)
0.98 (0.82, 1.17)
1.00 (0.83, 1.20)
753
1.00 (ref)
0.99 (0.81, 1.21)
0.93 (0.76, 1.14)
0.99 (0.80, 1.22)
572
1.00 (ref)
0.96 (0.76, 1.22)
0.92 (0.72, 1.16)
0.98 (0.77, 1.25)
98
1.00 (ref)
0.98 (0.54, 1.78)
1.16 (0.65, 2.05)
1.18 (0.66, 2.12)

High consumers
(≥5 g/day)
608
1.00 (ref)
0.84 (0.67, 1.05)
1.06 (0.85, 1.32)
1.01 (0.80, 1.26)
465
1.00 (ref)
0.90 (0.70, 1.15)
0.97 (0.76, 1.25)
0.99 (0.76, 1.28)
341
1.00 (ref)
0.81 (0.61, 1.08)
0.77 (0.57, 1.04)
0.90 (0.67, 1.21)
66
1.00 (ref)
1.08 (0.53, 2.21)
1.55 (0.79, 3.03)
1.36 (0.68, 2.72)

ER: estrogen receptor; ERDP: estrogen related dietary pattern.
aIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, age at
menarche, age at menopause, parity, and hysterectomy.
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6.1

Abstract

Lifestyle factors have been associated with estrogen metabolism, which has a strong
mechanistic role in the development of postmenopausal breast cancer. We aimed to
investigate the combined effect of estrogen-related lifestyle factors on postmenopausal
breast cancer risk using data from 27,153 women enrolled in the Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial. We created an estrogen-related lifestyle
score (ERLS) by incorporating a previously developed measure of estrogenic diet,
alcohol intake, body mass index (BMI), and physical activity. The scores ranged from 0-6
with alcohol and BMI accounting for higher weights than the other factors. To evaluate
the preventive possibilities of a low estrogen-related lifestyle, and to keep the direction of
the score consistent with other published lifestyle scores, higher scores were set to
correspond with potentially lower estrogenic lifestyle. The association between the ERLS
and incident breast cancer was examined using Cox proportional hazards models.
Participants with an ERLS of 4 or ≥5 had a 23% (HR: 0.77; 95%CI: 0.67-0.89) and 34%
(HR: 0.66; 95%CI: 0.56-0.78) lower risk of breast cancer, respectively, compared to
those with an ERLS ≤2 after multivariable adjustment. Estimates were similar when
restricting to invasive cases or estrogen receptor positive subtypes. No single lifestyle
component appeared to drive the association. Our findings suggest that the combined
effect of a lifestyle characterized by a low estrogenic diet, low alcohol consumption, low
body weight, and high levels of physical activity are associated with a reduction in
postmenopausal breast cancer risk, possibly through an influence on estrogen
metabolism.
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6.2

Introduction
Breast cancer is the second most diagnosed cancer worldwide.282 In the US, an

estimated 250,000 new cases of breast cancer will be diagnosed in 2017, accounting for
approximately 30% of all cancer diagnoses in women.277 Over two-thirds of breast
cancers occur in post-menopausal women over the age of 55.2 Although many wellestablished risk factors for postmenopausal breast cancer have been identified, not all
represent opportunities for primary prevention to help lessen this burden.
There is sufficient evidence to link several lifestyle factors to the development of
postmenopausal breast cancer.2,13 Both sides of the energy balance equation - excess
intake in the form of adiposity and greater energy expenditure in the form of physical
activity (PA) - show evidence of a positive and negative association with breast cancer,
respectively.2,24 Consumption of alcohol increases breast cancer risk.2,24 Although
evidence of a dietary association with breast cancer is less robust, it is still suggestive.18,44
Lifestyle factors often cluster together in individuals who adopt healthy or unhealthy
lifestyles, so it can be advantageous to study lifestyle factors using a combined lifestyle
score.245 A handful of studies have used indices to assess modifiable lifestyle factors as
one aggregate score and have reported consistent, yet moderate, inverse associations
between a healthy lifestyle and breast cancer.14–16,246–250 Previous lifestyle indices were
based on adherence to cancer prevention guidelines,14,250 included behaviors specific to a
study population,15 or were simply based on what is thought to constitute healthy
behaviors.16,246
Consideration of a disease mechanism in the development of a lifestyle score may
help to identify stronger associations than previous studies. In the case of postmenopausal
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breast cancer, the prominent influence of estrogen exposure on mammary carcinogenesis
is well-documented.4 Regarding modifiable lifestyle behaviors, increased adiposity and
consumption of alcohol are positively associated with estrogen,140 whereas PA is
inversely associated with estrogen;212 all of which are associated with breast cancer risk.2
There is recent evidence of dietary patterns developed to correlate with estrogen levels
that were subsequently associated with postmenopausal breast cancer risk in some
studies,27,278 but not all.32,283 One of those patterns, the estrogen-related dietary pattern
(ERDP) developed by our group, was based on an estrogen profile that is specific to
breast cancer risk: high unconjugated estradiol (E2) and a low ratio of 2- to 16hydroxylated metabolites (2/16).
In the present analysis, we aimed to assess the relationship between a lifestyle
score based on estrogen-related lifestyle factors and postmenopausal breast cancer risk.
We created the estrogen-related lifestyle score (ERLS) using the ERDP, alcohol
consumption, body mass index (BMI), and PA as scoring components, and examined
associations with overall postmenopausal breast cancer and by estrogen receptor (ER)
subtype, with consideration of potential effect modifiers. We hypothesized that higher
ERLS scores, representative of a lower combined estrogenic effect of lifestyle factors,
would be inversely associated with postmenopausal breast cancer, and that more
substantial associations would be present for ER+ cases, and among strata of effect
modifiers associated with lower estrogen exposure.
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6.3

Methods

6.3.1 Study Population
The Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial (PLCO) is an
initiative of the National Cancer Institute to examine the effects of screening on cancer
prognosis and mortality. Design and implementation have been described in detail
elsewhere.33 Briefly, recruitment of 76,685 men and 78,216 women aged 55 to 74 took
place at 10 different screening centers across the United States between 1993 and 2001.
Women in the screening arm participated in chest x-ray, flexible sigmoidoscopy, a digital
rectal examination, a CA-125 blood test and transvaginal ultrasound. The current
analyses used only data from women randomized to the intervention arm of the study
(n=39,104) who completed a dietary questionnaire (DQX) at baseline, because
participants in the control arm completed a different dietary questionnaire three years
post-baseline. The study population was limited to women who completed the baseline
questionnaire, had a valid DQX (between 1st and 99th percentiles of caloric intake, <8
missing line items), and without a personal history of cancer (except for non-melanoma
skin cancer) at baseline, bringing the sample to 28,438. Participants were further
excluded if they had an extreme (<15 or >55 kg/m2; n=74) or missing (n=179) BMI, did
not have data on PA (n=112), or if they did not contribute any person-time (n=58). After
excluding participants with missing covariate data (n=862) the final analytic sample
comprised 27,153 participants. A subsample of women had estrogen metabolite (EM)
data, measured by liquid chromatography-tandem mass spectrometry assay of serum
samples collected at baseline. This subsample, used in the development of the ERDP,278
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came from a nested case-control study35 and is comprised of 386 controls and 250
confirmed breast cancer cases who were diagnosed >2 years after blood sample donation.

6.3.2 Data Collection
Eligible participants filled out a questionnaire with information on demographics,
medical history, family history, lifestyle factors, and recent history of participation in
screening examinations at baseline. Participants self-reported their height and weight,
which was used to calculate BMI. Dietary data were collected via the DQX, a 137-item
food frequency questionnaire designed specifically for PLCO to assess typical frequency
of intake over the past year. Nutrient and food intake amounts were calculated using US
dietary data and the pyramid food group servings database from the US Department of
Agriculture (USDA).263 Separate line items were included for beer, liquor, and wine;
which were used to calculate alcohol drinks per day. The DQX also contained a question
on the number of hours per week spent performing vigorous PA, with the response
categories of: <1, 1, 2, 3, and ≥4.

6.3.3 Calculating of ERLS Scoring
The dietary component of the ERLS was characterized using previously described
ERDP scores (ref to submitted paper). Briefly, reduced rank regression modeling was
performed to identify a dietary pattern that was associated with serum levels of
unconjugated E2 and the 2/16 ratio in a nested case-control of 653 postmenopausal
women. The newly developed ERDP is comprised of non-whole/refined grains, tomatoes,
cruciferous vegetables, cheese, fish/shellfish high in ω-3 fatty acids, franks/luncheon
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meats, nuts and seeds, other vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, and
coffee. Intakes of these food groups were centered and scaled, then multiplied by their
corresponding model weights. The total ERDP score was calculated by summing over the
weighted intakes. Higher ERDP scores are positively associated with unconjugated E2
and inversely associated with the 2/16 ratio. The dietary component of the ERLS score
was based on the median ERDP score (-0.0206419) for the analytic PLCO population.
Women with a score greater than or equal to the median received a 0, as those diets are
hypothesized to be positively associated with estrogen metabolism and subsequent breast
cancer risk. Women with an ERDP score below the median received a 1.
Scoring parameters for the remaining ERLS components are similar to those
outlined in the WCRF/AICR Second Expert Report, and the USDA’s 2015 Dietary
Guidelines for Americans.13,25 Due to the strength of evidence for associations between
alcohol intake and obesity status with breast cancer risk, and evidence of an estrogenic
effect, these variables were given a stronger weight in the scoring of the ERLS,13 by
using a three-level variable rather than two-level variable in the scoring. For alcohol
intake, women who abstained from drinking (0 drink/week) were scored a 2; women who
consumed >0 to 7 drinks/week were scored a 1; and those who consumed >7 drinks/week
were scored a 0. Women were scored a 2 if they were normal weight (BMI <25.0 kg/m2),
a 1 if overweight (BMI 25.0-29.9 kg/m2), and 0 if obese (BMI ≥30.0 kg/m2). For PA,
women who reported >2 hours/week of vigorous PA were considered active and scored a
1, and those who reported ≤2 hours/week were scored a 0. The score for each of the four
different ERLS components was summed. Women with the minimum score of 0 were
hypothesized to have the largest risk profile, and those with a maximum of 6 were
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hypothesized to have the lowest combined risk profile from estrogen-related lifestyle
factors. A summary of the ERLS scoring is portrayed in Table 3.3.

6.3.4 Breast Cancer Ascertainment
Incident breast cancer cases were identified primarily through self-report via
annually mailed follow-up questionnaires. Follow-up was from start of enrollment in
1993 through December 31, 2009. Other sources of ascertainment included the National
Death Index, physician reports, state cancer registries, and next of kin reports. Over 96%
of the cases were confirmed through hospital records.252 In the analytic cohort, a total of
1,568 incident breast cancer cases occurred. A supplemental form was implemented in
2007 to capture more detailed information about the diagnosis, including estrogen
receptor status. Data on ER status was available for 70% of cases.

6.3.5 Statistical Approach
Baseline comparisons of participant characteristics by categories of the ERLS
were performed using t-tests and chi-square tests for continuous and categorical
variables, respectively. Pearson correlation coefficients were used to quantify the strength
of the relationship between the ERLS and EMs in the subsample of women with data on
EMs. Cox proportional hazards models were applied to analyze the relationship between
the ERLS and incident breast cancer events, with person-time calculated from date of
completed DQX to end of follow-up or event.284 The proportional hazards assumption
was evaluated using Martingale-based residuals and was not violated by exposure
variables or covariates.285 The ERLS was grouped as follows: ≤2 (referent group), 3, 4, or
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≥5. The three lowest scores (0, 1, and 2) and the two highest scores (5 and 6) were
combined into single categories due to low numbers of cases. The first category
hypothetically represents lifestyles with a higher exposure to estrogen. The hazard ratio
(HR) and 95% confidence intervals (CI) also were calculated for the continuous ERLS
score variable, and the p-value reported as a test for trend. Demographic factors of age
(years), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Asian, other)
and study center (10 categories) were included in the multivariable-adjusted models,
along with total caloric intake (kcal/day) for their putative roles as confounders for breast
cancer. The remaining covariates included in multivariable-adjusted models were chosen
using stepwise model selection with entry/exit criteria of p=0.2. Further adjustment for
hormone replacement therapy (HRT) use (current; former; never; unknown), family
history of breast cancer (yes; no; unknown), education (less than high school; high school
and some college; college degree; graduate degree), BMI at age 20 (kg/m2), bilateral
oophorectomy (yes; no), parity (6 categories), and age at menopause (5 categories) was
included in the multivariable models. Age at first birth, age at menarche, oral
contraceptive use, smoking status, and prior hysterectomy also were considered as
potential confounders but were not included after performing the stepwise model
selection. Effect modification by baseline HRT use (yes; no) and parity (nulliparous;
parous) was examined in stratified results, and by including an interaction term in the
model. All models were performed with overall breast cancer and within strata of ER
subtype. A competing risk model was performed to assess a differential association for
the ERLS on ER+ and ER- subtypes using a Wald test for heterogeneity in the stratified
Lunn-McNeil approach.259 In secondary analyses, we evaluated associations between
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individual components of the ERLS and postmenopausal breast cancer with additional
adjustment for each of the ERLS components that were not the main independent
variable of interest. Additionally, to evaluate whether the observed association between
the ERLS and postmenopausal breast cancer was primarily influenced by a single ERLS
component, we removed the components one at a time from the total ERLS score to see if
the estimate of association with breast cancer changed significantly. All statistical tests
were two-sided at α=0.05 and all analyses were conducted using SAS 9.4 (SAS Institute,
Cary, NC).

6.4

Results
Over an average follow-up of 10.9 years, 1,576 incident cases of breast cancer

were reported, with 1,261 of those cases being invasive. Among cases where ER status
was ascertained, 1,089 were ER+ and 187 were ER-. In our subsample of participants
with EM data that was used to derive the ERDP, the ERLS was moderately correlated
with unconjugated E2 (r=-0.33; p<0.01) and the 2/16 ratio (r=0.20; p<0.01). The
distribution of characteristics across ERLS categories for the full analytic cohort are
shown in Table 6.1. Participants in the highest ERLS category had the lowest occurrence
of total and ER+ breast cancer. In addition, they had the lowest total caloric intake,
lowest proportion of non-Hispanic Whites but highest proportion of Asians, were more
educated, and had the highest proportions of HRT users and never smokers at baseline.
In Cox models with varying levels of adjustment, participants in the highest
ERLS category, representing lifestyles hypothesized to have the least estrogenic
potential, experienced the lowest risk of postmenopausal breast cancer compared to the
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lowest ERLS category (Table 6.2). In the multivariable-adjusted model, participants with
an ERLS of 4 or ≥5 (lower estrogen) had a 23% (HR: 0.77; 95%CI: 0.67-0.89) and 34%
(HR: 0.66; 95%CI: 0.56-0.78) reduction in risk of breast cancer, respectively, compared
to those with an ERLS ≤2 (higher estrogen) (p-trend<0.0001). A 1-unit increase in ERLS
was associated with a 11% lower risk (HR: 0.89; 95%CI: 0.85-0.92) after adjustment.
Estimates were similar for invasive cases only. When restricting to ER+ subtype, the
magnitude of the inverse associations strengthened slightly for those with an ERLS of 4
(HR: 0.73, 95%: 0.62-0.87) and ERLS ≥5 (HR: 0.63; 95%CI: 0.51-0.77). No significant
effect estimates were observed for ER- subtypes, but the HR for ERLS ≥5 was reduced
and results from the competing risk model indicated there was no differential association
for the different ER subtypes (p=0.62). There was no evidence of effect modification by
baseline HRT use (pinteraction=0.54) or parity (pinteraction=0.75) (Table 6.3).
Table 6.4 shows results from investigations of individual ERLS scoring
components. In all models, the category that was associated with a score of 0,
representative of higher estrogen exposure, was the referent. A modest reduction in risk
was observed in participants with score of 1 for the ERDP (HR: 0.92; 95%CI: 0.83-1.02).
Significant reductions in risk were seen among individuals with an alcohol score of 2
(HR: 0.79; 95%CI: 0.66-0.95), or 1 (HR: 0.83; 95%CI: 0.72-0.95); individuals with a
BMI score of 2 (HR:0.72; 95%CI: 0.62-0.83), or 1 (HR: 0.88; 95%CI: 0.76-1.00); and for
those with a score of 1 for PA (HR: 0.92; 95%CI: 0.83-1.02). The estimates of
association for the ERLS remained relatively unchanged after removing individual
components, one at a time (Table 6.5).
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6.5

Discussion
In this large prospective cohort study of postmenopausal women, our findings

suggest that the combined effect of modifiable lifestyle factors, namely diet, alcohol
intake, BMI, and PA, is associated with risk of postmenopausal breast cancer.
Specifically, women who were consuming a diet with less estrogenic potential, less
alcohol, had a lower BMI, and were engaging in more physical activity were at reduced
risk for breast cancer compared to women with less healthy lifestyles. A 1-unit increase
in the ERLS score towards the direction of a lifestyle that was hypothesized to have
lower estrogen exposure was associated with a 11% reduction in risk. The ERLS was
moderately correlated with two EMs thought to be important indicators of breast cancer
risk in a subsample of women. However, the association between ERLS and breast
cancer did not differ by ER subtypes. The association was not modified by HRT use or
parity.
Considering the prominence of an estrogenic influence on the development of
breast cancer, the ERLS was developed to characterize the combined effect of estrogenrelated lifestyle factors. Other lifestyle components, such as smoking or breastfeeding,
were omitted from the ERLS as evidence of an estrogenic disease mechanism is not
substantial.67 All individual components of the ERLS exhibited inverse associations with
postmenopausal breast cancer in multivariable-adjusted models, but none of the estimates
of association were larger than their combined effect in the ERLS. According to the
World Cancer Research Fund (WCRF) and American Institute for Cancer Research’s
(AICR) 2017 Continuous Update Project (CUP),24 there is strong evince of increasing
risk of postmenopausal breast cancer with body fatness (represented by BMI in the
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ERLS) and alcohol. The CUP also has designated PA to have strong evidence of an
influence on breast cancer risk, therefore we anticipated seeing an association.24
Furthermore, in a prior PLCO investigation, a 1-unit increase in ERDP scores was
associated with a significant 9% increase in risk of developing postmenopausal breast
cancer.278 The association between ERLS and postmenopausal breast cancer remained
significant, with relatively no attenuation in effect estimates, even after individual ERLS
components were removed from the total score. These results suggest there was no single
component of the ERLS that drove the observed significant association in models with
total ERLS.
To the best of our knowledge, this was the first application of a lifestyle score
with a focus on estrogen metabolism as the primary mechanistic pathway. Prior research
on lifestyle scores and breast cancer in prospective studies have yielded similar results.
An a priori healthy lifestyle index score (HLIS) based on diet, tobacco use, alcohol, PA,
and BMI reported 21% lower risk of breast cancer (HR: 0.79, 95% CI: 0.73-0.85) among
the most healthy group in the European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort.246 When the HLIS was applied in the same cohort, but with a
slight dietary modification to include fish, folate, glycemic index, and other breast cancer
risk-specific dietary components, the estimate of the inverse association was slightly
stronger (HR: 0.74; 95% CI: 0.66–0.83).16 The association was strongest for ER/progesterone receptor (PR)- breast cancer (HR: 0.60; 95% CI: 0.40-0.90), but also
significant for ER+/PR+ (HR: 0.81; 95% CI: 0.67-0.98), suggesting disease pathways that
did not influence estrogen may have played a role.16 Also using data from EPIC, a
lifestyle score was developed to evaluate adherence to the WCRF/AICR
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recommendations on body fatness, PA, energy dense foods and drinks, plant foods,
animal foods, alcohol use, and breastfeeding in women. Compared to the lowest scores,
all categories showed a significant inverse association with breast cancer, with the
strongest association in those with greatest adherence to the prevention guidelines (HR:
0.84; 95% CI: 0.78-0.90).14 Adherence to WCRF/AICR recommendations has exhibited
positive associations with breast cancer risk in other populations, as well, 247–249 including
the Iowa Women’s Health Study where association did not differ in the presence of nonmodifiable risk factors for breast cancer.249
Evidence from case-control studies have shown similar, yet stronger associations.
In a case-control study of Mexican women, those in the highest quintile of a healthy
index comprised of diet, PA, alcohol consumption, and tobacco smoking had 80% less
odds of developing postmenopausal breast cancer compared to the lowest quintile (odds
ratio (OR): 0.20; 95% CI: 0.11-0.37).15 Increasing scores associated with a lifestyle score
focused on limiting red meat, cream, and cheese; consuming more white meat, fish, fruit
and vegetables; lower alcohol consumption; not smoking; higher PA; lower BMI; and
longer cumulative duration of breastfeeding was associated with a reduction in risk
among indigenous New Zealanders (OR: 0.47; 95% CI: 0.23-0.94), but not among nonindigenous participants (OR: 0.86; 95% CI: 0.67-1.11), when comparing the highest to
lowest quartiles.250
There is evidence that high levels of circulating unconjugated E2 and a low 2/16
ratio may be representative of an estrogen profile that increases the risk of
postmenopausal breast cancer.11 In our subsample of women with EM data, the ERLS
was inversely and positively correlated with unconjugated E2 and the 2/16 ratio,
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respectively. Additionally, each component of the ERLS has been associated with
estrogen metabolism.140,212,278 Therefore, it is plausible that the combined effect of these
lifestyle behaviors on postmenopausal breast cancer risk works through an influence on
estrogen metabolism. Dietary behaviors are known to influence the intestinal
microbiota,266 which can subsequently influence excretion or reabsorption of active
estrogens.267 Alcohol consumption may increase aromatase activity, promoting the
conversion of testosterone into estrogen.286 Adipose tissue is the largest source of
endogenous estrogen in postmenopausal women,2 and there is strong evidence for a
positive linear association between adipose tissue and estrogen levels in postmenopausal
women.207 The inverse association between PA and estrogen may be a result of reducing
adipose-derived estrogen, or possibly through increased levels of SHBG, limiting the
amount of available estrogen in active tissues.24,62
Some limitations should be considered. Similar to most prospective
investigations, there is the potential for bias due to the selection of subjects, loss to
follow-up, and measurement error. Although food frequency questionnaires may not
generate accurate estimates for absolute intakes of nutrients, they are useful for ranking
individuals, and only food or food groups (not nutrients) intakes were utilized in this
study.173 The use of BMI is an imperfect proxy for adiposity, and BMI values were
derived from self-reported height and weight. However a validation study in a similar
U.S. population showed strong correlation between self-reported and measured weight.287
Our ability to detect an association for ER- cases was limited due to low numbers,
however, this was not an issue for ER+ cases. A limitation for the PLCO study
population is the lack of racial/ethnic diversity. However, non-Hispanic White women
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experience the highest incidence of breast cancer in the US, so results are generalizable to
this high-risk group.
There are many strengths to our analysis, as well. The use of a large, prospective
cancer cohort provided adequate power to detect small associations with complete
information on known risk factors to appropriately adjust for confounders. The inclusion
of the ERDP and pre-identification of a plausible mechanistic pathway aided in making a
meaningful interpretation of our results. This was a novel approach to developing a
lifestyle score that is disease- and mechanism-specific.
In conclusion, our findings suggest that modifiable lifestyle behaviors have a
combined effect on postmenopausal breast cancer risk, possibly through an alteration of
estrogen metabolism. A lifestyle that is characterized by consumption of a diet with low
estrogenic potential, low alcohol consumption, a low BMI, and high levels of PA may
help to lower the risk of developing breast cancer in postmenopausal women. A
collective change in lifestyle is likely more influential than focusing on specific
behaviors.
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6.6

Tables

Table 6.1 Population characteristics across estrogen related lifestyle score (ERLS) categories
ERLS
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n
Breast cancer cases
Total
Invasive
ER+
ERERDP score (mean ± SD)
(ERLS: 0) ≥ median, %
(ERLS: 1) < median, %
Alcohol (drinks/week, mean ± SD)
(ERLS: 0) >7, %
(ERLS: 1) >0-7, %
(ERLS: 2) 0, %
2
BMI (kg/m , mean ± SD)
(ERLS: 0) ≥30, %
(ERLS: 1) 25.0-29.9, %
(ERLS: 2) <25, %
Hours of vigorous PA per week (%)
(ERLS: 0) ≤2
(ERLS: 1) >2
Age (mean ± SD)
Total caloric intake (kcal/day, mean± SD)
BMI at age 20 (kg/m2, mean ± SD)

≤2
7,469

3
7,565

4
7,345

≥5
4,774

459
368
321
56
0.31 ± 0.63
78.6
21.4
4.1 ± 8.1
22.2
69.4
8.4
31.9 ± 5.5
64.3
31.5
4.2

491
401
342
56
0.05 ± 0.62
56.8
43.2
3.4 ± 7.1
17.2
65.6
17.2
27.3 ± 4.7
20.5
50.9
28.6

400
308
272
48
-0.14 ± 0.58
38.6
61.4
2.3 ± 5.1
9.5
69.1
21.4
24.6 ± 3.3
3.6
37.6
58.8

226
184
154
27
-0.39 ± 54
12.0
88.0
0.8 ± 1.5
0.0
53.1
46.9
23.0 ± 2.3
0.0
11.6
88.4

81.1
18.9
61.9 ± 5.2
1,894 ± 639
22.3 ± 3.3

51.4
48.6
62.4 ± 5.3
1,763 ± 598
21.3 ± 2.8

28.6
71.4
62.7 ± 5.4
1,677 ± 572
20.7 ± 2.4

8.8
91.2
63.0 ± 5.5
1,577 ± 529
20.4 ± 2.1

HRT status (%)
Current
Former
Never
Unknown

45.4
17.8
36.2
0.6

51.7
15.9
32.1
0.3

54.3
15.4
29.8
0.5

57.2
14.8
27.7
0.3

White, Non-Hispanic
Black, Non-Hispanic
Hispanic
Asian
Other

92.3
5.2
1.2
0.6
0.7

91.8
4.7
1.2
1.8
0.5

91.4
3.3
1.2
3.5
0.6

89.3
2.4
1.1
6.8
0.4

Current
Former
Never

9.5
37.7
52.8

9.8
34.5
55.7

8.2
33.3
58.5

6.7
28.3
65.0

< HS
HS grad and some college
College grad
Postgraduate

6.7
68.2
13.5
11.6

6.1
64.0
15.8
14.1

4.7
62.3
17.4
15.6

4.6
61.7
16.6
17.1

6.6
6.9
21.7
25.7
39.1

7.6
7.3
23.3
25.3
36.5

7.6
7.1
25.5
26.1
33.7

7.8
7.3
26.3
26.2
32.4

15.3
14.1

13.5
14.0

12.6
13.4

12.9
14.3

Race (%)

Smoking (%)
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Education (%)

Live births (%)
None
1
2
3
≥4
Age at menopause (%)
< 40
40-44

45-59
50-54
≥55
Bilateral oophorectomy (%)
No
Yes
Family history of breast cancer (%)
No
Yes
Unknown

22.7
36.4
11.5

23.1
37.8
11.6

23.4
38.9
11.7

25.3
36.8
10.7

88.0
12.0

88.9
11.1

89.7
10.3

89.2
10.8

84.3
14.5
1.2

84.7
14.4
1.0

85.4
13.7
0.9

85.2
14.0
0.9

BMI: body mass index; ER: estrogen receptor; ERDP: estrogen related dietary pattern; ERLS: estrogen related lifestyle score; HRT: hormone replacement
therapy; HS: high school; PA: physical activity; SD: standard deviation
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Table 6.2 Hazard ratios (95% CI) for the relationship between estrogen related lifestyle score (ERLS) and postmenopausal breast
cancer
ERLS
≤2

3

4

≥5

459

491

400

226

Age-adjusted

1.00 (ref)

1.05 (0.92, 1.19)

0.87 (0.76, 0.99)

0.75 (0.64, 0.88)

Age- and HRT-adjusted

1.00 (ref)

1.02 (0.90, 1.16)

0.84 (0.73, 0.96)

0.72 (0.61, 0.84)

Multivariable-adjustedb

1.00 (ref)

0.97 (0.85, 1.11)

0.77 (0.67, 0.89)

0.66 (0.56, 0.78)

No. of cases

368

401

308

184

Age-adjusted

1.00 (ref)

1.07 (0.92, 1.23)

0.83 (0.72, 0.97)

0.76 (0.64, 0.91)

Age- and HRT-adjusted

1.00 (ref)

1.05 (0.91, 1.21)

0.81 (0.69, 0.94)

0.73 (0.61, 0.88)

Multivariable-adjustedb

1.00 (ref)

0.99 (0.86, 1.15)

0.74 (0.63, 0.87)

0.67 (0.56, 0.82)

No. of cases

321

342

272
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Age-adjusted

1.00 (ref)

1.04 (0.89, 1.21)

0.84 (0.71, 0.98)

0.73 (0.60, 0.88)

Age- and HRT-adjusted

1.00 (ref)

1.01 (0.87, 1.18)

0.81 (0.69, 0.95)

0.70 (0.57, 0.84)

Multivariable-adjustedb

1.00 (ref)

0.96 (0.82, 1.12)

0.73 (0.62, 0.87)

0.63 (0.51, 0.77)

No. of cases

56

56

48

27

Age-adjusted

1.00 (ref)

1.04 (0.72, 1.52)

0.91 (0.61, 1.34)

0.79 (0.50, 1.26)

Total breast cancer
No. of cases

Estimate for continuous
ERLS,a p-trend

0.92 (0.89, 0.96)
p<0.0001
0.91 (0.88, 0.95)
p<0.0001
0.89 (0.85, 0.92)
p<0.0001

Invasive
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0.92 (0.88, 0.96)
p=0.0003
0.91 (0.87, 0.95)
p<0.0001
0.89 (0.85, 0.93)
p<0.0001

ER+
0.91 (0.87, 0.96)
p=0.0001
0.90 (0.86, 0.94)
p<0.0001
0.87 (0.83, 0.92)
p<0.0001

ER0.95 (0.84, 1.06)
p=0.34

Age- and TEI-adjusted

1.00 (ref)

1.04 (0.71, 1.51)

0.90 (0.61, 1.34)

0.78 (0.49, 1.25)

Multivariable-adjustedb

1.00 (ref)

1.04 (0.71, 1.53)

0.92 (0.61, 1.38)

0.84 (0.52, 1.37)

0.94 (0.84, 1.06)
p=0.32
0.96 (0.85, 1.09)
p=0.52

CI: confidence interval; ER: estrogen receptor; ERLS: estrogen related lifestyle score; HRT: hormone replacement therapy; TEI: total energy intake
aHR corresponds to 1-unit increase in ERLS score.
bIncludes adjustment for age, TEI, HRT, education, BMI at age 20, bilateral oophorectomy, parity, age at menopause, family history of breast cancer,
race/ethnicity, and study center.
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Table 6.3 Hazard ratios (95% CI) for the relationship between the estrogen related lifestyle score (ERLS) and postmenopausal breast
cancer within strata of estrogen-related risk factorsa
ERLS
HRT use at baseline
No
Yes
Parity
Nulliparous
Parous

≤2

3

4

≥5

1.00 (ref)
1.00 (ref)

0.97 (0.80, 1.17)
0.97 (0.82, 1.16)

0.71 (0.57, 0.88)
0.82 (0.68, 0.98)

0.67 (0.51, 0.87)
0.66 (0.53, 0.82)

1.00 (ref)
1.00 (ref)

0.82 (0.52, 1.29)
0.99 (0.86, 1.14)

0.67 (0.41, 1.08)
0.78 (0.67, 0.90)

0.49 (0.27, 0.90)
0.67 (0.56, 0.80)

p interactionb
0.54

0.75

CI: confidence interval; ERLS: estrogen related lifestyle score; HRT: hormone replacement therapy; TEI: total energy intake
a
Includes adjustment for age, TEI, HRT, education, BMI at age 20, bilateral oophorectomy, parity, age at menopause, family history of breast cancer,
race/ethnicity, and study center.
b
P-value for the product term of ERDP quartiles with the potential effect modifier.
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2

Table 6.4 Hazard ratios (95% CI) for the relationship between the individual estrogen related lifestyle score (ERLS) components and
postmenopausal breast cancer

No. of cases

Age-adjusted

Age- and HRTadjusted

Multivariable-adjusteda

827
749

1.00 (ref)
0.91 (0.82, 1.00)

1.00 (ref)
0.90 (0.82, 1.00)

1.00 (ref)
0.92 (0.83, 1.02)

264
1,025
287

1.00 (ref)
0.79 (0.69, 0.91)
0.71 (0.60, 0.84)

1.00 (ref)
0.80 (0.70, 0.92)
0.71 (0.60, 0.84)

1.00 (ref)
0.83 (0.72, 0.95)
0.79 (0.66, 0.95)

388
578
610

1.00 (ref)
1.00 (0.88, 1.13)
0.90 (0.80, 1.03)

1.00 (ref)
0.97 (0.85, 1.10)
0.86 (0.76, 0.98)

1.00 (ref)
0.88 (0.76, 1.00)
0.72 (0.62, 0.83)

733
843

1.00 (ref)
0.95 (0.86, 1.05)

1.00 (ref)
0.93 (0.84, 1.03)

1.00 (ref)
0.92 (0.83, 1.02)

ERDP score
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≥ median
< median
Alcohol (drinks/week)
>7
>0 to 7
0
2
BMI (kg/m )
≥30
25.0 to 29.9
25
Hours of vigorous PA per week
≤2
>2

BMI: body mass index; CI: confidence interval; ERDP: estrogen related dietary pattern; ERLS: estrogen related lifestyle score; HRT: hormone replacement
therapy; PA: physical activity; TEI: total energy intake
aIncludes adjustment for each other ERLS component that is not the main predictor, age, TEI, HRT, education, BMI at age 20, bilateral oophorectomy, parity,
age at menopause, family history of breast cancer, race/ethnicity, and study center.

3

Table 6.5 Hazard ratios (95% CI) for the relationship between estrogen related lifestyle
score (ERLS) and postmenopausal breast cancer removing individual ERLS components
from the total scorea

Estimate for continuous
ERLS,b p-trend
0.88 (0.83, 0.92)
ERDP
p<0.0001
0.89 (0.85, 0.93)
Alcohol
p<0.0001
0.90 (0.85, 0.95)
BMI
p=0.0003
0.87 (0.83, 0.92)
PA
p<0.0001
a
Includes additional adjustment for age, TEI, HRT, education, BMI at age
20, bilateral oophorectomy, parity, age at menopause, family history of
breast cancer, race/ethnicity, and study center.
b
HR corresponds to 1-unit increase in ERLS score.
Component removed from total ERLS:
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CHAPTER 7
DIET, LIFESTYLE, AND ESTROGEN METABOLISM IN RELATION
TO POSTMENOPAUSAL BREAST CANCER: A SYNTHESIS OF
DISSERTATION FINDINGS
7.1

Summary of findings
We characterized women’s diets based on associations with an estrogen profile

that is hypothesized to be associated with increased postmenopausal breast cancer risk;
high unconjugated E2 and a low 2/16 ratio. Starting with 32 food and beverage groups,
we identified 11 key contributors to the variation in the EMs of interest. Intakes of nonwhole/refined grains, tomatoes, cruciferous vegetables, cheese, fish/shellfish high in ω-3
fatty acids, franks/luncheon meats were positively weighted for ERDP scoring; whereas
intakes for nuts and seeds, other vegetables, fish/shellfish low in ω-3 fatty acids, yogurt,
coffee were negatively weighted. Next, the ERDP was scored in two prospective cohorts
of postmenopausal women and examined for an association with breast cancer risk. In the
PLCO, the cohort from which the ERDP was developed, a positive association between
the ERDP and postmenopausal breast cancer risk was observed, in that the highest
quartile of the ERDP was associated with a 20% increased risk of invasive breast cancer
compared to the lowest quartile. However, the ERDP was not associated with
postmenopausal breast cancer risk among women in the SS.
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Possible reasons for the different findings between the two study populations
could be because all SS participants had a family history of breast cancer which reflected
shared genetic and early life environment, differences in dietary measurements and
subsequent ERDP scoring distributions between the studies, or due to a chance finding in
the PLCO when in truth there is no association. To examine the potential role of inherited
risk affecting the observed associations in the PLCO, we conducted further analyses
stratified by family history of breast cancer. As shown in Table 7.1, no association was
observed when restricting to PLCO participants with a family history of breast cancer, as
is characteristic of the full SS cohort, thus supporting the idea that high inherited risk
from shared genetic profiles and early life environments may be masking an association
with diet in the SS. Table 7.2 shows how intakes of some food groups differ significantly
between the two populations, likely due to differences in the descriptions and number of
line items containing foods within those groups in the different FFQs. These differences
in intake measurement translated to different distributions of ERDP scores across the two
populations. Scores in PLCO were slightly skewed right, whereas scores in SS were
slightly skewed left. Considering the more negative distribution in SS, it is possible that
participants in SS did not consume enough pro-estrogenic foods to observe an
association. Lastly, participants in SS had an average shorter duration of follow-up.
Therefore, if their dietary estrogenic potential measured at baseline requires a longer time
period to influence breast cancer risk, we may have only been able to evaluate the
association effectively in PLCO. This would not be relevant if their diet at baseline is
similar to their diet in previous years, but literature on the stability of dietary patterns in
adulthood is varied, so it is difficult to defend that assumption.288–291
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Lastly, the ERDP was incorporated into an estrogen-related lifestyle score
(ERLS) with other estrogen-related lifestyle factors. The ERLS was comprised of the
ERDP, alcohol consumption, BMI, and PA; with increasing scores hypothesized to have
a combined anti-estrogenic potential. An inverse association between the ERLS and
postmenopausal breast cancer risk was observed in PLCO, with women conforming to
more of the healthy lifestyle factors having a 34% reduced risk of breast cancer compared
to fewer healthy lifestyle factors, supporting the hypothesis that modifiable lifestyle
factors related to lower estrogenic potential are associated with reduced risk of breast
cancer.

7.2

Biological mechanisms
The ERDP was hypothesized to be related to postmenopausal breast cancer risk

through a biologic mechanism related to estrogen metabolism. One possible way by
which ERDP food groups may affect estrogen metabolism is through an influence on
microbiome diversity.265 Diversity of the intestinal microbiome, which is strongly
influenced by dietary behaviors, can impact many important physiological processes,
such as whether or not estrogens are excreted through feces or transformed to their
unconjugated forms and subsequently reabsorbed.267 If reabsorbed, there is a greater
estrogenic exposure throughout the body. Similarly, there is evidence of microbial effects
on interconversions of the parent estrogens and hydroxylation down the 16-pathway from
in vitro and human studies, suggesting the microbiome may also influence estrogen
metabolism.269,270 The intestinal microbiome is strongly influenced by fiber intake, or
lack thereof, through consumption of grains and vegetables, both of which are included in

151

the ERDP.266 The ERDP also is comprised of animal products, such as meats, cheese, and
yogurt, which can impact microbiome diversity.271–273 Therefore, diet may influence
breast cancer risk through an influences on a woman’s estrogen profile, mediated by
microbial effects. Many of the foods in the ERDP are also characteristic of a Western
dietary pattern , which has been associated with systemic inflammation.275 Conversely,
coffee, also a part of the ERDP, has exhibited anti-inflammatory effects.274 Inflammation
may play a role in mammary tumor development, therefore it may also play a role in a
potential association between the ERDP and breast cancer.276
In addition to the aforementioned mechanistic pathways for the relationship
between the ERDP and postmenopausal breast cancer, it is possible other components of
the ERLS also work through estrogen metabolism. Alcohol consumption may increase
aromatase activity, promoting the conversion of testosterone into estrogen.286 Adipose
tissue is the largest source of endogenous estrogen in postmenopausal women,2 and there
is strong evidence for a positive linear association between adipose tissue and estrogen
levels in postmenopausal women.207 The inverse association between PA and estrogen
may be a result of reducing adipose-derived estrogen, or possibly through increased
levels of SHBG, limiting the amount of available estrogen in active tissues.24,62 Similarly
to the ERDP, other components of the ERLS may work through inflammatory
mechanisms, as well, with alcohol, adipose tissue, and physical activity all exhibiting
associations with inflammatory markers.292
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7.3

Implications for public health
The results of the present dissertation help to address a critical gap in translational

breast cancer research. The burden of breast cancer is extensive, as it accounts for nearly
a third of all cancers diagnosed among women.2 Costs of treatment are extensive, as is
the potential for secondary health effects among the large numbers of breast cancer
survivors. To help ease this burden, primary prevention methods utilizing modifiable
lifestyle factors are needed.43 Diet is a commonly investigated lifestyle factor, though
previous studies have largely yielded inconsistent results in relation to breast cancer. By
focusing on the whole diet and a biologic mechanism specific to breast cancer, this
dissertation adds to the literature on whether disease-specific dietary recommendations
are warranted. Our findings suggest that a diet associated with estrogen metabolism may
influence breast cancer risk, although the dietary pattern established in one study was not
associated with breast cancer in a different study population. Thus, further research
capturing the “optimal” diet for estrogen metabolism across multiple populations is
warranted. Furthermore, we have shown that the combined effect of adopting lifestyle
factors associated with lower estrogen exposure may be efficacious to reduce the risk of
postmenopausal breast cancer.
Overall, our results suggest that a diet low in non-whole/refined grains, tomatoes,
cheese, franks/luncheon meats; while high in nuts and seeds, cruciferous vegetables,
other vegetables, fish/shellfish, yogurt, and coffee may protect against breast cancer
through an influence on estrogen metabolism. More research is needed to determine the
effects of an estrogen-related diet in other populations, including those with a strong
inherited risk or different dietary habits. In addition to diet, a lifestyle that is
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characteristic of a healthy body weight, low consumption of alcohol, and increased PA
may help to prevent postmenopausal breast cancer incidence.

7.4

Strengths and limitations
Some limitations must be considered when interpreting results from the present

dissertation. There was the potential for bias due to the selection of subjects, such as in
SS participants where some women with a particularly strong inherited risk may have
taken necessary lifestyle changes to reduce their risk. However, all women in the cohort
are aware of their family history of breast cancer therefore we do not expect a differential
effect based on inherited risk. Loss to follow-up represents the potential for selection
bias, however response rates in SS have been >90% for all survey periods. In PLCO, over
75% of participants were followed for at least 10 years and 95% of participants were
followed for at least 4 years, suggesting a low number of early drop outs. FFQs are prone
to measurement error, and specifically have been shown to poorly estimate current total
energy intake in relation to a recovery biomarker (doubly labeled water).293,294 We used
only food or food-group data from the FFQs, rather than macronutrient or micronutrient
data, thus, eliminating one source of error that results from converting food intake to
nutrient intake using food composition databases. Any dietary measurement error would
likely have been non-differential with respect to breast cancer outcome, thus biasing
effect estimates toward the null. Use of multiple FFQs to assess diet in adulthood would
have reduced intra-individual variation and better captured the estrogenic potential of
diet, however evidence of changes in adulthood diet is limited288–291 and FFQs are
designed to assess usual diet. Because FFQs contain a predetermined list of foods and
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beverages, the use of FFQs to develop the ERDP limited our ability to identify all foods
that were associated with EM in the RRR modeling, as compared with an open-ended
dietary assessment method such as 24 hour recalls or food records. While the PLCO and
SS populations were similar with regard to SES and race/ethnicity distributions,
differences in FFQs across the two study populations may have limited the comparability
of our findings from Aim #1 and #2. Differences in the descriptions and numbers of line
items for certain food groups may have affected our observed associations through an
impact on the distribution of ERDP scores. A minor limitation in regards to study
populations was the lack of heterogeneity of race and ethnicities. However, our
populations are predominately non-Hispanic White women who experience the highest
incidence of breast cancer, so the results have major public health relevance. While we
adjusted for important potential confounders, residual or unmeasured confounding cannot
be ruled out. A low percentage of variation in EMs was explained by the ERDP, therefore
it is difficult to assess the role of estrogen metabolism in explaining the association with
breast cancer. However, the percentage of EM variation explained in the ERDP was
similar and slightly larger than other RRR analyses using intermediate biomarkers.32,295
There are major strengths in the approach and design to offset some of the
limitations. Analyses were conducted with information on known confounders and with
enough power to detect moderately small effects through the use of large, prospective
cancer cohorts. Follow up was substantial enough for an adequate number of events to
accrue, although shorter duration in SS compared to PLCO may have contributed to the
difference in results across the two study populations. Equally small proportions (~5%)
of cases and controls were excluded because of missing exposure or covariate data for
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both populations, therefore we do not expect missing data to have influenced the
differential results.
Using RRR to create the ERDP based on EM biomarkers allowed for
consideration of an a priori mechanistic hypothesis to facilitate interpretation of results.
The EMs used to develop the ERDP were measured using a sensitive assay and have
been shown to be strongly related to breast cancer risk in the PLCO population.35 Finally,
the use of prospective cohort studies where diet was assessed prior to disease diagnosis
minimizes the potential for recall bias which can afflict case-control studies.

7.5

Suggestions for future work
Most large prospective cohort studies in the US and worldwide have used FFQs to

assess usual diet. FFQs are generally less expensive and more feasible in large
population-based studies than other dietary assessment methods, such as 24 hour recalls
or foods records. However, the previously mentioned limitations resulting from using an
FFQ to derive the dietary pattern may be improved upon through use of an open-ended
dietary assessment tool, such as a 24-hour recall of food record. In doing so, all foods
consumed that may influence estrogen metabolism in a given population can be
measured. Similarly, the development of an estrogenic dietary pattern should be
conducted in multiple populations with different dietary habits in order to examine how
the contributing foods vary, or if associations with breast cancer vary depending on the
diets of each population. Another suggestion for improvement in future studies is to
measure EMs at multiple times to reduce intra-individual variability in the intermediate
outcome used to develop the ERDP. To confirm a mechanistic pathway that works
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through estrogen metabolism, construct validation needs to be performed, such as by
evaluating the relationship between our diet score and serum EM in another study
population. Studies with serum EMs measured at an intermediate time point between
dietary exposure and breast cancer outcomes would help to clarify the potential role of
estrogen metabolism. Alternatively, clinical trials could be effective in determining
differences in EM levels across experimental groups of high and low adherers to the
ERDP.

7.6

Concluding remarks
In conclusion, we developed a dietary pattern associated with a high-risk estrogen

profile (high E2 and low 2/16 ratio) that is hypothesized to increase breast cancer risk.
Women who had high ERDP scores tended to consume higher amounts of nonwhole/refined grains, tomatoes, cheese, franks/luncheon meats; and lower amounts of
nuts and seeds, cruciferous vegetables, other vegetables, fish/shellfish, yogurt, and coffee.
A subsequent prospective investigation indicated that this estrogenic diet was associated
with an increased risk of postmenopausal breast cancer risk in the study cohort in which
it was developed, PLCO. However, application of the dietary pattern in a second
population with a high inherited risk, SS, resulted in no association with breast cancer.
Taking the results from Aims #1 and #2 together, we emphasize the importance of
considering dietary assessment tools when comparing interpretations from a posteriori
patterns across populations, as well as the need for studies of lifestyle factors across strata
of participants with or without a family history of breast cancer.
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When the dietary pattern was incorporated into a lifestyle score with alcohol
intake, BMI, and PA, a combined effect on postmenopausal breast cancer risk was
observed in the PLCO. A lifestyle that is characterized by consumption of a diet with low
estrogenic potential, low alcohol consumption, normal-weight BMI, and high levels of
PA may help to lower the risk of developing breast cancer in postmenopausal women. A
collective change in lifestyle is likely more influential than focusing on specific
behaviors.
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7.8

Tables

Table 7.1 Hazard ratios (95% CI) for the relationship between the estrogen related dietary pattern (ERDP) score and postmenopausal
breast cancer in PLCO participants stratified by family history of breast cancera

2nd

ERDP quartiles
3rd

4th

328

331

356

1.00 (ref)

1.11 (0.95, 1.30)

1.11 (0.95, 1.30)

1.17 (0.99, 1.37)

229

261

270

290

1.00 (ref)

1.15 (0.96, 1.37)

1.18 (0.99, 1.41)

1.23 (1.03, 1.48)

64

72

75

1.00 (ref)

1.00 (0.71, 1.42)

1.05 (0.75, 1.47)

1.03 (0.73, 1.45)

51

48

61

58

1.00 (ref)

0.99 (0.67, 1.48)

1.19 (0.82, 1.73)

1.10 (0.74, 1.63)

1st
Without family history of breast cancer
Total breast cancer cases
297

Invasive cases

159

With family history of breast cancer
Total breast cancer cases
69

Invasive cases

Estimate for continuous
ERDP scoreb

1.11 (1.02, 1.21)
p=0.02
1.17 (1.06, 1.29)
p=0.002

1.01 (0.83, 1.22)
p=0.94
1.01 (0.81, 1.26)
p=0.93

ERDP: estrogen-related dietary pattern
a
Includes adjustment for age, TEI, BMI, BMI at age 20, HRT, alcohol use, education, bilateral oophorectomy, parity, age at menopause, PA, race/ethnicity,
and recruitment center.
b
HR corresponds to 1-unit increase in ERDP score.

Table 7.2 Comparison of food group intakes in PLCO and the Sister Study
PLCO

Sister Study

160

Mean

SD

Min

Max

Mean

SD

Min

Max

Total ERDP Score

-0.01

0.65

-4.51

6.58

-0.05

0.71

-8.23

4.67

Non-whole/refined grains (oz/day)

4.19

1.95

0.3

16.3

2.87

1.62

0.0

18.7

Tomatoes (cups/day)

0.43

0.30

0.0

8.5

0.27

0.21

0.0

3.1

Other vegetables (cups/day)

0.99

0.55

0.0

6.2

0.48

0.38

0.0

5.4

Cruciferous vegetables (cups/day)

0.28

0.26

0.0

3.9

0.23

0.30

0.0

4.7

Cheese (cups/day)

0.35

0.30

0.0

4.3

0.39

0.32

0.0

2.6

Yogurt (cups/day)

0.12

0.20

0.0

2.2

0.12

0.19

0.0

1.8

Fish/shellfish high in ω-3 fatty acids (oz/day)

0.16

0.19

0.0

2.9

0.15

0.20

0.0

3.8

Fish/shellfish low in ω-3 fatty acids (oz/day)

0.50

0.47

0.0

10.3

0.45

0.46

0.0

8.9

Franks and luncheon meats (oz/day)

0.23

0.30

0.0

6.4

0.52

0.45

0.0

5.8

Nuts and seeds (oz/day)

0.42

0.63

0.0

9.9

1.44

1.60

0.0

23.2

Coffee (cups/day)

2.48

3.03

0.0

17.4

1.50

1.48

0.0

9.0

PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SD: standard deviation
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